<SEC-DOCUMENT>0001193125-25-235919.txt : 20251009
<SEC-HEADER>0001193125-25-235919.hdr.sgml : 20251009
<ACCEPTANCE-DATETIME>20251009163149
ACCESSION NUMBER:		0001193125-25-235919
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251008
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251009
DATE AS OF CHANGE:		20251009

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001744659
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38944
		FILM NUMBER:		251385453

	BUSINESS ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-487-6488

	MAIL ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d42650d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:akro="http://www.akerotx.com/20251008" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-423">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-10-08_to_2025-10-08">0001744659</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CurrentFiscalYearEndDate_duration_2025-10-08_to_2025-10-08" name="dei:CurrentFiscalYearEndDate" contextRef="duration_2025-10-08_to_2025-10-08">--12-31</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="akro-20251008.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-10-08_to_2025-10-08"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001744659</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-10-08</xbrli:startDate> <xbrli:endDate>2025-10-08</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-435">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-10-08_to_2025-10-08" format="ixt:datemonthdayyearen" id="ixv-436">October&#160;8, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-437">AKERO THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-10-08_to_2025-10-08" format="ixt-sec:stateprovnameen" id="ixv-438">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-439">001-38944</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-440">81-5266573</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File No.)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-441">601 Gateway Boulevard</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-442">Suite 350</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-443">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-444">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-445">94080</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices and zip code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-446">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-447">487-6488</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-10-08_to_2025-10-08" format="ixt-sec:boolballotbox" id="ixv-448">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-10-08_to_2025-10-08" format="ixt-sec:boolballotbox" id="ixv-449">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-10-08_to_2025-10-08" format="ixt-sec:boolballotbox" id="ixv-450">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-10-08_to_2025-10-08" format="ixt-sec:boolballotbox" id="ixv-451">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of Each Class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of Each Exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on Which Registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-452">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-453">AKRO</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-10-08_to_2025-10-08" format="ixt-sec:exchnameen" id="ixv-454">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-10-08_to_2025-10-08" format="ixt-sec:boolballotbox" id="ixv-455">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Agreement and Plan of Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;9, 2025, Akero Therapeutics, Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221; or &#8220;<span style="text-decoration:underline">Akero</span>&#8221;) entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;) with Novo Nordisk A/S, a Danish<span style="font-style:italic">&#160;aktieselska</span>b (&#8220;<span style="text-decoration:underline">Parent</span>&#8221;), and NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholly owned subsidiary of Parent (&#8220;<span style="text-decoration:underline">Merger Sub</span>&#8221;), providing for the merger of Merger Sub with and into the Company (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger (the &#8220;<span style="text-decoration:underline">Effective Time</span>&#8221;), each share of common stock, par value $0.0001 per share, of the Company (&#8220;<span style="text-decoration:underline">Company common stock</span>&#8221;) issued and outstanding immediately prior to the Effective Time (other than Excluded Shares and Dissenting Shares) will automatically be cancelled and converted into the right to receive (i)&#160;cash in an amount equal to $54.00, without interest thereon and subject to any applicable tax withholdings (the &#8220;<span style="text-decoration:underline">Closing Consideration</span>&#8221;) and (ii)&#160;one contractual contingent value right (a &#8220;<span style="text-decoration:underline">CVR</span>&#8221;) representing the right to receive $6.00 in cash, without interest and subject to any applicable tax withholdings, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined and further described below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consummation of the Merger is subject to customary closing conditions, including, without limitation, the absence of certain legal restraints preventing or otherwise making illegal the consummation of the Merger, no Material Adverse Effect with respect to the Company having occurred since the date of the Merger Agreement that is continuing, the expiration or termination of any waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#8220;<span style="text-decoration:underline">HSR Act</span>&#8221;) applicable to the Merger, the obtainment of any clearance or approval applicable to the Merger under the antitrust and foreign direct investment laws of other applicable foreign jurisdictions, and the adoption of the Merger Agreement by holders of Company common stock representing at least a majority of the outstanding Company&#8217;s common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties expect the Merger and the other transactions contemplated by the Merger Agreement to close around year end. The Merger Agreement provides that as promptly as reasonably practicable (and in any event within 10&#160;business days) after the date of the Merger Agreement, the Company will prepare and file a preliminary proxy statement relating to the Company&#8217;s meeting of its stockholders for the purpose of voting upon the adoption of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Effective Time of the Merger, Parent, a direct or indirect wholly owned subsidiary of Parent designated in the CVR Agreement and a rights agent will enter into a Contingent Value Rights Agreement, in the form attached as Annex I to the Merger Agreement, with such changes as may be permitted by the Merger Agreement (the &#8220;<span style="text-decoration:underline">CVR Agreement</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has made customary representations and warranties in the Merger Agreement and has agreed to customary covenants regarding the operation of the business of the Company and its Subsidiaries prior to the Effective Time. The Company is also subject to customary restrictions on its ability to solicit alternative acquisition proposals from third parties and to provide <span style="white-space:nowrap">non-public</span> information to, and participate in discussions and engage in negotiations with, third parties regarding alternative acquisition proposals, with customary exceptions to allow the Board of Directors to exercise its fiduciary duties. These exceptions include that, subject to the terms and conditions of the Merger Agreement, if the Company receives an acquisition proposal that did not result from the Company&#8217;s breach of its <span style="white-space:nowrap">no-shop</span> covenants, and following such receipt, the Board of Directors determines in good faith, after consultation with its outside legal counsel, that such acquisition proposal is or could lead to a Superior Offer and the failure to terminate the Merger Agreement and change its recommendation of the Merger to the Company&#8217;s stockholders would be inconsistent with the Board of Directors&#8217; fiduciary duties under applicable law, then the Company is permitted to terminate the Merger Agreement and the Board of Directors is permitted to change its recommendation of the Merger to the Company&#8217;s stockholders (subject to certain customary match rights in favor of Parent). </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains certain termination rights for the Company and Parent. Subject to the terms and conditions of the Merger Agreement, the Company or Parent may terminate the Merger Agreement if the Merger is not consummated by 11:59 PM Eastern Time, on April&#160;9, 2026, which period may be extended automatically for six months if at the end of the prior period, all conditions to closing of the Merger other than conditions relating to the HSR Act or other applicable antitrust and foreign direct investment laws have been obtained or waived as of such date, and extended for an additional <span style="white-space:nowrap">six-month</span> period if at the end of the prior period, all conditions to closing of the Merger other than conditions relating to the HSR Act or other applicable antitrust and foreign direct investment laws have been obtained or waived as of such date and either Company or Parent (in each of their sole discretion) provides prompt notice of such decision to extend (the &#8220;<span style="text-decoration:underline">End Date</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon termination of the Merger Agreement, under specified circumstances, the Company will be required to pay Parent a termination fee of $165,000,000. Such circumstances include where the Merger Agreement is terminated (i)&#160;in connection with the Company accepting a Superior Offer and entering an agreement for the consummation of a transaction which the Board of Directors determines constitutes a Superior Offer and (ii)&#160;due to the Board of Directors&#8217; change of, or failure to reaffirm as required by the Merger Agreement, its recommendation of the Merger to the Company&#8217;s stockholders. The termination fee will also be payable if the Merger Agreement is terminated (i)&#160;(a) by Parent or the Company because the Merger is not consummated before the End Date (but in the case of a termination by the Company, only if Parent would not be prohibited from terminating the Merger Agreement on this basis because its material breach had caused or resulted in the Merger not being consummated by the End Date), (b) by Parent or the Company due to failure to obtain the requisite Company stockholder vote to adopt the Merger Agreement, or (c)&#160;by Parent because the Company breaches its representations, warranties or covenants in a manner that would cause the related closing conditions to not be met (provided that neither Parent nor Merger Sub is then in breach of its representations, warranties or covenants in a manner that would cause the related closing conditions to not be met), (ii) prior to any such termination, a proposal to acquire 50% or more of the Company&#8217;s stock or assets is communicated to the Board of Directors or publicly disclosed and has not been withdrawn, and (iii)&#160;the Company enters into an agreement for, or consummates, a transaction involving an acquisition of 50% or more of the Company&#8217;s stock or assets within 12 months of such termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement further provides that Parent will be required to pay the Company a reverse termination fee of $185,000,000 in the event the Merger Agreement is terminated in certain specified circumstances, including if the Merger is not consummated before the End Date because certain conditions related to antitrust or foreign direct investment laws have not been satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is less than the Closing Consideration (each, an &#8220;<span style="text-decoration:underline">In the Money Option</span>&#8221;), will be cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such <span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Option, multiplied by the total number of shares of Company common stock subject to such <span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Option immediately prior to the Effective Time, plus one CVR for each share of Company common stock subject to such <span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Option immediately prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Company Options which have a per share exercise price equal to or exceeding the Closing Consideration (each, an &#8220;<span style="text-decoration:underline">Out of the Money Option</span>&#8221;) will be entitled to exercise such Out of the Money Options on a basis that allows such holders to participate in the Merger. Out of the Money Options that remain outstanding and unexercised as of the Effective Time will be cancelled for no consideration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time, each then outstanding Company RSU will be cancelled and the holder thereof will be entitled to receive a cash payment equal to the product of the Closing Consideration and the number of shares of Company common stock subject to such Company RSU, plus one CVR for each share of Company common stock subject to the Company RSU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations, warranties and covenants of the Company contained in the Merger Agreement have been made solely for the benefit of Parent and Merger Sub. In addition, such representations, warranties and covenants (i)&#160;have been made only for purposes of the Merger Agreement and (ii)&#160;have been included in the Merger Agreement for the purpose of allocating risk between the contracting parties rather than establishing matters as fact. In addition, the representations, warranties and covenants have been qualified by (a)&#160;matters specifically disclosed in certain of the Company&#8217;s filings with the United States Securities and Exchange Commission (&#8220;<span style="text-decoration:underline">SEC</span>&#8221;), (b) confidential </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosures made to Parent and Merger Sub in the disclosure letter delivered in connection with the Merger Agreement and (c)&#160;materiality qualifications contained in the Merger Agreement, which may differ from what may be viewed as material by investors. Accordingly, the Merger Agreement is included with this filing only to provide investors with information regarding the terms of the Merger Agreement, and not to provide investors with any other factual information regarding the Company or its business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contingent Value Rights Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Effective Time, Parent and a rights agent will enter into the CVR Agreement governing the terms of the CVRs. The CVRs are contractual rights only and are not transferable except under certain limited circumstances, will not be evidenced by a certificate or other instrument and will not be registered with the SEC or listed for trading. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Parent, any constituent corporation party to the Merger Agreement or any of their respective affiliates or subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each CVR represents a <span style="white-space:nowrap">non-tradeable</span> contractual contingent right to receive $6.00, without interest and subject to applicable tax withholdings (the &#8220;<span style="text-decoration:underline">Milestone Payment</span>&#8221;), upon receipt by Parent or one of its affiliates or assignees, prior to June&#160;30, 2031, of FDA Approval for efruxifermin for subcutaneous injection (whether alone or in combination with another product) for the treatment of patients with compensated cirrhosis (consistent with stage F4c fibrosis) due to metabolic dysfunction-associated steatohepatitis, and which expressly sets forth the foregoing as an indication in the indications and usage section of the <span style="white-space:nowrap">FDA-approved</span> prescribing information for such product (the &#8220;<span style="text-decoration:underline">CVR Milestone</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the CVR Milestone will be achieved by June&#160;30, 2031, or that the Milestone Payment will become payable to holders of CVRs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Merger Agreement and the CVR Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1, and the Form of CVR Agreement, which is attached as Annex I to the Merger Agreement, and the terms of which are incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company&#8217;s public disclosures. The Merger Agreement should not be read alone, but should instead be read in conjunction with the other information regarding the Company that is or will be contained in, or incorporated by reference into, the Annual Reports on Form <span style="white-space:nowrap">10-K,</span> Quarterly Reports on Form <span style="white-space:nowrap">10-Q</span> and other documents that the Company files with the SEC. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;5.03</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;8, 2025, the Board approved and adopted an amendment (the &#8220;<span style="text-decoration:underline">Forum Selection Amendment</span>&#8221;) to the Company&#8217;s existing Bylaws that amends and replaces the existing Article VI, Section&#160;8 forum selection provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Forum Selection Amendment is filed as Exhibit 3.1 hereto and incorporated by reference herein. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Press Release </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;9, 2025, the Company issued a press release announcing entry into the Merger Agreement, a copy of which is attached as Exhibit 99.1 to the Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(d)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit<br/>No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d42650dex21.htm">Agreement and Plan of Merger, dated as of October 9, 2025, by and among Akero Therapeutics, Inc., Novo Nordisk A/S and NN Invest Sub, Inc.* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d42650dex31.htm">Amendment to Akero Therapeutics, Inc.&#8217;s Bylaws, dated October&#160;8, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d42650dex991.htm">Press Release issued by Akero Therapeutics, Inc. on October 9, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Schedules have been omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, that the Company may request confidential treatment pursuant to Rule <span style="white-space:nowrap">24b-2</span> of the Securities Exchange Act of 1934, as amended, for any schedules so furnished. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">*&#8195;*&#8195;* </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Important Information and Where to Find It </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form 8-K may be deemed solicitation material in respect of the proposed transaction by and among Akero Therapeutics, Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221; or &#8220;<span style="text-decoration:underline">Akero</span>&#8221;), Novo Nordisk A/S (&#8220;<span style="text-decoration:underline">Parent</span>&#8221;) and NN Invest Sub, Inc. This Current Report on Form 8-K does not constitute a solicitation of any vote or approval. In connection with the proposed transaction between Akero and Parent, Akero intends to file with the Securities and Exchange Commission (&#8220;<span style="text-decoration:underline">SEC</span>&#8221;) a proxy statement (the &#8220;<span style="text-decoration:underline">Proxy Statement</span>&#8221;), the definitive version of which will be sent or provided to Akero stockholders. Akero may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other document which Akero may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by Akero through the website maintained by the SEC at www.sec.gov, Akero&#8217;s website at <span style="white-space:nowrap">https://ir.akerotx.com/financial-information/sec-filings</span> or by contacting the Akero investor relations department at the following: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christina Tartaglia </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(212) <span style="white-space:nowrap">362-1200</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR@akerotx.com </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Participants in the Solicitation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication does not constitute a solicitation of a proxy, an offer to purchase or a solicitation of an offer to sell any securities. Akero and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Akero&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i)&#160;the &#8220;Directors, Executive Officers and Corporate Governance,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; sections of Akero&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2024, which was filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001744659/000095017025029514/akro-20241231.htm">February&#160;28, 2025</a> and (ii)&#160;the &#8220;Proposal 1 &#8211; Election of Class&#160;III Directors,&#8221; &#8220;Executive Compensation,&#8221; and &#8220;Principal Stockholders&#8221; sections of Akero&#8217;s proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001744659/000095017025058964/akro-20250426.htm">April&#160;28, 2025</a>, and will be contained in the proxy statement to be filed by Akero in connection with the proposed transaction. Any change of the holdings of Akero&#8217;s securities by its directors or executive officers </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from the amounts set forth in the proxy statement for its 2025 annual meeting of stockholders have been reflected in the following Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC: by Jonathan Young, filed on <a href="http://www.sec.gov/Archives/edgar/data/1744659/000119312525230294/xslF345X05/ownership.xml">October&#160;3, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114666/xslF345X05/ownership.xml">September&#160;12, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000177980525000007/xslF345X05/ownership.xml">September&#160;4, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025108234/xslF345X05/ownership.xml">August&#160;13, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093321/xslF345X05/ownership.xml">July&#160;2, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088635/xslF345X05/ownership.xml">June&#160;20, 2025</a> and <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085667/xslF345X05/ownership.xml">June&#160;12, 2025</a>; by Catriona Yale, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114665/xslF345X05/ownership.xml">September&#160;12, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025097013/xslF345X05/ownership.xml">July&#160;18, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093322/xslF345X05/ownership.xml">July&#160;2, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088636/xslF345X05/ownership.xml">June&#160;20, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088207/xslF345X05/ownership.xml">June&#160;20, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085671/xslF345X05/ownership.xml">June&#160;12, 2025</a> and <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025074708/xslF345X05/ownership.xml">May&#160;19, 2025</a>; by Richard William White, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114664/xslF345X05/ownership.xml">September&#160;12, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093319/xslF345X05/ownership.xml">July&#160;2, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088637/xslF345X05/ownership.xml">June&#160;20, 2025</a> and <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085672/xslF345X05/ownership.xml">June&#160;12, 2025</a>; by Timothy Rolph, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114662/xslF345X05/ownership.xml">September&#160;12, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000177947925000007/xslF345X05/ownership.xml">September&#160;10, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025104623/xslF345X05/ownership.xml">August&#160;7, 2025</a>,<a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025094882/xslF345X05/ownership.xml"> July&#160;9, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093318/xslF345X05/ownership.xml">July&#160;2, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088638/xslF345X05/ownership.xml">June&#160;20, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085673/xslF345X05/ownership.xml">June&#160;12, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025083878/xslF345X05/ownership.xml">June&#160;9, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025067381/xslF345X05/ownership.xml">May&#160;8, 2025</a> and <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025059449/xslF345X05/ownership.xml">April&#160;28, 2025</a>; by Andrew Cheng, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/xslF345X05/ownership.xml">September&#160;12, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025108232/xslF345X05/ownership.xml">August&#160;13, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025095409/xslF345X05/ownership.xml">July&#160;11, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093316/xslF345X05/ownership.xml">July&#160;2, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088641/xslF345X05/ownership.xml">June&#160;20, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085674/xslF345X05/ownership.xml">June&#160;12, 2025</a> and <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025070811/xslF345X05/ownership.xml">May&#160;13, 2025</a>; by Scott Gangloff, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025110352/xslF345X05/ownership.xml">August&#160;19, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093317/xslF345X05/ownership.xml">July&#160;2, 2025</a> and <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088640/xslF345X05/ownership.xml">June&#160;20, 2025</a>; by Jane Henderson, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025107545/xslF345X05/ownership.xml">August&#160;12, 2025</a> and <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082311/xslF345X05/ownership.xml">June&#160;5, 2025</a>; by Patrick Lamy, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025094011/xslF345X05/ownership.xml">July&#160;3, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093320/xslF345X05/ownership.xml">July&#160;2, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088639/xslF345X05/ownership.xml">June&#160;20, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088206/xslF345X05/ownership.xml">June&#160;20, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085670/xslF345X05/ownership.xml">June&#160;12, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025081774/xslF345X05/ownership.xml">June&#160;4, 2025</a>, <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025077131/xslF345X05/ownership.xml">May&#160;23, 2025</a> and <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025068392/xslF345X05/ownership.xml">May&#160;9, 2025</a>; by Mark T. Iwicki, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082309/xslF345X05/ownership.xml">June&#160;5, 2025</a>; by Seth Loring Harrison, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082310/xslF345X05/ownership.xml">June&#160;5, 2025</a>; by Yuan Xu, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082308/xslF345X05/ownership.xml">June&#160;5, 2025</a>; by Tomas J. Heyman, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082307/xslF345X05/ownership.xml">June&#160;5, 2025</a>; by Judy Chou, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082303/xslF345X05/ownership.xml">June&#160;5, 2025</a>; and by Graham G. Walmsley, dated <a href="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082306/xslF345X05/ownership.xml">June&#160;5, 2025</a>. Akero stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Akero directors and executive officers in the transaction, which may be different than those of Akero stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the transaction. These documents (when available) may be obtained free of charge from the website maintained by the SEC at www.sec.gov and Akero&#8217;s website at <span style="white-space:nowrap">https://ir.akerotx.com/financial-information/sec-filings.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements Disclaimer </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains forward-looking statements related to Akero, Parent and the proposed acquisition of Akero by Parent (the &#8220;<span style="text-decoration:underline">Transaction</span>&#8221;) that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;goal,&#8221; &#8220;may&#8221;, &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions. In this communication, Akero&#8217;s forward-looking statements include, without limitation, statements regarding the Transaction, and about the parties&#8217; ability to satisfy the conditions to the consummation of the Transaction; statements about the expected timetable for completing the transaction; Akero&#8217;s plans, objectives, expectations and intentions, the financial condition, results of operations and business of Akero, the U.S. Food and Drug Administration&#8217;s (&#8220;<span style="text-decoration:underline">FDA</span>&#8221;) approval of Akero&#8217;s new drug application for efruxifermin for the treatment of metabolic dysfunction-associated steatohepatitis, Akero&#8217;s ability to commercialize current and future product candidates, the anticipated timing of closing of the Transaction and the accuracy of any assumptions underlying any of the foregoing. Forward-looking statements are not guarantees of future performances and are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the ability to obtain shareholder approval; the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement and Plan of Merger, dated as of October 9, 2025, among Akero Therapeutics, Inc., Novo Nordisk A/S and NN Invest Sub, Inc (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), including circumstances requiring a party to pay the other party a termination fee pursuant to the Merger Agreement; the ability for the parties to consummate the Transaction on a timely basis or at all; risks related to <span style="white-space:nowrap">non-achievement</span> of the CVR milestones and that holders of the CVRs will not receive any payments in respect of those CVRs; the possibility that competing offers will be made; the possibility that various closing conditions, including the ability to secure regulatory approvals and stockholder approval on terms expected, at all or in a timely manner, for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction; the effects of the Transaction (or the announcement or pendency thereof) on relationships with associates, customers, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; that Parent may not realize the potential benefits of the Transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; transaction costs; the risk that the Transaction will divert management&#8217;s attention from the Company&#8217;s ongoing business operations or otherwise disrupt the Company&#8217;s ongoing business operations; changes in the Company&#8217;s business during the period between now and the closing of the Transaction; certain restrictions during the pendency of the Transaction that may impact the Company&#8217;s ability to pursue certain business opportunities or strategic transactions; risks associated with litigation relating to the Transaction; the ability to maintain or expand regulatory approvals or commercialize the Company&#8217;s products; that the results of any ongoing or future clinical trials may not satisfy U.S. or non-U.S. regulatory authorities; the uncertainty associated with the current worldwide economic and financial conditions in the United States and around the word, including as a result of pandemics and epidemics, rising inflation, increased interest rates, natural disasters, military conflicts, terrorist attacks and other similar matters; actual or contingent liabilities; and other risks listed under the heading &#8220;Risk Factors&#8221; in Akero&#8217;s periodic reports filed with the SEC, including quarterly reports on Form <span style="white-space:nowrap">10-Q</span> and annual reports on Form <span style="white-space:nowrap">10-K.</span> These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the Proxy Statement to be filed with the SEC in connection with the Transaction. While the list of factors presented here is, and the list of factors presented in the Proxy Statement will be, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to Akero and Parent, and Akero and Parent disclaim any obligation to update the information contained in this communication as new information becomes available except to the extent required by law. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October&#160;9, 2025 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Akero Therapeutics, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Cheng</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Andrew Cheng, M.D., Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d42650dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>EXECUTION VERSION </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF
MERGER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">among: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AKERO
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVO NORDISK A/S, </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a
Danish <I>aktieselskab</I>; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NN INVEST SUB, INC, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as
of October&nbsp;9, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Section&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">MERGER TRANSACTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger of Merger Sub into the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of the Merger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing; Effective Time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of Incorporation and Bylaws; Directors and Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrender of Certificates; Stock Transfer Books</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dissenters&#8217; Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treatment of Company Equity Awards and Company ESPP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Further Action</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Section&nbsp;2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Due Organization; Subsidiaries, Etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certificate of Incorporation and Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Capitalization, Etc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SEC Filings; Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Absence of Changes; No Material Adverse Effect</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title to Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Real Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Compliance with Legal Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Regulatory Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certain Business Practices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Governmental Authorizations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.15</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.16</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employee Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.17</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employee Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.19</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Legal Proceedings; Orders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.21</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authority; Binding Nature of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.22</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Takeover Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.23</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.24</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Financial Advisor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.25</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brokers and Other Advisors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">2.26</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Acknowledgments by the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">30</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Section&nbsp;3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due Organization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger Sub</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authority; Binding Nature of Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Absence of Litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ownership of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acknowledgement by Parent and Merger Sub</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brokers and Other Advisors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Section&nbsp;4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">CERTAIN COVENANTS OF THE COMPANY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Access and Investigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operation of the Acquired Corporations&#8217; Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Solicitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preparation of Merger Proxy Statement; Stockholder Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Section&nbsp;5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">ADDITIONAL COVENANTS OF THE PARTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Board Recommendation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filings, Consents and Approvals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification of Officers and Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholder Litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Takeover Laws</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVR Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;16 Matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Exchange Delisting; Deregistration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification of Certain Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Section&nbsp;6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">CONDITIONS PRECEDENT TO THE MERGER </TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Each Party&#8217;s Obligations to Effect the Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Obligations of Parent and Merger Sub to Effect the Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to Obligations of the Company to Effect the Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Section&nbsp;7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Expenses; Termination Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">Section&nbsp;8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center">MISCELLANEOUS PROVISIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Survival of Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Obligation of Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Construction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Exhibits</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit&nbsp;A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certain Definitions</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>Annexes</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annex&nbsp;I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CVR Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annex&nbsp;II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Certificate of Incorporation of the Surviving Corporation</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS AGREEMENT AND PLAN OF MERGER</B> (&#8220;<U>Agreement</U>&#8221;) is made and entered into as of October&nbsp;9, 2025, by and among:
Novo Nordisk A/S, a Danish <I>aktieselsab</I> (&#8220;<U>Parent</U>&#8221;); NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholly owned subsidiary of Parent (&#8220;<U>Merger Sub</U>&#8221;); and Akero Therapeutics, Inc., a
Delaware corporation (the &#8220;<U>Company</U>&#8221;). Certain capitalized terms used in this Agreement are defined in <U>Exhibit A</U>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTRODUCTION</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parent
desires to acquire the Company through the merger of Merger Sub with and into the Company (the &#8220;<U>Merger</U>&#8221;), with the Company continuing as the surviving corporation in the Merger (the &#8220;<U>Surviving Corporation</U>&#8221;), on
the terms and subject to the conditions set forth in this Agreement, whereby (i)&nbsp;each issued and outstanding share of Company Common Stock (the &#8220;<U>Shares</U>&#8221;) as of the Effective Time (other than Excluded Shares and Dissenting
Shares) shall be cancelled and converted into the right to receive (x) $54.00 per Share, in cash, without interest thereon and subject to any withholding of Taxes (the &#8220;<U>Closing Consideration</U>&#8221;) and (y)&nbsp;one (1) contractual
contingent value right (a &#8220;<U>CVR</U>&#8221;), which shall represent the right to receive the Approval Milestone Payment (as such term is defined in the CVR Agreement) subject to the terms and conditions set forth in the CVR Agreement (the
consideration contemplated by (x)&nbsp;and (y), together, the &#8220;<U>Merger Consideration</U>&#8221;), and (ii)&nbsp;the Company shall become a direct or indirect wholly owned Subsidiary of Parent as a result of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of the Company (the &#8220;<U>Board of Directors</U>&#8221;) has unanimously (i)&nbsp;determined that this Agreement
and the Transactions, including the Merger, are advisable and fair to, and in the best interest of, the Company and its stockholders, (ii)&nbsp;declared it advisable to enter into this Agreement, (iii)&nbsp;approved the execution, delivery and
performance by the Company of this Agreement and the consummation of the Transactions, including the Merger, (iv)&nbsp;resolved that the Merger shall be governed by Section&nbsp;251(c) of the DGCL, upon the terms and subject to the conditions set
forth in this Agreement, and (v)&nbsp;resolved to recommend that the stockholders of the Company adopt this Agreement at any meeting of the Company&#8217;s stockholders held for such purpose and any adjournment or postponement thereof (the preceding
<U>clauses (i)</U>, <U>(ii)</U> and <U>(v)</U>&nbsp;collectively, the &#8220;<U>Company Board Recommendation</U>&#8221;), in each case, on the terms and subject to the conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of each of Parent and Merger Sub have approved this Agreement and declared it advisable for Parent and Merger Sub,
respectively, to enter into this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or immediately prior to the Effective Time, Parent, a direct or indirect wholly owned
subsidiary of Parent designated in the CVR Agreement (the &#8220;<U>CVR Parent</U>&#8221;), and an agent selected by Parent and reasonably acceptable to the Company (the &#8220;<U>Rights Agent</U>&#8221;) will enter into a Contingent Value Rights
Agreement, in the form attached hereto as <U>Annex I</U> (subject to changes permitted by <U>Section</U><U></U><U>&nbsp;5.9</U>) (the &#8220;<U>CVR Agreement</U>&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties to this Agreement, intending to be legally bound, agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MERGER TRANSACTION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>Merger of Merger Sub into the Company</B>. Upon the terms and subject to the conditions set forth in this Agreement and in
accordance with the DGCL, at the Effective Time, the Company and Parent shall consummate the Merger, whereby Merger Sub shall be merged with and into the Company, the separate existence of Merger Sub shall cease, and the Company will continue as the
Surviving Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B>Effect of the Merger</B>. The Merger shall have the effects set forth in this Agreement and in the
applicable provisions of the DGCL. Without limiting the generality of the foregoing, at the Effective Time, all of the property, rights, privileges, immunities, powers and franchises of the Company and Merger Sub shall vest in the Surviving
Corporation, and all of the debts, liabilities and duties of the Company and Merger Sub shall become the debts, liabilities and duties of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> <B>Closing; Effective Time</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Unless this Agreement shall have been terminated pursuant to <U>Section</U><U></U><U>&nbsp;7</U>, and unless otherwise mutually agreed in
writing among the Company, Parent and Merger Sub, the consummation of the Merger (the &#8220;<U>Closing</U>&#8221;) shall take place via the electronic exchange of documents by the Parties, as soon as practicable (and in no event later than three
(3)&nbsp;business days) following the satisfaction or, to the extent permitted by applicable Legal Requirements, waiver (by the Party or parties entitled to the benefits thereof) of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6</U>
(other than conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted by applicable Legal Requirements, waiver of such conditions at the Closing); <I>provided</I>, that if any of
the conditions set forth in <U>Section</U><U></U><U>&nbsp;6</U> are not satisfied or, to the extent permitted by applicable Legal Requirements, waived as of such date, then the Closing shall take place on the third (3<SUP
STYLE="font-size:75%; vertical-align:top">rd</SUP>) business day on which all conditions set forth in <U>Section</U><U></U><U>&nbsp;6</U> are satisfied or, to the extent permitted by applicable Legal Requirements, waived, unless another date or
place is agreed to in writing by the Company and Parent. The date on which the Closing occurs is referred to in this Agreement as the &#8220;<U>Closing Date</U>&#8221;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to the provisions of this Agreement, as soon as practicable on the Closing Date, the Company and Merger Sub shall file or cause to
be filed a certificate of merger with the Secretary of State of the State of Delaware with respect to the Merger, in such form reasonably agreed upon between the Parties and as required by, and executed and acknowledged in accordance with, the
relevant provisions of the DGCL, and the Parties shall take all such further actions as may be required by applicable Legal Requirements to make the Merger effective. The Merger shall become effective upon the date and time of the filing of that
certificate of merger with the Secretary of State of the State of Delaware or such later date and time as is agreed upon in writing by the Parties and specified in the certificate of merger (such date and time the Merger is effective, the
&#8220;<U>Effective Time</U>&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> <B>Certificate of Incorporation and Bylaws; Directors and Officers</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As of the Effective Time, the certificate of incorporation of the Company shall by virtue of the Merger and without any further action, be
amended and restated to read in its entirety as set forth on <U>Annex II</U> and, as so amended and restated, shall be the certificate of incorporation of the Surviving Corporation until thereafter changed or amended as provided therein or by
applicable Legal Requirements, subject to <U>Section</U><U></U><U>&nbsp;5.4(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the Effective Time, the bylaws of the
Surviving Corporation shall be amended and restated to conform to the bylaws of Merger Sub as in effect immediately prior to the Effective Time, until thereafter changed or amended as provided therein or by applicable Legal Requirements, subject to
<U>Section</U><U></U><U>&nbsp;5.4(a)</U>, except that references to the name of Merger Sub shall be replaced by references to the name of the Surviving Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As of the Effective Time, the directors and officers of the Surviving Corporation shall be the respective individuals who served as the
directors and officers of Merger Sub as of immediately prior to the Effective Time, until their respective successors are duly elected and qualified, or their earlier death, resignation or removal. Prior to the Effective Time, each director of the
Company immediately prior to the Effective Time shall execute and deliver a letter effectuating such director&#8217;s resignation as a member of the Board of Directors, conditioned upon and effective as of the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B> <B>Conversion of Shares</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any
stockholder of the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any Shares held immediately prior to the Effective Time by the Company (or held in the Company&#8217;s
treasury) shall be cancelled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)
any Shares held immediately prior to the Effective Time by Parent, Merger Sub or any other direct or indirect wholly owned Subsidiary of Parent or Merger Sub shall be cancelled and retired and shall cease to exist, and no consideration shall be
delivered in exchange therefor (such Shares together with the Shares described in the preceding <U>clause (i)</U>, the &#8220;<U>Excluded Shares</U>&#8221;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) except as provided in <U>clauses </U><U>(i)</U>&nbsp;and <U>(ii)</U> above and subject to <U>Section</U><U></U><U>&nbsp;1.5(b)</U>,
each Share outstanding immediately prior to the Effective Time (other than any Dissenting Shares, which shall have only those rights set forth in <U>Section</U><U></U><U>&nbsp;1.7</U>) shall be converted into the right to receive the Merger
Consideration, in each case without any interest thereon and subject to any withholding of Taxes in accordance with <U>Section</U><U></U><U>&nbsp;1.6(e)</U>; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) each share of the common stock, $0.001 par value per share, of Merger Sub then
outstanding shall be converted into one share of common stock of the Surviving Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From and after the Effective Time, subject to this
<U>Section</U><U></U><U>&nbsp;1.5(a)</U>, all Shares shall no longer be outstanding and shall automatically be cancelled and shall cease to exist, and each applicable holder of such Shares (other than Dissenting Shares) shall cease to have any
rights with respect thereto, except the right to receive the Merger Consideration therefor upon the surrender of such Shares in accordance with <U>Section</U><U></U><U>&nbsp;1.6</U>, or, in the case of Dissenting Shares, the rights set forth in
<U>Section</U><U></U><U>&nbsp;1.7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If, between the date of this Agreement and the Effective Time, the outstanding Shares are
changed into a different number or class of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction, then
the Merger Consideration shall be appropriately adjusted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B> <B>Surrender of Certificates; Stock Transfer Books</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Prior to the Closing Date, Parent shall designate a bank or trust company reasonably acceptable to the Company to act as agent (the
&#8220;<U>Paying Agent</U>&#8221;) for the holders of Shares to receive the aggregate Merger Consideration to which holders of such Shares shall become entitled pursuant to <U>Section</U><U></U><U>&nbsp;1.5</U>. Parent shall deposit, or shall cause
to be deposited, with the Paying Agent cash sufficient to pay the aggregate Merger Consideration as and when payable pursuant to <U>Section</U><U></U><U>&nbsp;1.5</U> (the &#8220;<U>Payment Fund</U>&#8221;). The Payment Fund shall not be used for
any purpose other than to pay the aggregate Merger Consideration in the Merger. The Payment Fund shall be invested by the Paying Agent as directed by Parent;<I> provided</I> that such investments shall be (w)&nbsp;in obligations of or guaranteed by
the United States of America, (x)&nbsp;in commercial paper obligations rated <FONT STYLE="white-space:nowrap">A-1</FONT> or <FONT STYLE="white-space:nowrap">P-1</FONT> or better by Moody&#8217;s Investors Service, Inc. or Standard&nbsp;&amp;
Poor&#8217;s Corporation, respectively, (y)&nbsp;in certificates of deposit, bank repurchase agreements or banker&#8217;s acceptances of commercial banks with capital exceeding $1&nbsp;billion, or (z)&nbsp;in money market funds having a rating in
the highest investment category granted by a recognized credit rating agency at the time of acquisition or a combination of the foregoing and, in any such case, no such instrument shall have a maturity exceeding three (3)&nbsp;months. To the extent
that (i)&nbsp;there are any losses with respect to any such investments or (ii)&nbsp;the Payment Fund has diminished for any reason below the level required for the Paying Agent to make prompt cash payment pursuant to
<U>Section</U><U></U><U>&nbsp;1.5</U>, Parent or the Surviving Corporation shall promptly replace or restore the cash in the Payment Fund so as to ensure that the Payment Fund is, at all times during the duration of the Payment Fund, maintained at a
level sufficient for the Paying Agent to promptly make such payments pursuant to <U>Section</U><U></U><U>&nbsp;1.5</U>. Parent shall not be required to deposit any funds related to any CVR with the Rights Agent unless and until such deposit is
required pursuant to the CVR Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the Effective Time (but in no event later than three (3)&nbsp;business
days thereafter), the Surviving Corporation shall cause to be delivered to each Person who was, at the Effective Time, a holder of record of (i)&nbsp;Shares represented by a certificate evidencing such Shares (&#8220;<U>Certificated
Shares</U>&#8221;) or (ii)&nbsp;Book-Entry Shares, who, in each case <U>(i)</U>&nbsp;and <U>(ii)</U> was entitled to receive the Merger Consideration pursuant to <U>Section</U><U></U><U>&nbsp;1.5</U>, (A)&nbsp;a form of letter of transmittal, which
shall be in reasonable and customary form and shall specify that delivery shall be effected, and risk of loss and title to the Certificated Shares shall pass, only upon proper delivery of the certificates evidencing such Certificated Shares (the
&#8220;<U>Certificates</U>&#8221;) (or affidavits of loss in lieu thereof and the posting of a customary bond in accordance with <U>Section</U><U></U><U>&nbsp;1.6(f)</U>, if applicable) to the Paying Agent, or a customary agent&#8217;s message with
respect to Book-Entry Shares, and (B)&nbsp;instructions for use in effecting the surrender of the Certificates or Book-Entry Shares in exchange for the Merger Consideration payable in respect of such Shares pursuant to
<U>Section</U><U></U><U>&nbsp;1.5</U>. Upon surrender to the Paying Agent of Certificates (or affidavits of loss in lieu thereof and the posting of a customary bond in accordance with <U>Section</U><U></U><U>&nbsp;1.6(f)</U>, if applicable) or
Book-Entry Shares, together with such letter of transmittal in the case of Certificates, duly completed and validly executed in accordance with the instructions thereto, and such other documents as may be required pursuant to the instructions, the
holder of such Certificated Shares or Book-Entry Shares shall be entitled to receive in exchange therefor the Merger Consideration for each Certificated Share or Book-Entry Share, and such Certificates and Book-Entry Shares shall then be cancelled.
No interest shall accrue or be paid on the Merger Consideration payable upon the surrender of any Certificates or Book-Entry Shares for the benefit of the holder thereof. If the payment of any Merger Consideration is to be made to a Person other
than the Person in whose name the surrendered Certificates formerly evidencing the Certificated Shares is registered on the stock transfer books of the Company, it shall be a condition of payment that the Certificate so surrendered shall be endorsed
properly or otherwise be in proper form for transfer and that the Person requesting such payment shall have paid all transfer and other similar Taxes required by reason of the payment of the Merger Consideration to a Person other than the registered
holder of the Certificate surrendered, or shall have established to the satisfaction of the Surviving Corporation that such transfer or other Taxes either have been paid or are not applicable. None of Parent, Merger Sub or the Surviving Corporation
shall have any liability for the transfer and other similar Taxes described in this <U>Section</U><U></U><U>&nbsp;1.6(b)</U> under any circumstance. Payment of the applicable Merger Consideration with respect to Book-Entry Shares shall only be made
to the Person in whose name such Book-Entry Shares are registered. Until surrendered as contemplated by this <U>Section</U><U></U><U>&nbsp;1.6</U>, each Certificated Share and Book-Entry Share (in each case, other than Dissenting Shares) shall be
deemed at any time after the Effective Time to represent only the right to receive the Merger Consideration as contemplated by <U>Section</U><U></U><U>&nbsp;1.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At any time following twelve (12)&nbsp;months after the Effective Time, Parent shall be entitled to require the Paying Agent to deliver to
it any funds (with respect to the aggregate Merger Consideration to which holders of Shares shall become entitled pursuant to <U>Section</U><U></U><U>&nbsp;1.5</U>) which had been made available to the Paying Agent and not disbursed to holders of
Certificated Shares or Book-Entry Shares, (including all interest and other income received by the Paying Agent in respect of all funds made available to it), and, thereafter, such holders shall be entitled to look to the Surviving Corporation
(subject to abandoned property, escheat and other similar Legal Requirements) only as general creditors thereof with respect to the Merger Consideration that may be payable upon due surrender of the Certificates or Book-Entry Shares held by them,
without any interest thereon. Notwithstanding the foregoing, neither the Surviving </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation nor the Paying Agent shall be liable to any holder of Certificated Shares or Book-Entry Shares for the Merger Consideration delivered in respect of such Share to a public official
pursuant to any abandoned property, escheat or other similar Legal Requirements. Any amounts remaining unclaimed by such holders at such time at which such amounts would otherwise escheat to or become property of any Governmental Body shall become,
to the extent permitted by applicable Legal Requirements, the property of the Surviving Corporation or its designee, free and clear of all claims or interest of any Person previously entitled thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) At the close of business on the day of the Effective Time, the stock transfer books of the Company with respect to the Shares shall be
closed and thereafter there shall be no further registration of transfers of Shares on the records of the Company. From and after the Effective Time, the holders of the Shares outstanding immediately prior to the Effective Time shall cease to have
any rights with respect to such Shares except as otherwise provided herein or by applicable Legal Requirements. If, after the Effective Time, Certificates or Book-Entry Shares are presented to the Surviving Corporation for any reason, they shall be
cancelled and exchanged as provided in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Each of the Company, the Surviving Corporation, Parent and Merger Sub, and
their Affiliates, shall be entitled to deduct and withhold (or cause the Paying Agent or the Rights Agent to deduct and withhold) from the Merger Consideration payable to any holder of the Shares or Company Equity Awards or any other amount
otherwise payable pursuant to this Agreement or the CVR Agreement such amounts as it is required by any Legal Requirement to deduct and withhold with respect to Taxes. Any compensatory amounts payable pursuant to or as contemplated by this Agreement
shall be remitted to the applicable payor for payment to the applicable Person through regular payroll procedures, as applicable. Each such withholding agent shall take all action that may be necessary to ensure that any such amounts so withheld are
timely and properly remitted to the appropriate Governmental Body. To the extent that amounts are so withheld and remitted to the appropriate Governmental Body, such withheld amounts (not including any such additional amounts caused by the
withholding agent&#8217;s failure to timely and properly remit the deducted or withheld amount to the appropriate Governmental Body) shall be treated for all purposes of this Agreement or the CVR Agreement as having been paid to the holder of the
Shares, holder of Company Equity Awards or other recipient of consideration hereunder in respect of which such deduction and withholding was made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the holder of the
Certificated Shares formerly represented by that Certificate, or by a representative of that holder, claiming that Certificate to be lost, stolen or destroyed and, if required by the Surviving Corporation, the posting by that holder of a bond, in
such reasonable amount as Parent may direct, as indemnity against any claim that may be made against it with respect to such Certificate (which amount shall not exceed the Merger Consideration payable with respect to such Certificated Shares), the
Paying Agent will pay (less any amounts entitled to be deducted or withheld pursuant to <U>Section</U><U></U><U>&nbsp;1.6(e)</U>), in exchange for such lost, stolen or destroyed Certificate, the applicable Merger Consideration to be paid in respect
of the Certificated Shares formerly represented by such Certificate, as contemplated by this <U>Section</U><U></U><U>&nbsp;1</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B> <B>Dissenters</B><B>&#8217;</B><B> Rights</B>. Notwithstanding anything to the
contrary in this Agreement, any Shares outstanding immediately prior to the Effective Time which are held by holders who are entitled to appraisal rights under Section&nbsp;262 of the DGCL and have properly exercised and perfected their respective
demands for appraisal of such Shares in the time and manner provided in Section&nbsp;262 of the DGCL and, as of the Effective Time, have neither effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL (the
&#8220;<U>Dissenting Shares</U>&#8221;), shall not be converted into the right to receive the Merger Consideration, but shall, by virtue of the Merger, be automatically cancelled and no longer outstanding, shall cease to exist and shall be entitled
to only such consideration as shall be determined pursuant to Section&nbsp;262 of the DGCL; <I>provided </I>that if any such holder shall have failed to perfect or shall have effectively withdrawn or lost such holder&#8217;s right to appraisal and
payment under the DGCL, such holder&#8217;s Shares shall be deemed to have been converted as of the Effective Time into the right to receive the Merger Consideration (less any amounts entitled to be deducted or withheld pursuant to
<U>Section</U><U></U><U>&nbsp;1.6(e)</U>), and such Shares shall no longer be deemed to be Dissenting Shares. The Company shall give prompt notice to Parent and Merger Sub of any demands received by the Company for appraisal of any Shares,
withdrawals of such demands and any other instruments served pursuant to Section&nbsp;262 of the DGCL, in each case prior to the Effective Time. Parent and Merger Sub shall have the right to participate in and, after the Effective Time, control all
negotiations and proceedings with respect to such demands, and the Company shall not, without the prior written consent of Parent and Merger Sub (which consent shall not be unreasonably withheld, conditioned or delayed), settle or offer to settle,
or make any payment with respect to, any such demands, approve any withdrawal of any such demands or agree or commit to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B> <B>Treatment of Company Equity Awards and Company ESPP</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, each Company Option that is then outstanding and unexercised, whether or not vested, and which has a per Share
exercise price that is less than the Closing Consideration (each, an &#8220;<U>In the Money Option</U>&#8221;), shall be (i)&nbsp;deemed fully vested and (ii)&nbsp;cancelled and converted into the right of the holder thereof to receive (i)&nbsp;a
cash payment (without interest and less applicable Tax withholdings and other authorized deductions) equal to the product of (A)&nbsp;the excess of (x)&nbsp;the Closing Consideration over (y)&nbsp;the per Share exercise price of such <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">In-the-Money</FONT></FONT> Option, multiplied by (B)&nbsp;the total number of Shares subject to such
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">In-the-Money</FONT></FONT> Option immediately prior to the Effective Time, which shall be payable in accordance with <U>Section</U><U></U><U>&nbsp;1.8(d)</U> and (ii)&nbsp;one (1) CVR
for each Share subject to such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">In-the-Money</FONT></FONT> Option immediately prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At the Effective Time, each Company Option that is then outstanding and unexercised, whether or not vested, and which has a per Share
exercise price that equals or exceeds the Closing Consideration (each, an &#8220;Out of the Money Option&#8221;), to the extent not vested, will become fully vested as of prior to the Effective Time, and the Company shall permit the holders of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-the-Money</FONT></FONT></FONT> Options to exercise such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Out-of-the-Money</FONT></FONT></FONT> Options prior to the Effective Time on a basis that allows such holders to participate in the Merger with respect to any Shares acquired under such <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-the-Money</FONT></FONT></FONT> Options as a holder of Shares, with any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-the-Money</FONT></FONT></FONT> Options that remain outstanding and unexercised as of the Effective Time cancelled for no consideration at the
Effective Time, without any action on the part of Parent, the Company or any other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At the Effective Time, each then outstanding Company RSU shall be (i)&nbsp;deemed fully
vested and (ii)&nbsp;cancelled and converted into the right of the holder thereof to receive (i)&nbsp;a cash payment (without interest and less applicable Tax withholdings and other authorized deductions) equal to the product of (A)&nbsp;the Closing
Consideration multiplied by (B)&nbsp;the number of Shares subject to such Company RSU immediately prior to the Effective Time, which shall be payable in accordance with <U>Section</U><U></U><U>&nbsp;1.8(d)</U>, and (ii)&nbsp;one (1) CVR for each
Share subject to such Company RSU immediately prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As soon as reasonably practicable (but in any event no
later than the second payroll date) after the Effective Time or as soon as reasonably practicable following the date the Approval Milestone Payment is made in respect of a CVR, as applicable, the Surviving Corporation shall pay the Company Equity
Award holders through its payroll system, payroll provider or the Company&#8217;s standard accounts payable procedures, as applicable, all amounts required to be paid to such holders in respect of In the Money Options and Company RSUs that are
canceled and converted pursuant to this <U>Section</U><U></U><U>&nbsp;1.8</U>, less applicable Tax withholdings and other authorized deductions. Notwithstanding anything to the contrary in this Agreement, no Approval Milestone Payment that
constitutes nonqualified deferred compensation subject to Section&nbsp;409A of the Code shall be allocated or paid in respect of any Company Option or Company RSU, except to the extent permissible under Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)(iv)(A).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the extent a payment made pursuant to the timing set forth
in this <U>Section</U><U></U><U>&nbsp;1.8</U> would trigger a Tax or penalty under Section&nbsp;409A of the Code, such payment shall be made on the earliest date that payment would not trigger such Tax or penalty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Prior to the Effective Time, the Company, the Board of Directors or the applicable committee thereof, as applicable, shall take all
actions required to effect the transactions described in this <U>Section</U><U></U><U>&nbsp;1.8</U> and to terminate the Company Equity Plans effective immediately prior to, and contingent upon, the Effective Time with no further liability or
obligation with respect to any awards granted thereunder other than the right of the holders of Company Equity Awards to receive the consideration set forth in this <U>Section</U><U></U><U>&nbsp;1.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Board of Directors (or the applicable committee thereof) shall adopt resolutions or take such other actions as may be required to
(i)&nbsp;provide that (A)&nbsp;the commencement of any future offering period will be suspended following the date of this Agreement under the Company ESPP unless and until this Agreement is terminated, (B)&nbsp;there will be no increase in the
amount of participants&#8217; payroll deduction elections under the Company ESPP during the current offering period from those in effect as of the date of this Agreement, (C)&nbsp;no individuals shall commence participation in the Company ESPP
during the period from the date of this Agreement through the Effective Time, and (D)&nbsp;each outstanding purchase right issued pursuant to the Company ESPP shall be fully exercised on the earlier of (x)&nbsp;the scheduled purchase date for such
offering period and (y)&nbsp;the date that is no later than five (5)&nbsp;business days prior to the Effective Time (with any participant payroll deductions not applied to the purchase of Shares returned to the participant), and (ii)&nbsp;terminate
the Company ESPP effective immediately prior to, and contingent upon, the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B> <B>Further Action</B>. If, at any time after the Effective Time, any further
action is reasonably determined by Parent to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and property of Merger Sub and the
Company, the officers and directors of the Surviving Corporation and Parent shall be fully authorized (in the name of Merger Sub, in the name of the Company and otherwise) to take such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B> <B>Certain Tax Deliverables</B>. Unless prohibited by applicable Law, at the Closing, the Company shall deliver to Parent and
Merger Sub a properly executed certification that complies with the requirements under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1445-2(c)(3),</FONT> and a properly executed notice to the Internal Revenue Service in
accordance with the requirements of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h)(2),</FONT> in each case, dated as of the Closing Date and in a form reasonably acceptable to Parent. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REPRESENTATIONS AND WARRANTIES OF THE COMPANY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents and warrants to Parent and Merger Sub as follows (it being understood that each representation and warranty
contained in this <U>Section</U><U></U><U>&nbsp;2</U> is subject to (a)&nbsp;exceptions and disclosures set forth in the section or subsection of the Company Disclosure Schedule corresponding to the particular section or subsection in this
<U>Section</U><U></U><U>&nbsp;2</U>; (b) any exception or disclosure set forth in any other section or subsection of the Company Disclosure Schedule to the extent it is reasonably apparent that such exception or disclosure is applicable to qualify
such other section or subsection; and (c)&nbsp;disclosure in the Company SEC Documents filed after January&nbsp;1, 2025 and publicly available prior to the close of business on the third (3rd) business day preceding the date of this Agreement (other
than any information in the &#8220;Risk Factors&#8221; or &#8220;Forward-Looking Statements&#8221; sections of such Company SEC Documents or other general cautionary or forward-looking statements in any other sections of such Company SEC
Documents)); <I>provided</I> that (i)&nbsp;<U>clauses (b)</U> and <U>(c)</U>&nbsp;of this paragraph shall not apply to the representation and warranty set forth in <U>Section</U><U></U><U>&nbsp;2.5(b)</U> (No Material Adverse Effect) and
(ii)&nbsp;<U>clause (c)</U> of this paragraph shall not apply to any of the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;2.1(a)</U> and <U>(b)</U> (Due Organization; Subsidiaries, Etc.),
<U>Section</U><U></U><U>&nbsp;2.3</U> (Capitalization, Etc.), <U>Section</U><U></U><U>&nbsp;2.21</U> (Authority; Binding Nature of Agreement), <U>Section</U><U></U><U>&nbsp;2.22</U> (Takeover Laws), or <U>Section</U><U></U><U>&nbsp;2.23</U> <FONT
STYLE="white-space:nowrap">(Non-Contravention;</FONT> Consents): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Due Organization; Subsidiaries, Etc</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and the
Company&#8217;s only Subsidiary is set forth on <U>Section</U><U></U><U>&nbsp;2.1</U> of the Company Disclosure Schedule (the Company and its Subsidiary, each an &#8220;<U>Acquired Corporation</U>&#8221; and collectively, the &#8220;<U>Acquired
Corporations</U>&#8221;). Each Acquired Corporation has all necessary power and authority: (i)&nbsp;to conduct its business in the manner in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which its business is currently being conducted; and (ii)&nbsp;to own and use its assets in the manner in which its assets are currently owned and used. Each Acquired Corporation is qualified or
licensed to do business as a foreign corporation, and is in good standing, in each jurisdiction where the nature of its business requires such qualification or licensing, except where such failure does not have, and would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect. The Company&#8217;s Subsidiary is duly organized, validly existing and in good standing under the laws of Massachusetts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company owns beneficially and of record all of the outstanding shares of capital stock of the other Acquired Corporations, free and
clear of all Encumbrances and transfer restrictions, except for Encumbrances or transfer restrictions of general applicability as may be provided under the Securities Act or applicable securities laws. Except for the shares of capital stock of the
other Acquired Corporations held by the Company, no Acquired Corporation owns, directly or indirectly, any capital stock or equity interests of, or subscriptions, options, calls, warrants or rights (whether or not currently exercisable) to acquire,
or other securities convertible into or exchangeable or exercisable for, any capital stock or equity interests of, any Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B>
<B>Certificate of Incorporation and Bylaws</B>. The Company has delivered or made available to Parent accurate and complete copies of the certificate of incorporation, bylaws and other charter and organizational documents of each Acquired
Corporation, including all amendments thereto, as in effect on the date hereof.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Capitalization, Etc</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of the Company consists of: (i)&nbsp;150,000,000 Shares, of which 80,164,822 Shares had been issued and were
outstanding as of the close of business on October&nbsp;7, 2025 (the &#8220;<U>Reference Date</U>&#8221;); and (ii)&nbsp;10,000,000 shares of Company Preferred Stock, of which no shares are outstanding. All of the outstanding shares of the capital
stock of the Company have been duly authorized and validly issued, and are fully paid and nonassessable. Since the Reference Date through the date of this Agreement, the Company has not issued any new Shares or other Company Securities except upon
the vesting of Company RSUs outstanding as of the Reference Date or upon the exercise of Company Options or Company Warrants outstanding as of the Reference Date in accordance with their terms, and, since the Reference Date through the date of this
Agreement, the Company has not issued any Company Options, Company Warrants or other equity-based awards, in each case, other than pursuant to any offer of employment or Contract executed on or prior to the Reference Date and made available in the
Data Room. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding shares of the capital stock of the Company&#8217;s Subsidiary have been duly authorized and validly
issued and are fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) (i)&nbsp;None of the outstanding shares of capital stock of the Acquired Corporations
are entitled or subject to any preemptive right, right of repurchase or forfeiture, right of participation, right of maintenance or any similar right; (ii)&nbsp;none of the outstanding shares of capital stock of the Acquired Corporations are subject
to any right of first refusal in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
favor of any Acquired Corporation; (iii)&nbsp;there are no outstanding bonds, debentures, notes or other indebtedness of any Acquired Corporation having a right to vote on any matters on which
the stockholders of the Acquired Corporations have a right to vote; and (iv)&nbsp;there is no Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or from
granting any option or similar right with respect to), any shares of capital stock of the Acquired Corporations. No Acquired Corporation is under any obligation, or bound by any Contract pursuant to which it may become obligated, to repurchase,
redeem or otherwise acquire any outstanding shares of capital stock of the Acquired Corporations, except in connection with any acquisitions, or deemed acquisitions, of Shares or other equity securities of the Company in connection with (x)&nbsp;the
withholding of Taxes in connection with the exercise, vesting or settlement of Company Equity Awards and (y)&nbsp;forfeitures of Company Equity Awards. The Shares constitute the only outstanding class of securities of the Company registered under
the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As of the close of business on the Reference Date: (i) 7,351,422 Shares were issuable upon the exercise of
outstanding Company Options; (ii) 722,728 Shares were issuable upon the vesting or settlement of outstanding Company RSUs; (iii) 2,365,270 Shares remain available for future issuance under the Company ESPP; (iv) 10,824 Shares were issuable upon the
exercise of outstanding purchase rights for the current offering period under the Company ESPP (assuming a purchase price equal to the closing price of a Share on the first day of the offering period under the Company ESPP); (v) 64,257 Shares were
issuable upon the exercise of the Hercules Warrants; and (vi) 1,958,247 Shares were issuable upon the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. Other than as set forth in this <U>Section</U><U></U><U>&nbsp;2.3</U>,
there are no issued, reserved for issuance, outstanding or authorized stock option, stock appreciation, phantom stock, profit participation or similar rights or equity-based awards with respect the Company. Except for the Hercules Warrants and the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, there are no Company Warrants outstanding as of the close of business on the Reference Date. Other than the execution of this Agreement, there has been no event that would cause an adjustment to
the number of Shares issuable upon exercise, or the strike price of, the Company Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Section 2.3(e)</U> of the Company
Disclosure Schedule sets forth a schedule of each outstanding Company Equity Award as of the close of business on the Reference Date, including (i)&nbsp;the type of award (e.g., stock option, restricted stock unit, etc.), (ii) the number and class
of equity interests underlying such award, (iii)&nbsp;the name or identification number of the holder thereof, (iv)&nbsp;the grant date, and (v)&nbsp;the exercise price, if applicable. Each Company Equity Award was granted in accordance with the
terms of the applicable Company Equity Plan and in compliance with all applicable Legal Requirements, and each Company Option (i)&nbsp;has an exercise price that is no less than the fair market value of the Shares underlying such Company Option on
the grant date and (ii)&nbsp;does not constitute &#8220;nonqualified deferred compensation&#8221; for purposes of Section&nbsp;409A of the Code. No later than five (5)&nbsp;business days prior to the anticipated Closing Date, the Company shall
provide Parent with a revised version of the schedule required under this <U>Section</U><U></U><U>&nbsp;2.3(e)</U>, updated as of the date such updated schedule is delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Section</U><U> 2.3(f)</U> of the Company Disclosure Schedule sets forth a schedule of
each outstanding Company Warrant as of the Reference Date, including, for each Company Warrant, (i)&nbsp;the number of Shares subject thereto, (ii)&nbsp;the holder thereof, (iii)&nbsp;the issuance date, (iv)&nbsp;the exercise price and (v)&nbsp;the
expiration date, if applicable. No later than five (5)&nbsp;business days prior to the anticipated Closing Date, the Company shall provide Parent with a revised version of the listing required under this <U>Section</U><U></U><U>&nbsp;2.3(f)</U>,
updated as the date such updated schedule is delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) There are no issued, reserved for issuance, outstanding or authorized stock
option, stock appreciation, phantom stock, profit participation or similar rights or equity-based awards with respect to any Subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Except (x)&nbsp;as set forth in this <U>Section</U><U></U><U>&nbsp;2.3</U>, (y) for the Company Equity Awards outstanding as of the date
of this Agreement and purchase rights under the Company ESPP and (z)&nbsp;the Company Warrants, there are no: (i)&nbsp;outstanding shares of capital stock of or other securities of any Acquired Corporation; (ii)&nbsp;outstanding subscriptions,
options, calls, warrants or rights (whether or not currently exercisable) to acquire any shares of the capital stock, restricted stock unit, stock-based performance unit, equity-based, incentive equity or any other right that is linked to, or the
value of which is in any way based on or derived from the value of any shares of capital stock or other securities of any Acquired Corporation, in each case other than derivative securities not issued by an Acquired Corporation;
(iii)&nbsp;outstanding securities, instruments, bonds, debentures, notes or obligations that are or may become convertible into or exchangeable for any shares of the capital stock or other securities of any Acquired Corporation; or
(iv)&nbsp;stockholder rights plans (or similar plans commonly referred to as a &#8220;poison pill&#8221;) or Contracts under which any Acquired Corporation is or may become obligated to sell or otherwise issue any shares of its capital stock or any
other securities (<U>clauses (i)</U>&nbsp;through <U>(iv)</U>, collectively, the &#8220;<U>Company Securities</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B>
<B>SEC Filings; Financial Statements</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since January&nbsp;1, 2022, the Company has filed or furnished on a timely basis all
reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated therein) required to be filed or furnished by the Company with the SEC (as supplemented, modified or amended since the time of
filing, the &#8220;<U>Company SEC Documents</U>&#8221;). No Subsidiary of the Company is required to file any form, report, registration statement, schedule, statement, exhibit or other document with the SEC. As of their respective dates, or, if
amended prior to the date of this Agreement, as of the date of (and giving effect to) the last such amendment (and, in the case of registration statements and proxy statements, on the date of effectiveness and the dates of the relevant meetings,
respectively), the Company SEC Documents complied in all material respects with the requirements of the Securities Act, the Exchange Act or the Sarbanes-Oxley Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder
applicable to those Company SEC Documents, and, except to the extent that information contained in such Company SEC Document has been revised, amended, modified or superseded (prior to the date of this Agreement) by a later filed Company SEC
Document, none of the Company SEC Documents when filed or furnished contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The financial statements (including any related notes and schedules) contained or
incorporated by reference in the Company SEC Documents: (i)&nbsp;complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii)&nbsp;were prepared in accordance with United States generally
accepted accounting principles (&#8220;<U>GAAP</U>&#8221;) applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited interim financial statements,
as may be permitted by the SEC on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> <FONT STYLE="white-space:nowrap">8-K</FONT> or any successor form under the Exchange Act); and (iii)&nbsp;fairly presented, in all material respects, the financial
position of the Company as of the respective dates thereof and the results of operations and cash flows of the Company for the periods covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company maintains, and at all times since January&nbsp;1, 2022 has maintained, a system of internal control over financial reporting
(as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the Exchange Act) which is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, and includes those policies and procedures that: (i)&nbsp;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;
(ii)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and that receipts and expenditures are being made only in accordance with authorizations of
management and the Board of Directors; and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of the Company that could have a material effect on the
financial statements. The Company&#8217;s management has completed an assessment of the effectiveness of the Company&#8217;s system of internal control over financial reporting in compliance with the requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act for the fiscal year ended December&nbsp;31, 2024, and, except as set forth in the Company SEC Documents filed prior to the date of this Agreement, that assessment concluded that those controls were effective. To the knowledge of
the Company, since January&nbsp;1, 2025, neither the Company nor the Company&#8217;s independent registered accountant has identified or been made aware of: (1)&nbsp;any significant deficiency or material weakness in the design or operation of the
internal control over financial reporting utilized by the Company, which is reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information; (2)&nbsp;any fraud, whether or not
material, that involves the management or other employees of the Company who have a significant role in the Company&#8217;s internal control over financial reporting; or (3)&nbsp;any claim or allegation of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company maintains, and at all times since January&nbsp;1, 2022 has maintained, disclosure controls and procedures as defined in and
required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> or <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act that are reasonably designed to ensure that all information required to be disclosed in the Company&#8217;s
reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that all such information is accumulated and communicated to the
Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure and to enable the principal executive officer of the Company and the principal financial officer of the Company to make the certifications required
under the Exchange Act with respect to such reports. The Company is in compliance in all material respects with all current listing and corporate governance requirements of Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company is not a party to, nor does it have any obligation or other commitment to
become a party to, <FONT STYLE="white-space:nowrap">&#8220;off-balance</FONT> sheet arrangements&#8221; (as defined in Item 303(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Exchange Act) where the result, purpose or
intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Company in the Company SEC Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to
the Company SEC Documents. None of the Company SEC Documents is the subject of ongoing SEC review, and there are no inquiries or investigations by the SEC or any internal investigations pending or threatened, in each case regarding any accounting
practices of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Each document required to be filed by the Company with the SEC in connection with the Transactions,
including the Merger Proxy Statement, when filed, distributed or otherwise disseminated to the Company&#8217;s stockholders, as applicable, will comply as to form in all material respects with the applicable requirements of the Exchange Act. The
Merger Proxy Statement, at the time of the filing of such Merger Proxy Statement or any supplement or amendment thereto with the SEC and at the time such Merger Proxy Statement or any supplements or amendments thereto are first distributed or
otherwise disseminated to the Company&#8217;s stockholders and at the time of the Company Stockholder Meeting, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in
order to make the statements made therein, in light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Notwithstanding
the foregoing, the Company makes no representation with respect to statements made or incorporated by reference therein based on information supplied by or on behalf of Parent or Merger Sub, specifically for inclusion or incorporation by reference
in the Merger Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B>Absence of Changes</B><B>; No Material Adverse Effect</B>. From January&nbsp;1, 2025 through
the date of this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) except for discussions, negotiations and activities related to this Agreement or other potential
strategic transactions, the Acquired Corporations have operated in all material respects in the ordinary course of business consistent with past practice and (ii)&nbsp;no Acquired Corporation has taken any action that would have constituted a breach
of <U>Section</U><U></U><U>&nbsp;4.2(b)</U> had such action been taken after the execution of this Agreement without the prior consent of Parent; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) there has not occurred any event, occurrence, circumstance, change or effect that, individually or in the aggregate, has had or would
reasonably be expected to have, a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B> <B>Title to Assets</B>. Each Acquired Corporation has good and valid title to all
material assets (excluding Intellectual Property Rights) set forth in its most recent financial statements or otherwise purported to be owned by an Acquired Corporation, and such assets are owned by the Acquired Corporations free and clear of any
Encumbrances (other than Permitted Encumbrances). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7</B> <B>Real Property</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Acquired Corporations do not own any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Section 2.7(b)</U> of the Company Disclosure Schedule sets forth an accurate and complete list in all material respects of all real
property currently leased, subleased or licensed by or from the Acquired Corporations or otherwise used or occupied by the Acquired Corporations. The Acquired Corporations hold valid and existing leasehold interests in the real property that is
leased or subleased by the Acquired Corporations from another Person (the &#8220;<U>Leased Real Property</U>&#8221;), free and clear of all Encumbrances other than Permitted Encumbrances. There are no outstanding options, rights of first offer or
rights of first refusal in favor of any other party to purchase or lease the Leased Real Property or any portion thereof or interest therein. Since January&nbsp;1, 2022, no Acquired Corporation has received any written notice regarding any material
violation or breach or default under any lease related to the Leased Real Property that has not since been cured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8</B>
<B>Intellectual Property</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section 2.8(a)</U> of the Company Disclosure Schedule sets forth a complete and accurate (in all
material respects) list, as of the date of this Agreement, of all Patents, Trademarks and Copyrights included within Company IP that are registered or issued under the authority of any Governmental Body, and all applications for any of the foregoing
(the foregoing, the &#8220;<U>Company Registered IP</U>&#8221;), including for each item (i)&nbsp;the name of the current record owner, (ii)&nbsp;the jurisdiction of application or registration and (iii)&nbsp;the application or registration number,
and all such Patents, Trademarks and Copyrights included therein are subsisting and, to the knowledge of the Company, other than pending applications therefor, valid and enforceable. As of the date of this Agreement, no interference, opposition,
reissue, reexamination proceeding, cancellation proceeding, or other Legal Proceeding (other than routine examination proceedings with respect to pending applications) is pending or, to the knowledge of the Company, threatened in writing against any
Acquired Corporation, (i)&nbsp;in which the scope, validity, enforceability, priority, inventorship or ownership of any Company Owned IP or Company <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP exclusively licensed to any Acquired
Corporation is being contested or challenged or (ii)&nbsp;based upon, or challenging, or seeking to deny or restrict, any right of any Acquired Corporation in any of the Company IP. All registration, maintenance and renewal fees applicable to any
Company Registered IP that are currently due have been paid, and all documents related thereto have been timely filed with the relevant Governmental Body for the purposes of maintaining such items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Acquired Corporations (i)&nbsp;are the sole and exclusive owners of, and have good
and valid title to, all Company Owned IP, free and clear of all Encumbrances other than Permitted Encumbrances, and (ii)&nbsp;own, or have a valid and enforceable license to use, all Intellectual Property Rights necessary for, or used or held for
use in, the conduct of the business of the Acquired Corporations as presently conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the knowledge of the Company, (i)&nbsp;no
funding, facilities or personnel of any Governmental Body, university, research institute or other educational institution has been used to develop any of the material Company Owned IP or Company <FONT STYLE="white-space:nowrap">In-Licensed</FONT>
IP exclusively licensed to any Acquired Corporation, nor (ii)&nbsp;has any such Company IP been developed pursuant to, or in connection with, a Contract between an Acquired Corporation, on the one hand, and a Governmental Body, university, research
institute or other educational institution, on the other hand, with respect to <U>clauses (i)</U>-<U>(ii)</U>, except for any such Contract, funding or use of facilities or personnel that does not result in such Governmental Body, university,
research institute or other educational institution, having any right, title, or interest to such Intellectual Property Rights (including any &#8220;march in&#8221; or <FONT STYLE="white-space:nowrap">co-ownership</FONT> rights). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Acquired Corporations have taken reasonable steps to maintain the confidentiality of Trade Secrets included in the Company IP and, to
the knowledge of the Company, there has not been any disclosure of or access to any such Trade Secrets in a manner that has resulted in the loss of trade secret or other similar rights in and to such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the knowledge of the Company, the operation of the Acquired Corporations&#8217; business as currently conducted does not infringe,
misappropriate or otherwise violate, and has not infringed, misappropriated or otherwise violated, any Intellectual Property Rights owned by any other Person. As of the date of this Agreement, (i)&nbsp;no Legal Proceeding is pending (or threatened
in writing or, to the knowledge of the Company, otherwise threatened) against an Acquired Corporation alleging infringement, misappropriation or other violation of any Intellectual Property Rights of another Person and (ii)&nbsp;since
January&nbsp;1, 2022, to the knowledge of the Company, no Acquired Corporation has received any written notice or other written communication alleging infringement, misappropriation or other violation of any Intellectual Property Right of another
Person by an Acquired Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To the knowledge of the Company, no Person is infringing, misappropriating or otherwise violating,
and no Person has infringed, misappropriated or otherwise violated, any Company Owned IP or Company <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP exclusively licensed to any Acquired Corporation. As of the date of this Agreement, no Legal
Proceeding is pending or threatened in writing by an Acquired Corporation alleging infringement, misappropriation or other violation of any Company Owned IP or Company <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP exclusively licensed to
any Acquired Corporation by any Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) There exist no restrictions on the disclosure, use, license or transfer of any Company Owned
IP or, to the knowledge of the Company, any Company <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP. The consummation of the Transactions will not alter, encumber, impair or extinguish any Company Owned IP or any Acquired Corporation&#8217;s
rights under any Company <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) All founders, key employees and any other employees involved in the development of
Company Owned IP have signed confidentiality and invention assignment agreements or similar agreements for the transfer or assignment of such Company Owned IP with an Acquired Corporation pursuant to which such Acquired Corporation has obtained
ownership of and are the exclusive owners of such Company Owned IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Except as has not had, and would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect, (i)&nbsp;the Company IT Assets operate and perform in a manner that permits the Acquired Corporations to conduct their businesses as currently conducted, (ii)&nbsp;the Acquired
Corporations have taken commercially reasonable actions, consistent with current industry standards, to protect the confidentiality, integrity and security of the Company IT Assets (and all information and transactions stored therein or transmitted
thereby) against any unauthorized use, access, interruption, modification or corruption and (iii)&nbsp;to the knowledge of the Company, there has been no unauthorized use, access, interruption, modification, corruption, damage, disclosure, loss or
other misuse of any Company IT Assets (or any information or transactions stored therein or transmitted thereby). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.9</B>
<B>Contracts</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section 2.9(a)</U> of the Company Disclosure Schedule identifies each Contract to which any Acquired Corporation
is a party, or by which it is bound, that constitutes a Material Contract as of the date of this Agreement. For purposes of this Agreement, each of the following (excluding any Employee Plan) to which any Acquired Corporation is a party or by which
it is bound as of the date of this Agreement constitutes a &#8220;<U>Material Contract</U>&#8221;: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any Contract that is a settlement,
conciliation or similar agreement between any Acquired Corporation and any Governmental Body and pursuant to which (A)&nbsp;an Acquired Corporation will be required after the date of this Agreement to pay any monetary obligations or (B)&nbsp;that
contains material obligations or limitations on such Acquired Corporation&#8217;s conduct; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any Contract between any Acquired
Corporation and any third Person (A)&nbsp;materially&nbsp;limiting the freedom or right of any Acquired Corporation to engage in any line of business or to compete with any other Person in any location or line of business, (B)&nbsp;containing any
&#8220;most favored nations&#8221; terms and conditions (including with respect to pricing) granted by any Acquired Corporation, or (C)&nbsp;containing exclusivity obligations or otherwise materially limiting the freedom or right of any Acquired
Corporation (or, following the Closing, Parent or any of its Affiliates) to solicit, sell, distribute or manufacture any products or services for any other Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any Contract that requires by its terms or is reasonably expected to require the payment or delivery of cash or other consideration
(A)&nbsp;to any Acquired Corporation in an amount having an expected value in excess of $500,000 in the fiscal year ending December&nbsp;31, 2025 or (B)&nbsp;by any Acquired Corporation in an amount having an expected value in excess of $2,000,000
for the fiscal year ending December&nbsp;31, 2025 or any future fiscal year and, in the case of <U>clause (B)</U>, which cannot be cancelled by such Acquired Corporation without penalty or further payment without more than ninety
(90)&nbsp;days&#8217; notice (excluding any <FONT STYLE="white-space:nowrap">In-bound</FONT> License or <FONT STYLE="white-space:nowrap">Out-bound</FONT> License); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any Contract relating to Indebtedness in an aggregate principal amount in excess of
$500,000 (whether incurred, assumed, guaranteed or secured by any asset); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any Contract between an Acquired Corporation and a third
Person (A)&nbsp;for the disposition of any material assets or business of the Acquired Corporations or (B)&nbsp;for the acquisition of a material portion of the assets or business of, or ownership interests in, any third Person (whether by merger,
sale of stock or assets or otherwise), in each case (A)&nbsp;or (B) that contains continuing indemnities or other material obligations or any continuing &#8220;earn out&#8221; or other royalties, milestone payments or similar contingent payment
obligations on the part of an Acquired Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any Contract between any Acquired Corporation and any third Person constituting
or relating to the formation, creation, operation, management or control of a joint venture, collaboration, partnership or similar revenue sharing arrangement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any Contract that by its express terms requires an Acquired Corporation, or any successor to, or acquirer of, an Acquired Corporation,
to make any payment to another Person as a result of a change of control of such Acquired Corporation (a &#8220;<U>Change of Control Payment</U>&#8221;) or gives another Person a right to receive or elect to receive a Change of Control Payment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) any Contract that prohibits the declaration or payment of dividends or distributions in respect of the capital stock of an Acquired
Corporation, the pledging of the capital stock or other equity interests of an Acquired Corporation or the issuance of any guaranty by an Acquired Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) any Contract pursuant to which an Acquired Corporation is granted any license or other right (including any option, right of first
refusal, other preferential right or covenant not to be sued) from a third Person under any Intellectual Property Right (each an &#8220;<U><FONT STYLE="white-space:nowrap">In-bound</FONT> License</U>&#8221;), or grants a license or other right
(including any option, right of first refusal, other preferential right or covenant not to be sued) to a third Person under any Intellectual Property Right owned, purported to be owned or exclusively
<FONT STYLE="white-space:nowrap">in-licensed</FONT> by an Acquired Corporation (each an &#8220;<U><FONT STYLE="white-space:nowrap">Out-bound</FONT> License</U>&#8221;) (<I>provided</I>, that, <FONT STYLE="white-space:nowrap">(a)&nbsp;In-bound</FONT>
Licenses shall exclude licenses for commercially available <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> software and agreements (including clinical trial, sponsored research and service agreements) in
which the license of Intellectual Property Rights is incidental to the performance of such Contract, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements or material transfer agreements, and
<FONT STYLE="white-space:nowrap">(b)&nbsp;Out-bound</FONT> Licenses shall exclude <FONT STYLE="white-space:nowrap">non-exclusive</FONT> outbound licenses granted in the ordinary course of business consistent with past practice and in which the
license of Intellectual Property Rights is incidental to the performance of such Contract (including, for clarity, such licenses contained in clinical trial agreements, manufacturing or supply agreements,
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements, sponsored research agreements, service agreements, or material transfer agreements)); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) any other Contract that is currently in effect and has been filed (or is required to be
filed) by the Company as an exhibit pursuant to Item 601(b)(10) of Regulation S- K under the Securities Act or that would be required to be disclosed under Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) any Contract with any Affiliate (other than another Acquired Corporation), director or executive officer (as such term is defined
in the Exchange Act) of the Company, Person holding five percent (5%) or more of the Shares, or, to the knowledge of the Company, any Affiliate (other than the Company) or immediate family member of any of the foregoing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) any Contract that is a lease to which the Leased Real Property is subject; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) any hedging, derivative or similar Contract (including interest rate, currency or commodity swap agreements, cap agreements, collar
agreements and any similar Contract designed to protect a Person against fluctuations in interest rates, currency exchange rates or commodity prices). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the date of this Agreement, the Company has either delivered or made available to Parent an accurate and complete copy of each
Material Contract or has publicly made available an unredacted version of such Material Contract in the Electronic Data Gathering, Analysis and Retrieval (&#8220;<U>EDGAR</U>&#8221;) database of the SEC. No Acquired Corporation nor, to the knowledge
of the Company, any other party thereto (i)&nbsp;is in material breach of, or material default under, any Material Contract or (ii)&nbsp;has taken or failed to take any action that with or without notice, lapse of time or both would constitute a
material breach of or material default under any Material Contract. Each Material Contract is, with respect to the Acquired Corporations and, to the knowledge of the Company, each other party thereto, a valid and binding agreement in full force and
effect, enforceable in accordance with its terms, except as such enforcement may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating to or affecting
creditors&#8217; rights, and by general equitable principles. Since January&nbsp;1, 2022, the Acquired Corporations have not received any written notice regarding any material violation or breach or default under any Material Contract that has not
since been cured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.10</B> <B>Liabilities</B>. The Acquired Corporations do not have any liabilities (whether accrued, absolute,
contingent or otherwise), except for: (i)&nbsp;liabilities reflected or reserved against in the most recent financial statements or notes thereto included in the Company SEC Documents filed prior to the date of this Agreement; (ii)&nbsp;liabilities
or obligations incurred pursuant to the terms of this Agreement; (iii)&nbsp;liabilities for performance of obligations under Contracts binding upon the Acquired Corporations (other than resulting from any breach or acceleration thereof) either
delivered or made available to Parent prior to the date of this Agreement or entered into in the ordinary course of business consistent with past practice; (iv)&nbsp;liabilities incurred in the ordinary course of business consistent with past
practice since January&nbsp;1, 2025 (none of which is a liability for breach of contract, breach of warranty, tort, infringement, violation of a Legal Requirement or that relates to any cause of action, claim or lawsuit); and (v)&nbsp;liabilities
that have not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.11</B> <B>Compliance with Legal Requirements</B>. The Acquired Corporations are, and
since January&nbsp;1, 2022 have been, in compliance with all applicable Legal Requirements and, since January&nbsp;1, 2022, no Acquired Corporation has been given written notice of, or been charged with, any violation of, any applicable Legal
Requirement, except, in each case, as would not be, individually or in the aggregate, material to the Acquired Corporations taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.12</B> <B>Regulatory Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Acquired Corporation is, and since January&nbsp;1, 2022 has been, in compliance in all material respects with all Health Care Laws
and Data Protection and Security Requirements, in each case as applicable to the operation of its business. No Acquired Corporation is subject to any ongoing enforcement, regulatory or administrative proceedings against such Acquired Corporation
alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Health Care Laws or similar Legal Requirements, and no such enforcement, regulatory or administrative proceeding has been threatened in writing. Since January&nbsp;1, 2022, no
Acquired Corporation has received any written notice or other communication from any Governmental Body alleging or asserting any material noncompliance with any applicable Health Care Law, including any warning letter, untitled letter, Form <FONT
STYLE="white-space:nowrap">FDA-483,</FONT> or similar written notice. The Company and the Acquired Corporations have implemented a compliance program that ensures compliance in all material respects with applicable Health Care Laws, Data Protection
and Security Requirements and industry standards, including, without limitation, ensuring that all compensation paid to health care professionals does not take into account the volume or value of any future potential business generated for the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Acquired Corporations hold all Regulatory Permits required for their business as currently conducted, and each such
Regulatory Permit is valid and in full force and effect. The Acquired Corporations are in compliance in all material respects with the terms and requirements of such Regulatory Permits. Since January&nbsp;1, 2022, there has been no material
violation of or default under any Regulatory Permits, and no material deficiencies have been asserted in writing by any applicable Governmental Body with respect to any Regulatory Permits of the Acquired Corporations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All preclinical and clinical investigations sponsored by or on behalf of the Acquired Corporations have been and are being conducted in
material compliance with applicable Health Care Laws, Data Protection and Security Requirements, clinical trial protocols, and other contractual or other requirements that regulate or limit the maintenance, use, disclosure, or transmission of
medical records, clinical trial data, patient information, or other Personal Data made available to or collected by or on behalf of any of the Acquired Corporations in connection with the operation of the Acquired Corporations&#8217; businesses. All
preclinical and clinical study results described in the Company SEC Documents or otherwise made available to Parent (including summaries thereof) are accurate and complete in all material respects and fairly present the data derived from such
studies in accordance with generally accepted industry standards and applicable Health Care Laws, and to the knowledge of the Company, there are no other studies or trials the results of, or other undisclosed data discrepancies, which are
inconsistent with or otherwise could reasonably be expected to discredit or call into question the results described or referred to therein. No Acquired Corporation has received any written notice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from the FDA or any other Governmental Body performing functions similar to those performed by the FDA, any institutional review board, or any clinical investigator with respect to any ongoing
clinical or preclinical studies or tests alleging a lack of material compliance with any Health Care Laws, imposing a clinical hold, or requiring or recommending the termination, suspension or material modification of such studies or tests. Since
January&nbsp;1, 2022, no Acquired Corporation has initiated any recall, safety alert, or investigator notice relating to an alleged lack of safety or material regulatory noncompliance of any of the Acquired Corporations&#8217; product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Acquired Corporations have filed with the FDA or any other Governmental Body performing functions similar to those performed by
the FDA all required material applications, filings, declarations, listings, registrations, reports or submissions. All such applications, filings, declarations, listings, registrations, reports or submissions were in material compliance with
applicable Health Care Laws when filed or have been supplemented in a subsequent filing, and no material deficiencies have been asserted in writing by any applicable Governmental Body with respect to any such filings, declarations, listings,
registrations, reports or submissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No Acquired Corporation has (i)&nbsp;made an untrue statement of a material fact or fraudulent
statement to the FDA or any Governmental Body, (ii)&nbsp;failed to disclose a material fact required to be disclosed to the FDA or (iii)&nbsp;committed any other act, made any statement or failed to make any statement, that (in any such case)
establishes a reasonable basis for the FDA to invoke its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Final Policy. As of the date of this Agreement, no Acquired Corporation is the subject of any pending or, to the
knowledge of the Company, threatened investigation by the FDA pursuant to its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Final Policy. No Acquired Corporation nor, to the knowledge of the Company, any officer,
employee, or agent of the Company, has been debarred, excluded from participation in federal healthcare programs or convicted of any crime or engaged in any conduct that would reasonably be expected to result in (A)&nbsp;debarment under 21 U.S.C.
&#167; 335a or any similar Legal Requirement or (B)&nbsp;exclusion under 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7</FONT> or any similar Legal Requirement. No Legal Proceeding that would reasonably be expected to result in such a
material debarment or exclusion are pending or, to the knowledge of the Company, threatened against the Acquired Corporations or any of its officers, employees or agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as set forth in <U>Section</U><U></U><U>&nbsp;2.12(f)</U> of the Company Disclosure Schedule, the Company has (i)&nbsp;obtained
from all clinical trial participants all consents required under applicable Health Care Laws and Data Protection and Security Requirements, and (ii)&nbsp;provided to all clinical trial participants all notices required under applicable Health Care
Laws and Data Protection and Security Requirements, to provide their Personal Data (including in pseudonymized or coded format) to Parent in connection with the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) To the knowledge of the Company, there are no clinical trial participant injuries that should have been reported but were not yet reported
to any applicable Governmental Body or institutional review board with respect to any clinical trials conducted by or on behalf of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Each of the Acquired Corporations has Processed and continues to Process all Personal
Data in compliance in all material respects with applicable Data Protection and Security Requirements, and each member of the Acquired Corporations has and continues to be in compliance with the DOJ Data Security Program to the extent that it
processes &#8220;bulk U.S. sensitive personal data&#8221; (as defined in the DOJ Data Security Program). To the Company&#8217;s knowledge, no member of the Acquired Corporations is under investigation by any Governmental Body for a violation of Data
Protection and Security Requirements with respect to Personal Data Processed by, or under the control of, the Acquired Corporations, or for violation of the DOJ Data Security Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Acquired Corporations have implemented and maintain reasonable and appropriate organizational, physical, administrative and technical
measures that are commercially reasonable for the Company&#8217;s stage of development in the industry in which the Acquired Corporations operate to protect the operation, confidentiality, integrity, and security of all Personal Data of the Acquired
Corporations, confidential information, and other data and information, in any format, generated or used in the conduct of the business, against unauthorized access, acquisition, interruption, alteration, modification, or use. The Acquired
Corporations have not experienced (nor have any third parties acting on behalf of the Acquired Corporations) any actual or alleged Security Incident, including any breach of unsecured Personal Data for which notification to individuals, the media,
or any Governmental Body is required under applicable Data Protection and Security Requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) No Acquired Corporation is a
&#8220;covered entity&#8221; or &#8220;business associate&#8221; as that term is defined in the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health and the
regulations promulgated thereunder governing privacy, security and breach notification obligations with respect to individually identifiable health information (&#8220;<U>HIPAA</U>&#8221;), and no Acquired Corporation has entered into any business
associate contracts as described in 45 C.F.R. &#167; 164.504(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.13</B> <B>Certain Business Practices</B>. No Acquired Corporation
nor, to the knowledge of the Company, any of its Representatives (in each case, acting in the capacity of a Representative of such Acquired Corporation) has (i)&nbsp;used any funds (whether of an Acquired Corporation or otherwise) for unlawful
contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii)&nbsp;made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns,
(iii)&nbsp;accepted any unlawful payments, or (iv)&nbsp;violated any provision of any Anti-Corruption Laws, Global Trade Laws or any rules or regulations promulgated thereunder, anti-money laundering laws or any rules or regulations promulgated
thereunder or any applicable Legal Requirement of similar effect. No Acquired Corporation has received any written communication from a Governmental Body that alleges any of the foregoing <U>clauses (i)</U>&nbsp;through <U>(iv)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.14</B> <B>Governmental Authorizations</B>. The Acquired Corporations hold all material Governmental Authorizations necessary to enable
the Acquired Corporations to conduct their business in the manner in which such business is currently being conducted. The material Governmental Authorizations held by the Acquired Corporations are valid and in full force and effect. The Acquired
Corporations are in compliance with the terms and requirements of such Governmental Authorizations, except as would not be, individually or in the aggregate, material to the Acquired Corporations taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.15</B> <B>Tax Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All income and other material Tax Returns required to be filed by or with respect to an Acquired Corporation with any Governmental Body
(the &#8220;<U>Company Returns</U>&#8221;) have been timely filed (taking into account any extension of time within which to file that are automatically granted under applicable Legal Requirement or obtained in the ordinary course of business
consistent with past practice) and all such Tax Returns are true, correct and complete in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All income and other
material Taxes of each Acquired Corporation (whether or not shown to be due and payable on any such Tax Return) have been timely paid, except any such Taxes being contested in good faith by appropriate proceedings and for which a reserve has been
established in accordance with GAAP in the financial statements included in the Company SEC Documents filed prior to the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) (i) There is no threatened (to the knowledge of the Company), pending or ongoing material deficiency, dispute, audit or claim concerning
any material Tax liability of any Acquired Corporation and (ii)&nbsp;no unresolved written claim has been received by any Acquired Corporation from any Governmental Body in any jurisdiction where such Acquired Corporation does not file material Tax
Returns or pay material Taxes with respect to a particular type of Tax that such Acquired Corporation is or may be required to file any Tax Returns or subject to material Taxes with respect to such type of Tax in that jurisdiction. No extension or
waiver of the statute of limitation period applicable to any material Company Returns has been granted and is currently in effect other than automatic extensions or waivers obtained in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No Acquired Corporation (i)&nbsp;has been a member of an affiliated group (within the meaning of Section&nbsp;1504(a) of the Code) filing
a consolidated federal income Tax Return or any similar affiliated, consolidated, combined or unitary group for U.S. state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax purposes (other than a group the common parent of which is or
was the Company or another Acquired Corporation), or (ii)&nbsp;has any material liability for the Taxes of any other Person (other than another Acquired Corporation) under <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> of the Treasury
Regulations (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> law), or as a transferee or successor, by contract (other than pursuant to commercial agreements not primarily related to Taxes and entered
into in the ordinary course of business) or otherwise pursuant to applicable Legal Requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) During the two (2)-year period ending
on the date hereof, none of the Acquired Corporations has been either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; in a distribution of stock intended to be governed in whole or in part by Section&nbsp;355 or
Section&nbsp;361 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No Acquired Corporation has participated in any &#8220;listed transaction&#8221; within
the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) No Acquired Corporation (or
any consolidated or combined group which includes any Acquired Corporation) will be required to include any material item of income in, or exclude any material item of deduction from, the computation of taxable income for any taxable period (or
portion thereof) ending after the Closing Date as a result of any (i)&nbsp;change in method of accounting for a taxable period (or portion thereof) ending on or prior to the Closing Date as a result of transactions or events occurring, or accounting
methods employed, prior to the Closing, (ii) &#8220;closing agreement&#8221; as described in Section&nbsp;7121 of the Code (or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax law)
executed prior to the Closing, (iii)&nbsp;installment sale or open transaction disposition made prior to the Closing, (iv)&nbsp;deferred revenue or advance payment received on or prior to the Closing Date, or (v)&nbsp;any intercompany transaction or
excess loss account described in Treasury Regulations under Section&nbsp;1502 of the Code (or any corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax law) entered into or incurred on or prior to
the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Adequate accruals and reserves in accordance with the applicable accounting standard (e.g., GAAP, IFRS) have been
made in the financial statements (with respect to all periods covered thereby) for all material Taxes not yet due and payable by or with respect to the Acquired Corporations for periods prior to the Closing Date.&nbsp;Since the latest date covered
by the financial statements, no material Tax liability has been incurred by or with respect to any Acquired Corporation outside the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) There are no material Encumbrances with respect to Taxes upon any of the assets or properties of any Acquired Corporation, other than
Permitted Encumbrances described in sentence (a)&nbsp;of the definition of &#8220;Permitted Encumbrances.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) All material Taxes
required to be withheld by an Acquired Corporation has been withheld and timely paid to the appropriate Governmental Body, and each Acquired Corporation has complied in all material respects with all related record keeping and information reporting
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Each Acquired Corporation has at all times been exclusively a resident for all Tax purposes in its country of
incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Except as disclosed in <U>Section</U><U></U><U>&nbsp;2.15(l)</U> to the Company Disclosure Schedule, no Acquired
Corporation is a party to any arrangement that is classified as a partnership for United States tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.16</B> <B>Employee
Matters</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Acquired Corporation is a party to any collective bargaining agreement or other labor-related Contract with a labor
union or other employee representative body representing any of its employees, and no employees of the Acquired Corporations are represented by any labor union or other labor organization with respect to their employment with the Acquired
Corporations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Since January&nbsp;1, 2022, there have been no labor disruptions or activities
(including any strike, lockout work slowdown, work stoppage, unfair labor practice charge, handbilling or union organizing activity) pending or, to the knowledge of the Company, threatened, by any employees of the Acquired Corporations with respect
to their employment with the Acquired Corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Acquired Corporation is, and since January&nbsp;1, 2022 has been, in
material compliance with all applicable Legal Requirements respecting employment and employment practices and terms and conditions of employment, including wages and hours and the classification and compensation of employees and independent
contractors. Since January&nbsp;1, 2022, the Acquired Corporations have not incurred, and would not reasonably be expected to incur, any material liability arising from the failure to pay wages (including overtime wages), the misclassification of
employees as consultants or independent contractors and/or the misclassification of employees as exempt from the requirements of the Fair Labor Standards Act or applicable Legal Requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No employee of an Acquired Corporation with the title of Senior Director or above has given notice to an Acquired Corporation that such
employee intends to terminate his or her employment within the twelve (12)-month period following the date hereof. To the knowledge of the Company, no employee, director, officer, independent contractor or other individual service provider is in
violation of any term of any employment, consulting or similar contract, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement or other restrictive covenant agreement in
effect as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) There are no, and since January&nbsp;1, 2022 there have been no, pending or, to the knowledge of the
Company, threatened against any Acquired Corporation (i)&nbsp;material Legal Proceedings concerning employment-related matters or (ii)&nbsp;(A) material acts, allegations or breaches of any policy of an Acquired Corporation or (B)&nbsp;material
settlements or similar <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-court</FONT></FONT> or <FONT STYLE="white-space:nowrap">pre-litigation</FONT> arrangements entered into by any Acquired Corporation, in the case of
<U>(A)</U>&nbsp;and <U>(B)</U> relating to sexual or other type of discrimination, harassment or misconduct involving any Acquired Corporation or any of their current or former employees, directors, officers, independent contractor or other
individual service providers, in respect to their employment or service with the Acquired Corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.17</B> <B>Employee
Plans</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Section 2.17(a)</U> of the Company Disclosure Schedule sets forth an accurate and complete list of each material
Employee Plan (other than (x)&nbsp;any employment agreement for <FONT STYLE="white-space:nowrap">non-executive</FONT> employees of the Acquired Corporations below the level of vice president
(&#8220;<U><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Employees</U>&#8221;), (y) equity grant notices, and related documentation, with respect to employees of the Acquired Corporations and (z)&nbsp;agreements with individual consultants,
in each case of <U>clauses (x)</U>&nbsp;through <U>(z)</U>, that does not materially deviate from the forms made available to Parent in accordance with this <U>Section</U><U></U><U>&nbsp;2.17(a)</U> and that are entered into in the ordinary course
of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business consistent with past practice). To the extent applicable, the Company has either delivered or made available to Parent prior to the execution of this Agreement with respect to each
material Employee Plan accurate, current and complete copies of: (i)&nbsp;all plan documents and all amendments thereto, and all related trust or other funding documents, and in the case of unwritten Employee Plans, written descriptions of the
material terms thereof, (ii)&nbsp;the current determination letter or opinion letter issued by the IRS, (iii)&nbsp;the most recent summary plan descriptions and any material modifications thereto, (iv)&nbsp;the three (3)&nbsp;most recent annual
report on Form 5500, including all schedules and attachments, (v)&nbsp;any trust agreements, custodial agreements, insurance policies, administrative agreements, advisory agreements and similar Contracts or funding arrangements, (vi)&nbsp;results of
<FONT STYLE="white-space:nowrap">non-discrimination</FONT> testing for each of the last three (3)&nbsp;years, (vii) all Forms <FONT STYLE="white-space:nowrap">1094-C</FONT> for any Acquired Corporation that served as an employing entity for each of
the last three (3)&nbsp;years and (viii)&nbsp;any <FONT STYLE="white-space:nowrap">non-routine</FONT> correspondence (including any applications or submissions under any voluntary correction programs) with any Governmental Body within the last three
(3)&nbsp;years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of the Acquired Corporations nor any other Person that is considered a single employer with any Acquired
Corporation under the Code or ERISA maintains, contributes to or is required to contribute to, or in the past six (6)&nbsp;years, maintained, contributed to or was required to contribute to, or has any liability (contingent or actual) with respect
to (i)&nbsp;a plan subject to Title IV of ERISA or Code Sections 412 or 430, including any &#8220;single employer&#8221; defined benefit plan or any &#8220;multiemployer plan,&#8221; each as defined in Section&nbsp;4001 of ERISA, (ii)&nbsp;a
&#8220;multiple employer plan&#8221; as described in Section&nbsp;413(c) of the Code or Section&nbsp;210 of ERISA or (iii)&nbsp;a &#8220;multiple employer welfare arrangement&#8221; as defined in Section&nbsp;3(40) of ERISA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Employee Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has obtained a favorable determination letter
(or opinion letter, if applicable) as to its qualified status under the Code and each trust created thereunder has been determined by the IRS to be exempt from Tax under the provisions of Section&nbsp;501(a) of the Code, and, to the knowledge of the
Company, there are no existing circumstances or any events that have occurred that would reasonably be expected to affect the qualified status of any such Employee Plan or result in any material liability to an Acquired Corporation. Each Employee
Plan is now and has been operated in compliance in all material respects with its terms and all applicable Legal Requirements, including but not limited to ERISA and the Code and all required contributions, distributions and premiums under each
Employee Plan for any period ending on or before the Closing Date that are not yet due have been made or properly accrued, to the extent required to be accrued under GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No Employee Plan obligates any Acquired Corporation to provide any current or former employee, director, officer, independent contractor
or other individual service provider (or any beneficiary or dependent thereof) any life insurance or medical or health benefits after his or her termination of employment or service with the Acquired Corporations, other than as required under Part 6
of Subtitle B of Title I of ERISA, Section&nbsp;4980B of the Code or any similar applicable Legal Requirement, and at the applicable employee&#8217;s, director&#8217;s, officer&#8217;s, independent contractor&#8217;s or other individual service
provider&#8217;s sole expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) There is no pending or, to the knowledge of the Company, threatened Legal Proceeding or
other material claim with respect to any Employee Plan (other than routine claims for benefits), and to the knowledge of the Company, no fact or circumstance exists that would be reasonably likely to give rise to any such Legal Proceeding or
material claim. No Employee Plan is, or within the last six (6)&nbsp;years has been, the subject of an examination or audit by a Governmental Body, or the subject of an application or filing under, or a participant in, a government-sponsored
amnesty, voluntary compliance, self-correction or similar program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as provided in <U>Section</U><U></U><U>&nbsp;1.8</U>, the
consummation of the Transactions (including in combination with other events or circumstances) will not (i)&nbsp;entitle any current or former employee, director, officer, independent contractor or other individual service provider of the Acquired
Corporations to severance pay or any other payment or benefit, (ii)&nbsp;accelerate the funding, time of payment or vesting, or increase the amount of, compensation or benefits due to any such employee, director, officer, independent contractor or
other individual service provider of the Acquired Corporations, (iii)&nbsp;limit or restrict the right of the Acquired Corporations, Parent, Merger Sub or any of their respective Affiliates to merge, amend or terminate any Employee Plan or any
related Contract, (iv)&nbsp;result in any forgiveness of indebtedness of any current or former employee, director, officer, independent contractor or other individual service provider of the Acquired Corporations, or (v)&nbsp;result in any amounts
payable or benefits provided to any current or former employee, director, officer, independent contractor or other individual service provider of the Acquired Corporations to fail to be deductible for federal income Tax purposes by virtue of
Section&nbsp;280G of the Code. No Person is entitled to any <FONT STYLE="white-space:nowrap">gross-up,</FONT> make-whole, indemnification, reimbursement or other additional payment from any Acquired Corporation in respect of any Tax or interest or
penalty related thereto under Section&nbsp;409A of the Code or Section&nbsp;4999 of the Code. The Company has provided to Parent prior to the date hereof calculations, prepared by an independent third-party valuation or other similar firm, regarding
whether any payments made or which may be made to &#8220;disqualified individuals&#8221; are &#8220;excess parachute payments&#8221;, as such terms are defined in Section&nbsp;280G of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.18</B> <B>Environmental Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Acquired Corporations are and since January&nbsp;1, 2022 have been in compliance with all applicable Environmental Laws, which
compliance includes obtaining, maintaining or complying with all Governmental Authorizations required under Environmental Laws for the operation of their business, except as would not be material to the Acquired Corporations taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There is no Legal Proceeding relating to or arising under any Environmental Law that is pending or, to the knowledge of the Company,
threatened against any Acquired Corporation or in respect of any Leased Real Property, except as would not be material to the Acquired Corporations taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Since January&nbsp;1, 2022, except as would not be material to the Acquired Corporations taken as a whole, no Acquired Corporation has
received any written notice, report or other information of or entered into any legally binding agreement, order, settlement, judgment, injunction or decree involving uncompleted, outstanding or unresolved material violations, liabilities or
requirements on the part of any Acquired Corporation relating to or arising under Environmental Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) There are and since January&nbsp;1, 2022 have been no Hazardous Materials present or
Releases on, at, under or from any property or facility, including the Leased Real Property, in a manner and concentration that would reasonably be expected to result in any material claim against or material liability of an Acquired Corporation
under any Environmental Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the knowledge of the Company, (i)&nbsp;no Person has been exposed to any Hazardous Material at a
property or facility of the Company at levels in excess of applicable permissible exposure levels; and (ii)&nbsp;there have been no allegations of or investigations into research misconduct (i.e., falsification or fabrication of data or plagiarism)
or material animal or human subject protection deficiencies with respect to any preclinical studies, tests or clinical trials conducted by or on behalf of any Acquired Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No Acquired Corporations has assumed, undertaken, or otherwise become subject to any material liability of another Person relating to
Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.19</B> <B>Insurance</B>. The Company has delivered or made available to Parent an accurate and complete copy of
all material insurance policies relating to the business, assets and operations of the Acquired Corporations. The Acquired Corporations maintain insurance coverage in such amounts and covering such risks as are in accordance in all material respects
with normal industry practice for companies of similar size and stage of development. To the knowledge of the Company, all such insurance policies are in full force and effect, no notice of cancellation or material modification has been received
(other than a notice in connection with ordinary renewals), and there is no existing material default or event which, with the giving of notice or lapse of time or both, would constitute a material default, by any insured thereunder. There is no
claim pending under any of the Company&#8217;s insurance policies as to which coverage has been questioned, denied or disputed by the underwriters of such policies, except as would not be, or would not reasonably be expected to be, material to the
Acquired Corporations taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.20</B> <B>Legal Proceedings; Orders</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) There are no Legal Proceedings pending and served (or, to the knowledge of the Company, pending and not served or threatened) against any
Acquired Corporation or, to the knowledge of the Company, against any present or former officer, director or employee of an Acquired Corporation in such individual&#8217;s capacity as such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the knowledge of the Company, there is no material order, writ, injunction or judgment to which an Acquired Corporation is subject.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the knowledge of the Company, no material investigation or review by any Governmental Body with respect to an Acquired Corporation
is pending or has been threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.21</B> <B>Authority; Binding Nature of Agreement</B>. The Company has the corporate
power and authority to execute and deliver and to perform its obligations under this Agreement and to consummate the Transactions, including the Merger, subject to the adoption of this Agreement by holders of at least a majority of the outstanding
Shares (the &#8220;<U>Company Stockholder Approval</U>&#8221;). The Board of Directors has unanimously (a)&nbsp;determined that this Agreement and the Transactions, including the Merger, are advisable and fair to, and in the best interest of, the
Company and its stockholders, (b)&nbsp;declared it advisable to enter into this Agreement, (c)&nbsp;approved the execution, delivery and performance by the Company of this Agreement and the consummation of the Transactions, including the Merger,
(d)&nbsp;resolved that the Merger shall be governed by Section&nbsp;251(c) of the DGCL, upon the terms and subject to the conditions set forth in this Agreement and (e)&nbsp;resolved to recommend that the stockholders of the Company adopt this
Agreement at any meeting of the Company&#8217;s stockholders held for such purpose and any adjournment or postponement thereof on the terms and subject to the conditions of this Agreement. The resolutions in the foregoing sentence, subject to
<U>Section</U><U></U><U>&nbsp;5.1</U>, have not been subsequently withdrawn or modified in a manner adverse to Parent as of the date of this Agreement. This Agreement has been duly executed and delivered by the Company, and assuming due
authorization, execution and delivery by Parent and Merger Sub, this Agreement constitutes the legal, valid and binding obligation of the Company and is enforceable against the Company in accordance with its terms, except as such enforcement may be
subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors&#8217; rights, and by general equitable principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.22</B> <B>Takeover Laws</B>. Assuming the accuracy of the representations and warranties of Parent and Merger Sub set forth in
<U>Section</U><U></U><U>&nbsp;3.8</U>, the Board of Directors has taken and will take all actions so that the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL and any other Takeover Laws are, and will be
inapplicable to the execution, delivery and performance of this Agreement, the CVR Agreement and to the consummation of the Merger and the other Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.23</B> <B><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Assuming compliance with the applicable provisions of the DGCL, the HSR Act, any applicable filing, notification or approval in any
Required Jurisdiction required by Antitrust Laws (if any), and the rules and regulations of the SEC and Nasdaq, and assuming the accuracy of the representations and warranties of Parent and Merger Sub herein, the execution and delivery of this
Agreement by the Company and the consummation of the Transactions will not: (i)&nbsp;cause a violation of any of the provisions of the certificate of incorporation or bylaws (or other organizational documents) of any Acquired Corporation;
(ii)&nbsp;cause a violation by any Acquired Corporation of any Legal Requirement or order applicable to an Acquired Corporation, or to which an Acquired Corporation is subject; (iii)&nbsp;require any consent or notice under, conflict with, result in
breach of, or constitute a default under (or an event that with notice or lapse of time or both would become a default), or give rise to any right of payment, purchase, termination, amendment, cancellation, acceleration or other adverse change of
any right or obligation or the loss of any benefit to which an Acquired Corporation is entitled under any provision of any Material Contract; or (iv)&nbsp;result in an Encumbrance (other than a Permitted Encumbrance) on any of the property or assets
of any Acquired Corporation; except, in the case of <U>clauses (ii)</U>, <U>(iii)</U> and <U>(iv)</U>, as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except for the filing of the certificate of merger with the Secretary of State of the
State of Delaware or as may be required by the Exchange Act (including the filing with the SEC of the Merger Proxy Statement and such reports under the Exchange Act as may be required in connection with this Agreement and the Transactions), the
DGCL, the HSR Act and any applicable filing, notification or approval in any Required Jurisdiction required by Antitrust Laws (if any) and the applicable rules and regulations of the SEC and any national securities exchange, the Acquired
Corporations are not required to give notice to, make any filing with, or obtain any Consent from any Governmental Body at any time prior to the Closing in connection with the execution and delivery of this Agreement by the Company, or the
consummation by the Company of the Merger or the other Transactions, except those that the failure to make or obtain would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No Acquired Corporation is a
TID U.S. business (within the meaning of 31 C.F.R. &#167; 800.248 as in effect as of the date of this Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.24</B> <B>Opinion
of Financial Advisor</B>. The Board of Directors has received the oral opinions of each of Morgan Stanley&nbsp;&amp; Co. LLC and J.P. Morgan Securities LLC, financial advisors to the Company, to be subsequently confirmed by delivery of written
opinions to the Board of Directors, to the effect that, as of the date of such opinions, and based on and subject to the various assumptions made, procedures followed, matters considered, limitations, qualifications and other matters as set forth in
the written opinions, the Merger Consideration to be received by the holders of Shares (other than Excluded Shares, Dissenting Shares or any Shares held by any Affiliate of the Company or Parent) in the Merger, pursuant to this Agreement, is fair,
from a financial point of view, to such holders. The Company will make available to Parent, solely for informational purposes and on a <FONT STYLE="white-space:nowrap">non-reliance</FONT> basis, a signed copy of each such written opinion as soon as
possible following the date of this Agreement. As of the date of this Agreement, such opinions have not been withdrawn, revoked or otherwise modified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.25</B> <B>Brokers and Other Advisors</B>. Except for Morgan Stanley&nbsp;&amp; Co. LLC and J.P. Morgan Securities LLC, no broker, finder,
investment banker, financial advisor or other Person performing similar functions is entitled to any brokerage, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission, or the reimbursement of expenses in connection therewith,
in connection with the Transactions based upon arrangements made by or on behalf of the Company. <U>Section</U><U></U><U>&nbsp;2.25</U> of the Company Disclosure Schedule sets out each Contract with Morgan Stanley&nbsp;&amp; Co. LLC and J.P. Morgan
Securities LLC to which any Acquired Corporation is a party, or by which it is bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.26</B> <B>Acknowledgments by the Company</B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company is not relying and the Company has not relied on any representations or warranties whatsoever regarding the subject
matter of this Agreement or the CVR Agreement, express or implied, except for the representations and warranties of Parent and Merger Sub in <U>Section</U><U></U><U>&nbsp;3</U>. Such representations and warranties by Parent and Merger Sub constitute
the sole and exclusive representations and warranties of Parent and Merger Sub in connection with the Transactions and the Company understands, acknowledges and agrees that all other representations and warranties of any kind or nature, including
with respect to the Milestone whether express, implied or statutory, and whether written or oral are specifically disclaimed by Parent and Merger Sub. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with the due diligence investigation of Parent and Merger Sub by the
Company and their respective Affiliates, stockholders or Representatives, the Company and their respective Affiliates, stockholders and Representatives have received and may continue to receive after the date hereof from Parent or Merger Sub and
their respective Affiliates, shareholders and Representatives certain estimates, projections, forecasts and other forward-looking information, as well as certain business plan information, regarding Parent, Merger Sub, their respective Affiliates
and their respective businesses and operations. The Company hereby acknowledges that there are uncertainties inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such business
plans, and agree that the Company will have no claim against Parent, Merger Sub, or any of their respective Affiliates, shareholders or Representatives, or any other Person with respect thereto except for any such representation or warranty
expressly set forth in <U>Section</U><U></U><U>&nbsp;3</U>. Accordingly, the Company hereby acknowledges and agrees that neither Parent or Merger Sub nor any of their respective Affiliates, shareholders or Representatives, nor any other Person, has
made or is making any express or implied representation or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans except for any such representation or warranty expressly set forth in
<U>Section</U><U></U><U>&nbsp;3</U>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parent and Merger Sub represent and warrant to the Company as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Due Organization</B>. Each of Parent and Merger Sub is a corporation or other Entity duly organized, validly existing and in good
standing (or local equivalent) under the laws of its jurisdiction of organization and has all necessary power and authority: (a)&nbsp;to conduct its business in the manner in which its business is currently being conducted; and (b)&nbsp;to own and
use its assets in the manner in which its assets are currently owned and used, except as would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Merger Sub</B>. Merger Sub was formed solely for the purpose of engaging in the Transactions and activities incidental thereto
and has not engaged, and prior to the Effective Time will not engage, in any business activities or conducted any operations other than as contemplated by this Agreement in connection with the Transactions and those incident to Merger Sub&#8217;s
formation. Either Parent or a direct or indirect wholly owned Subsidiary of Parent owns beneficially and of record all of the outstanding capital stock of Merger Sub, free and clear of all Encumbrances and transfer restrictions, except for
Encumbrances or transfer restrictions of general applicability as may be provided under the Securities Act or applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Authority; Binding Nature of Agreement</B>. Parent and Merger Sub each have
the corporate power and authority to execute and deliver and perform their respective obligations under this Agreement (and with respect to Parent and the CVR Parent, the CVR Agreement) and to consummate the Transactions, subject, in the case of the
Merger, to the adoption of this Agreement by the sole stockholder of Merger Sub (which shall occur immediately following the execution of this Agreement). The board of directors of each of Parent and Merger Sub have approved the execution, delivery
and performance by Parent and Merger Sub of this Agreement (and with respect to Parent and the CVR Parent, the CVR Agreement) and the consummation of the Transactions, including the Merger. This Agreement has been duly executed and delivered by
Parent and Merger Sub, and assuming due authorization, execution and delivery by the Company, this Agreement constitutes the legal, valid and binding obligation of Parent and Merger Sub and is enforceable against Parent and Merger Sub in accordance
with its terms, except as such enforcement may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors&#8217; rights, and by general
equitable principles. The CVR Agreement, when executed and delivered by Parent and the CVR Parent, will be a valid and binding agreement of Parent and the CVR Parent, respectively, enforceable against Parent and the CVR Parent in accordance with its
terms, except as such enforcement may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors&#8217; rights, and by general equitable
principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B><FONT STYLE="white-space:nowrap">Non-Contravention;</FONT> Consents</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Assuming compliance with the applicable provisions of the DGCL, the Exchange Act, the HSR Act and any applicable filing, notification or
approval in any Required Jurisdiction required by Antitrust Laws (if any), and the rules and regulations of the SEC and Nasdaq, and subject, in the case of the Merger, to the adoption of this Agreement by the sole stockholder of Merger Sub (which
shall occur immediately following the execution of this Agreement), the execution and delivery of this Agreement by Parent and Merger Sub and of the CVR Agreement by Parent and the CVR Parent, and the consummation of the Transactions, will not:
(i)&nbsp;cause a violation of any of the provisions of the certificate of incorporation or bylaws (or other organizational documents) of Parent or Merger Sub; (ii)&nbsp;cause a violation by Parent or Merger Sub of any Legal Requirement or order
applicable to Parent or Merger Sub, or to which Parent or Merger Sub are subject; or (iii)&nbsp;require any consent or notice under, conflict with, result in breach of, or constitute a default under (or an event that with notice or lapse of time or
both would become a default), or give rise to any right of purchase, termination, amendment, cancellation, acceleration or other adverse change of any right or obligation or the loss of any benefit to which Parent or Merger Sub is entitled under any
provision of any Contract to which Parent or any of its Subsidiaries is party, except in the case of <U>clauses </U><U>(ii)</U>&nbsp;and <U>(iii)</U>, as would not reasonably be expected to have, individually or in the aggregate, a Parent Material
Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except for the filing of the certificate of merger with the Secretary of State of the
State of Delaware, or as may be required by the Exchange Act, Takeover Laws, the DGCL, the HSR Act and any applicable filing, notification or approval in any Required Jurisdiction required by the Antitrust Laws (if any) and the applicable rules and
regulations of the SEC and any national securities exchange, neither Parent nor Merger Sub, nor any of Parent&#8217;s other Affiliates, is required to give notice to, make any filing with or obtain any Consent from any Governmental Body at any time
prior to the Closing in connection with the execution and delivery of this Agreement or the CVR Agreement by Parent, Merger Sub or CVR Parent, as applicable, or the consummation by Parent or Merger Sub of the Merger or the other Transactions, except
those that the failure to make or obtain would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. No vote of Parent&#8217;s stockholders is necessary to approve this Agreement, the CVR Agreement
or any of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>Disclosure</B>. None of the information with respect to Parent or Merger Sub supplied or to be
supplied by or on behalf of Parent or Merger Sub, specifically for inclusion or incorporation by reference in the Merger Proxy Statement, will, (a)&nbsp;at the time such document is filed with the SEC, (b)&nbsp;at any time such document is amended
or supplemented or (c)&nbsp;at the time such document is first published, sent or given to the Company&#8217;s stockholders, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. For clarity, the representations and warranties in this <U>Section</U><U></U><U>&nbsp;3.5</U> will not apply to statements
or omissions included or incorporated by reference in the Merger Proxy Statement based upon information supplied to Parent or Merger Sub or any of their respective Representatives by the Company or any of its Representatives on behalf of the Company
specifically for inclusion therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6</B> <B>Absence of Litigation</B>. As of the date of this Agreement, there is no Legal
Proceeding pending and served or, to the knowledge of Parent, pending and not served, against Parent or Merger Sub, except as would not, and would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse
Effect. To the knowledge of Parent or Merger Sub, as of the date of this Agreement, neither Parent nor Merger Sub is subject to any continuing order of, consent decree, settlement agreement or similar written agreement with, or continuing
investigation by, any Governmental Body, or any order, writ, judgment, injunction, decree, determination or award of any Governmental Body, except as would not, and would not reasonably be expected to, individually or in the aggregate, have a Parent
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7</B> <B>Funds</B>. As of the Effective Time, Parent has (and will make available to Merger Sub in a timely
manner) available funds in an amount sufficient to carry out all of Parent and Merger Sub&#8217;s obligations under this Agreement and the CVR Agreement and to consummate the Transactions by payment in cash of the aggregate Merger Consideration
payable following the Effective Time and the aggregate amounts payable to holders of Company Equity Awards following the Effective Time pursuant to <U>Section</U><U></U><U>&nbsp;1.8</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.8</B> <B>Ownership of Shares</B>. Neither Parent nor Merger Sub is, nor for the past
three (3)&nbsp;years has been, an &#8220;interested stockholder&#8221; of the Company under Section&nbsp;203(c) of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.9
Acknowledgement by Parent and Merger Sub </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither Parent nor Merger Sub is relying and neither Parent nor Merger Sub has relied on
any representations or warranties whatsoever regarding the Transactions or the subject matter of this Agreement, express or implied, except for the representations and warranties expressly set forth in <U>Section</U><U></U><U>&nbsp;2</U>. Such
representations and warranties by the Acquired Corporations constitute the sole and exclusive representations and warranties of the Acquired Corporations in connection with the Transactions and each of Parent and Merger Sub understands, acknowledges
and agrees that all other representations and warranties of any kind or nature whether express, implied or statutory are specifically disclaimed by the Acquired Corporations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with the due diligence investigation of the Acquired Corporations by Parent and Merger Sub and their respective Affiliates,
stockholders or Representatives, Parent and Merger Sub and their respective Affiliates, stockholders and Representatives have received and may continue to receive after the date hereof from the Company, the other Acquired Corporations and their
respective Affiliates, stockholders and Representatives certain estimates, projections, forecasts and other forward-looking information, as well as certain business plan information, regarding the Acquired Corporations and their respective
businesses and operations. Parent and Merger Sub hereby acknowledge that there are uncertainties inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such business plans, and agree
that Parent and Merger Sub will have no claim against the Acquired Corporations, or any of their respective Affiliates, stockholders or Representatives, or any other Person with respect thereto except for any such representation or warranty
expressly set forth in <U>Section</U><U></U><U>&nbsp;2</U>. Accordingly, Parent and Merger Sub hereby acknowledge and agree that neither the Acquired Corporations nor any of their respective Affiliates, stockholders or Representatives, nor any other
Person, has made or is making any express or implied representation or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans except for any such representation or warranty expressly set forth
in <U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.10</B> <B>Brokers and Other Advisors</B>. Except for Persons, if any, whose fees and
expenses shall be paid by Parent or Merger Sub, no broker, finder, investment banker, financial advisor or other Person is entitled to any brokerage, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission, or the reimbursement
of expenses in connection therewith, in connection with the Transactions based upon arrangements made by or on behalf of Parent, Merger Sub, or any of their respective Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTAIN COVENANTS OF THE COMPANY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Access and Investigation</B>. During the period from the execution and delivery of this Agreement until the earlier of the
Effective Time and the valid termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7</U> (the &#8220;<U><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period</U>&#8221;), upon reasonable advance notice to the Company, the
Acquired Corporations shall, and shall cause the respective Representatives of the Acquired Corporations to, provide Parent and Parent&#8217;s Representatives with reasonable access during normal business hours of the Company to the Company&#8217;s
designated Representatives and assets and to all existing books, records, documents and information relating to the Acquired Corporations, and promptly provide Parent and Parent&#8217;s Representatives with all reasonably requested information
regarding the business of the Acquired Corporations and such additional financial, operating and other data and information regarding the Acquired Corporations, as Parent may reasonably request, in each case for any reasonable business purpose in
furtherance of the consummation of the Merger; <I>provided</I>,<I> however</I>, that any such access shall be conducted at Parent&#8217;s expense, at a reasonable time, under the supervision of appropriate personnel of the Acquired Corporations and
in such a manner as not to unreasonably interfere with the normal operation of the business of the Acquired Corporations. Nothing herein shall require any of the Acquired Corporations to disclose any information to Parent if such disclosure would,
in the Company&#8217;s reasonable discretion and after notice to Parent (i)&nbsp;jeopardize any attorney-client or other legal privilege (so long as the Acquired Corporations have reasonably cooperated with Parent to permit such inspection of or to
disclose such information on a basis that does not waive such privilege with respect thereto), (ii)&nbsp;contravene any applicable Legal Requirement (so long as the Acquired Corporations have reasonably cooperated with Parent to permit disclosure to
the extent not prohibited by Legal Requirements) or (iii)&nbsp;contravene any Contract to which an Acquired Corporation is a party or by which an Acquired Corporation is bound (so long as the Acquired Corporations have reasonably cooperated with
Parent to permit disclosure to the extent permitted by such Contract). Notwithstanding the foregoing, nothing in this <U>Section</U><U></U><U>&nbsp;4.1</U> shall require an Acquired Corporation to disclose any information to Parent or Parent&#8217;s
Representatives if such information relates to the applicable portions of the minutes of the meetings of the Board of Directors or any committee thereof (including any presentations or other materials prepared by or for the Board of Directors or
such committee thereof) where the Board of Directors or committee thereof discussed (x)&nbsp;the Transactions, or any similar transaction involving an Acquired Corporation, (y)&nbsp;any Acquisition Proposal or (z)&nbsp;a Company Adverse Change
Recommendation. Parent shall, and shall instruct Parent&#8217;s Representatives to, hold and use the information disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;4.1</U> in accordance with its obligations under the Mutual Confidentiality
Agreement dated January&nbsp;8, 2025, between the Company and Parent (the &#8220;<U>Confidentiality Agreement</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>
<B>Operation of the Acquired Corporations</B><B>&#8217;</B><B> Business</B>. During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, except (x)&nbsp;as expressly required by this Agreement or as required by applicable Legal
Requirements, (y)&nbsp;with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed), or (z)&nbsp;as set forth in <U>Section</U><U></U><U>&nbsp;4.2</U> of the Company Disclosure Schedule: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Company shall, and shall cause each Acquired Corporation to, use reasonable best efforts to (i)&nbsp;conduct its business in the
ordinary course consistent with past practice in all material respects and (ii)&nbsp;execute the Development Plan; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Company shall not, and shall cause each Acquired Corporation to not: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) (1) establish a record date for, declare, set aside or pay any dividend or make any other distribution in respect of any shares of its
capital stock (including the Shares), or (2)&nbsp;repurchase, redeem or otherwise reacquire any of the Shares, or any rights, warrants or options to acquire any of the Shares, other than: (A)&nbsp;repurchases of Shares outstanding as of the date
hereof pursuant to the Company&#8217;s right (under written commitments in effect as of the date hereof) to purchase Shares held by a director, officer, employee or independent contractor of the Acquired Corporations only upon termination of such
Person&#8217;s employment or engagement by the Company; (B)&nbsp;forfeitures of Company Equity Awards (or Shares issued upon the exercise, vesting or forfeiture thereof) outstanding on the date hereof in accordance with the terms of such Company
Equity Awards as of the date hereof; (C)&nbsp;in connection with withholding to satisfy the exercise price and/or Tax obligations with respect to Company Equity Awards or Company Warrants outstanding on the date hereof in accordance with the terms
of such Company Equity Awards or Company Warrants as of the date hereof; or (D)&nbsp;among Acquired Corporations; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) split, combine,
subdivide or reclassify any Shares or other equity interests; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) sell, issue, grant, deliver, pledge, transfer, encumber or authorize
the sale, issuance, grant, delivery, pledge, transfer or encumbrance of (A)&nbsp;any capital stock, equity interest or other security, (B)&nbsp;any option, call, warrant, restricted securities or right to acquire any capital stock, equity interest
or other security, or (C)&nbsp;any instrument convertible into or exchangeable for any capital stock, equity interest or other security (except that the Company may issue Shares as required to be issued upon the exercise or vesting (as the case may
be) of the Company Equity Awards or Company Warrants outstanding as of the date hereof, or issuable to participants in the Company ESPP in accordance with the terms thereof as of the date hereof); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) except as required under any Employee Plan as in effect on the date of this Agreement, (A)&nbsp;establish, adopt, terminate, materially
amend or increase the benefits under any Employee Plan (or any plan, program, arrangement or agreement that would be an Employee Plan if it were in existence on the date hereof), including, without limitation, any Employee Plan providing for
severance or termination benefits, (B)&nbsp;amend or waive any of its rights under, or accelerate the vesting, funding or payment under, any provision of any of the Employee Plans or Company Equity Awards (or any plan, program, arrangement or
agreement that would be an Employee Plan if it were in existence on the date hereof), (C) grant any current or former employee, director, officer, independent contractor or other individual service provider any compensation, bonuses, equity or
equity-like award, severance or other benefits (or increase any of the foregoing), or (D)&nbsp;hire, promote, engage or terminate (other than for cause) the employment or engagement of any employee, director, officer, independent contractor or other
individual service provider other than in the ordinary course of business consistent with past practice for employees below the level of vice president and independent contractors with base </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation below $300,000 (except that the Acquired Corporations may (1)&nbsp;provide increases in annual base salary or base wages or immaterial increases in benefits, in each case, to
employees below the level of vice president in the ordinary course of business consistent with past practice, (2)&nbsp;amend any broad-based Employee Plans in connection with the renewal of such Employee Plans in the ordinary course of business
consistent with past practice to the extent such amendment will not result in an increase in the costs of such broad-based Employee Plan of greater than five percent (5%) to the Acquired Corporations or Parent and (3)&nbsp;make usual and customary
annual bonus payments in the ordinary course of business consistent with past practice on the terms set forth on <U>Section</U><U></U><U>&nbsp;4.2(b)(iv)</U> of the Company Disclosure Schedule); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) amend or permit the adoption of any amendment to its certificate of incorporation or bylaws or other charter or organizational documents;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) form any Subsidiary, acquire any equity interest in any other Entity or enter into any material joint venture, partnership or
similar arrangement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) make or authorize any capital expenditure in excess of $500,000 in the aggregate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) acquire, lease, license, sublicense, pledge, sell or otherwise dispose of, divest or <FONT STYLE="white-space:nowrap">spin-off,</FONT>
abandon, waive, create or incur any Encumbrance (other than any Permitted Encumbrances) on, relinquish or permit to lapse, transfer or assign any material right or other tangible asset or property (except (A)&nbsp;in the ordinary course of business
consistent with past practice (including entering into clinical trial agreements, sponsored research agreements, service agreements and material transfer agreements in the ordinary course of business consistent with past practice), (B)&nbsp;pursuant
to dispositions of obsolete, surplus or worn out assets that are no longer useful in the conduct of the business of the Acquired Corporations, (C)&nbsp;capital expenditures permitted by <U>Section</U><U></U><U>&nbsp;4.2(b)(vii)</U> or
(D)&nbsp;transactions among Acquired Corporations); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) acquire, lease, license, sublicense, pledge, sell or otherwise dispose of, or
create an Encumbrance (other than a Permitted Encumbrance) with respect to, or abandon or permit to lapse, or transfer or assign any material item of Company IP, except (A)&nbsp;granting <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses
of Company IP in the ordinary course of business consistent with past practice, including entering into clinical trial agreements, sponsored research agreements, service agreements and material transfer agreements, (B)&nbsp;abandoning or permitting
to lapse any Company Registered IP at the end of its statutory term or (C)&nbsp;transactions among Acquired Corporations; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) lend money
or make capital contributions or advances to or make investments in, any Person, or assume, incur, issue or guarantee any Indebtedness (except for (A)&nbsp;advances to directors, employees and consultants for travel and other business related
expenses in the ordinary course of business consistent with past practice and in compliance with applicable Legal Requirements and the Company&#8217;s policies related thereto; (B)&nbsp;advances of expenses as required under the Company&#8217;s
certificate of incorporation or bylaws or any Contract made available to Parent; (C)&nbsp;loans, extensions of credit or other Indebtedness to the extent among Acquired Corporations; and (D)&nbsp;Indebtedness in an aggregate principal amount not to
exceed $500,000); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) (A) waive, release, amend or modify in any material respect, or voluntarily terminate,
any Material Contract or (B)&nbsp;enter into any (x)&nbsp;material supply contract or binding letter of intent with respect to any material supply contract (y)&nbsp;Contract that would have been a Material Contract if such Contract was effective as
of the execution and delivery of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) except as required by applicable Legal Requirements: (A)&nbsp;change any method
of Tax accounting or any Tax accounting period of any Acquired Corporation; (B)&nbsp;make (outside of the ordinary course of business), change or revoke any material Tax election; (C)&nbsp;file a material amended Tax Return; (D)&nbsp;enter into a
closing agreement with any Governmental Body regarding any material Tax liability or assessment; (E)&nbsp;settle, compromise or consent to any material Tax claim or assessment or surrender a right to a material Tax refund, offset or other reduction
in Tax liability; (F)&nbsp;waive or extend the statute of limitations with respect to any material Tax or material Tax Return, other than automatic waivers or extensions of time to file Tax Returns obtained in the ordinary course of business, or
(G)&nbsp;take any other similar action outside of the ordinary course of business relating to any Tax Return or Tax, if such action would have the effect of materially increasing the Tax liability of any Acquired Corporation (or any consolidated or
combined group which includes any Acquired Corporation) for any taxable period (or portion thereof) or materially decreasing any Tax attribute of any Acquired Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) settle, release, waive or compromise any (A)&nbsp;amounts owed to the Acquired Corporations greater than $1,000,000 in the aggregate
or (B)&nbsp;Legal Proceeding or other claim (or threatened Legal Proceeding or other claim) against any Acquired Corporation, other than any settlement, release, waiver or compromise that (1)&nbsp;results solely in monetary obligations involving
only the payment of monies by the Acquired Corporations of not more than $1,000,000 in the aggregate (excluding monetary obligations that are funded by an indemnity obligation to, or an insurance policy of, any Acquired Corporations) or
(2)&nbsp;results in no monetary or other material <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligation of any Acquired Corporation; <I>provided</I> that the settlement, release, waiver or compromise of any Legal Proceeding or claim
brought by the stockholders of the Company against the Company and/or its directors relating to the Transactions or a breach of this Agreement or any other agreements contemplated hereby shall instead be subject to
<U>Section</U><U></U><U>&nbsp;1.7</U> or <U>Section</U><U></U><U>&nbsp;5.5</U>, as applicable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) enter into or negotiate any
collective bargaining agreement or other labor-related Contract with any labor union or other employee representative body; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) adopt
or implement any stockholder rights plan or similar arrangement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvi) adopt a plan or agreement of complete or partial liquidation or
dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of any of the Acquired Corporations; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvii) authorize any of, or agree or commit to take, any of the actions described in the
foregoing <U>clauses (i)</U>&nbsp;through <U>(xvi)</U> of this <U>Section</U><U></U><U>&nbsp;4.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, nothing contained
herein shall give to Parent or Merger Sub, directly or indirectly, rights to control or direct the operations of the Acquired Corporations prior to the Effective Time. Prior to the Effective Time, each of Parent and the Company shall exercise,
consistent with the terms and conditions hereof and subject to the remainder of this Agreement, complete control and supervision of its and its, if applicable, Subsidiaries&#8217; respective operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>No Solicitation</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For the purposes of this Agreement, &#8220;<U>Acceptable Confidentiality Agreement</U>&#8221; means any customary confidentiality
agreement that (i)&nbsp;contains provisions that are not less favorable to the Company than those contained in the Confidentiality Agreement and (ii)&nbsp;does not prohibit the Company from providing any information to Parent in accordance with this
<U>Section</U><U></U><U>&nbsp;4.3</U> or otherwise prohibit the Company from complying with its obligations under this <U>Section</U><U></U><U>&nbsp;4.3</U> or <U>Section</U><U></U><U>&nbsp;5.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as permitted by this <U>Section</U><U></U><U>&nbsp;4.3</U>, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period
the Acquired Corporations shall not, and shall use reasonable best efforts to cause their Representatives not to, directly or indirectly, (i)&nbsp;continue any solicitation, knowing encouragement, discussions or negotiations with any Persons that
may be ongoing with respect to an Acquisition Proposal; (ii)&nbsp;(A) solicit, initiate or knowingly facilitate or encourage (including by way of furnishing <FONT STYLE="white-space:nowrap">non-public</FONT> information) any inquiries regarding, or
the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal, (B)&nbsp;engage in, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any other
Person any <FONT STYLE="white-space:nowrap">non-public</FONT> information in connection with, or for the purpose of soliciting or knowingly encouraging or facilitating, an Acquisition Proposal or any proposal or offer that could reasonably be
expected to lead to an Acquisition Proposal or (C)&nbsp;enter into any letter of intent, acquisition agreement, agreement in principle or similar agreement with respect to an Acquisition Proposal or any proposal or offer that could reasonably be
expected to lead to an Acquisition Proposal; or (iii)&nbsp;waive or release any Person from, forebear in the enforcement of, or amend any standstill agreement or any standstill provisions of any other Contract unless, in the case of this <U>clause
(iii)</U>, the Board of Directors determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s
stockholders under applicable Legal Requirements. As promptly as reasonably practicable following the date hereof (and in any event within twenty-four (24)&nbsp;hours), the Company shall terminate access to any data room or similar facility
established by the Company or its Representatives in connection with a potential Acquisition Proposal and request not later than two (2)&nbsp;business days following the date hereof the prompt return or destruction (to the extent provided for by the
applicable confidentiality agreement) of all <FONT STYLE="white-space:nowrap">non-public</FONT> information previously furnished to any Person (other than Parent and Parent&#8217;s Representatives) that has, within the one (1)-year period prior to
the date of this Agreement, made or indicated an intention to make an Acquisition Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything in this Agreement to the contrary, if at any time after the
execution and delivery of this Agreement and prior to the receipt of the Company Stockholder Approval (the &#8220;<U><FONT STYLE="white-space:nowrap">Cut-off</FONT> Time</U>&#8221;) any Acquired Corporation or any of their Representatives receives
an unsolicited <I>bona fide</I> written Acquisition Proposal from any Person or group of Persons, which Acquisition Proposal was made or renewed after the execution and delivery of this Agreement, and the Board of Directors determines in good faith,
after consultation with its financial advisors and outside legal counsel, that such Acquisition Proposal constitutes or could reasonably be expected to lead to a Superior Offer, then the Company and its Representatives may (i)&nbsp;furnish, pursuant
to an Acceptable Confidentiality Agreement, information (including <FONT STYLE="white-space:nowrap">non-public</FONT> information) with respect to the Acquired Corporations to the Person or group of Persons who has made such Acquisition Proposal and
the Representatives of such Person or group of Persons; <I>provided </I>that the Company shall as promptly as practicable (and no later than within twenty-four (24)&nbsp;hours) provide to Parent any <FONT STYLE="white-space:nowrap">non-public</FONT>
information concerning the Acquired Corporations that is provided to any Person to the extent access to such information was not previously provided to Parent or its Representatives and (ii)&nbsp;engage in or otherwise participate in discussions or
negotiations with the Person or group of Persons making such Acquisition Proposal and the Representatives of such Person or group of Persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, the Company shall (i)&nbsp;promptly (and in any event within
twenty-four (24)&nbsp;hours) notify Parent if any inquiries, proposals or offers with respect to an Acquisition Proposal or that could reasonably be expected to lead to an Acquisition Proposal or any written inquiries, proposals or offers with
respect thereto that are received by any Acquired Corporation and provide to Parent a copy of any written Acquisition Proposal (including any proposed term sheet, letter of intent, acquisition agreement or similar agreement with respect thereto
provided to the Company or any of its Affiliates or Representatives) and a summary of any material unwritten terms and conditions thereof, and (ii)&nbsp;keep Parent reasonably informed of the status of, and any material developments, discussions or
negotiations regarding, any such inquiry, proposal, offer or Acquisition Proposal on a prompt basis (and in any event within twenty-four (24)&nbsp;hours of such material development, discussion or negotiation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Nothing in this <U>Section</U><U></U><U>&nbsp;4.3</U> or elsewhere in this Agreement shall prohibit the Company from (i)&nbsp;taking and
disclosing to the stockholders of the Company a position contemplated by Rule <FONT STYLE="white-space:nowrap">14e-2(a),</FONT> Rule <FONT STYLE="white-space:nowrap">14d-9</FONT> or Item 1012(a) of Regulation
<FONT STYLE="white-space:nowrap">M-A</FONT> promulgated under the Exchange Act, including any &#8220;stop, look and listen&#8221; communication pursuant to Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> promulgated under the Exchange Act, or
(ii)&nbsp;making any disclosure to the stockholders of the Company that is required by applicable Legal Requirements; <I>provided</I>, that nothing in this <U>Section</U><U></U><U>&nbsp;4.3(e)</U> shall permit the Board of Directors to make a
Company Adverse Change Recommendation other than in accordance with the provisions of <U>Section</U><U></U><U>&nbsp;5.1(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B>Preparation of Merger Proxy Statement; Stockholder Meeting</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As promptly as reasonably practicable (and in any event within ten (10)&nbsp;business days) after the date of this Agreement, the Company
shall prepare and file with the SEC a proxy statement in preliminary form related to the Company Stockholder Meeting (together with any amendments thereof or supplements thereto, the &#8220;<U>Merger Proxy Statement</U>&#8221;). The Company shall
give Parent and its Representatives a reasonable opportunity to review and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comment on the initial preliminary Merger Proxy Statement and all subsequent forms or versions of or amendments or supplements to the Merger Proxy Statement prior to the filing thereof with the
SEC or dissemination to the holders of Shares and the Company shall give reasonable and good faith consideration to any timely comments thereon made by Parent or its Representatives. Parent and Merger Sub shall promptly supply to the Company in
writing, for inclusion in the Merger Proxy Statement, all information concerning Parent and Merger Sub and their controlled Affiliates required under applicable Legal Requirements to be included in the Merger Proxy Statement as is reasonably
requested by the Company. The Company covenants and agrees that the Merger Proxy Statement (i)&nbsp;at the time the Merger Proxy Statement (including the preliminary Merger Proxy Statement and all subsequent forms or versions of or amendments or
supplements to the Merger Proxy Statement) is filed with the SEC, (ii)&nbsp;at the time the Merger Proxy Statement is first published, sent or disseminated to the holders of Shares, and (iii)&nbsp;at the time of the Company Stockholder Meeting, will
(A)&nbsp;comply in all material respects with the Exchange Act and other applicable Legal Requirements and (B)&nbsp;not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>, that no covenant is made by the Company with respect to information supplied by or on behalf of Parent
or Merger Sub specifically for inclusion or incorporation by reference in the Merger Proxy Statement. Each of Parent, Merger Sub and the Company agrees to respond promptly to any comments of the SEC or its staff and to promptly correct any
information provided by it for use in the Merger Proxy Statement if and to the extent that such information shall have become false or misleading in any material respect, and the Company further agrees to take all steps necessary to cause the Merger
Proxy Statement as so corrected to be promptly filed with the SEC and to be disseminated to holders of Shares, in each case as and to the extent required by applicable Legal Requirements. The Company shall (x)&nbsp;promptly notify Parent of the
receipt of, and promptly provide Parent copies of, all comments (including oral comments) from, and all correspondence with, the SEC or its staff with respect to the Merger Proxy Statement and shall promptly notify Parent of any request by the SEC
or its staff for any amendment or supplement thereto or for additional information, (y)&nbsp;provide Parent and its counsel with a reasonable opportunity to review and comment on any proposed correspondence between the Company or any of its
Representatives, on the one hand, and the SEC or its staff, on the other hand, with respect to the Merger Proxy Statement and shall give reasonable and good faith consideration to any timely comments thereon made by Parent or its Representatives and
(z)&nbsp;promptly provide Parent with final copies of any correspondence sent by the Company or any of its Representatives to the SEC or its staff with respect to the Merger Proxy Statement, and of any amendments or supplements to the Merger Proxy
Statement. The Merger Proxy Statement shall include the Company Board Recommendation, unless the Board of Directors has made a Company Adverse Change Recommendation in compliance with <U>Section</U><U></U><U>&nbsp;5.1</U>. The Merger Proxy Statement
shall include (i)&nbsp;the fairness opinion of the Company&#8217;s financial advisors referenced in <U>Section</U><U></U><U>&nbsp;2.24</U>, (ii) the notice of the Company Stockholder Meeting and (iii)&nbsp;the notice and other information required
by Section&nbsp;262(d) of the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall establish a record date for, duly call, convene and hold a meeting of
its stockholders for the purpose of voting upon the adoption of this Agreement (together with any adjournments or postponements thereof, the &#8220;<U>Company Stockholder </U><U>Meeting</U>&#8221;) as promptly as reasonably practicable after the SEC
Clearance Date (and shall initially schedule the Company Stockholder Meeting to be held within twenty (20)&nbsp;business days from the date of the mailing of the Merger Proxy Statement, or if the Company&#8217;s nationally recognized proxy solicitor
advises the Company that twenty (20)&nbsp;business days from the date of the mailing of the Merger Proxy Statement is insufficient time to obtain the Company Stockholder Approval, such later date to which Parent consents in writing (such consent not
to be unreasonably withheld, conditioned or delayed)), and any adjournments or postponements of such meeting shall require the prior written consent of Parent (not to be unreasonably withheld, conditioned or delayed). Within five (5)&nbsp;business
days after the date of this Agreement (and thereafter, upon the reasonable request of Parent), the Company shall conduct &#8220;broker searches&#8221; in accordance with Rule <FONT STYLE="white-space:nowrap">14a-13</FONT> of the Exchange Act in a
manner to enable the Company Stockholder Meeting to be held by such date. Notwithstanding the foregoing, (i)&nbsp;the Company may, without the prior written consent of Parent, adjourn or postpone the Company Stockholder Meeting up to two
(2)&nbsp;times, in the aggregate (A)&nbsp;for the absence of a quorum or to solicit additional votes in favor of the Merger or (B)&nbsp;to allow reasonable additional time for the filing and/or mailing, and review by the Company&#8217;s stockholders
prior to the date of the Company Stockholder Meeting, of any supplemental or amended disclosure that the Board of Directors determines in good faith is required by applicable Legal Requirements or the rules and regulations of Nasdaq (in each case,
for a period of not more than ten (10)&nbsp;business days each but not past four (4)&nbsp;business days prior to the End Date), unless prior to such adjournment or postponement, the Company shall have received an aggregate number of proxies voting
for the adoption of this Agreement, which have not been withdrawn, such that the condition in <U>Section</U><U></U><U>&nbsp;6.1(a)</U> would be satisfied at such meeting if it were to be held without such postponement or adjournment and
(ii)&nbsp;Parent may require the Company to, adjourn or postpone the Company Stockholder Meeting up to two (2)&nbsp;times, in the aggregate, to a date specified by Parent under the circumstances described in <U>clause (i)(A)</U> or <U>(i)(B)</U> of
this sentence; <I>provided</I>, <I>however</I>, that in no event shall the Company Stockholder Meeting be so postponed or adjourned at the request of Parent for more than twenty (20)&nbsp;business days in the aggregate, or to a date that is less
than four (4)&nbsp;business days prior to the End Date, without the prior written consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed). In connection with the foregoing, the Company shall (i)&nbsp;file
the definitive Merger Proxy Statement with the SEC and cause the definitive Merger Proxy Statement to be mailed to the Company&#8217;s stockholders as of the record date established for the Company Stockholder Meeting as reasonably promptly as
practicable (and in any event within two (2)&nbsp;business days) after the date on which the SEC confirms that it has no further comments on the Merger Proxy Statement (the &#8220;<U>SEC Clearance Date</U>&#8221;); <I>provided</I>, that if the SEC
has failed to affirmatively notify the Company within ten (10)&nbsp;days after the initial filing of the Merger Proxy Statement with the SEC that it will or will not be reviewing the Merger Proxy Statement, then such date shall be the &#8220;<U>SEC
Clearance Date</U>&#8221;. Once the Company has established a record date for the Company Stockholder Meeting, the Company shall not change such record date or establish a different record date for the Company Stockholder Meeting without the prior
written consent of Parent (such consent not to be unreasonably withheld, conditioned or delayed), unless required to do so by applicable Legal Requirements. Unless the Board of Directors shall have made a Company Adverse Change Recommendation in
compliance with <U>Section</U><U></U><U>&nbsp;5.1</U>, the Company shall use reasonable best efforts to obtain the Company Stockholder Approval, including to solicit proxies in favor of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adoption of this Agreement. Unless this Agreement is validly terminated in accordance with <U>Section</U><U></U><U>&nbsp;7.1</U>, the Company shall submit this Agreement to its stockholders at
the Company Stockholder Meeting even if the Board of Directors shall have made a Company Adverse Change Recommendation or proposed or announced any intention to do so. The Company shall, upon the reasonable request of Parent, advise Parent at least
on a daily basis on each of the last seven (7)&nbsp;business days prior to the date of the Company Stockholder Meeting as to the aggregate tally of proxies received by the Company with respect to the Company Stockholder Approval. Without the prior
written consent of Parent, the adoption of this Agreement shall be the only matter (other than related procedural matters including adjournments proposed in compliance with this <U>Section</U><U></U><U>&nbsp;4.4(b)</U> or any <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory vote required under applicable Legal Requirement) that the Company shall propose to be acted on by the stockholders of the Company at the Company Stockholder Meeting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;5 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ADDITIONAL COVENANTS OF THE PARTIES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Company Board Recommendation</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to <U>Section</U><U></U><U>&nbsp;5.1(b)</U>, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, neither the
Board of Directors nor any committee thereof may (i)(A) withdraw (or modify in a manner adverse to Parent or Merger Sub), or publicly propose to withdraw (or modify in a manner adverse to Parent or Merger Sub), the Company Board Recommendation or
(B)&nbsp;approve, recommend or declare advisable, or publicly propose to approve, recommend or declare advisable, any Acquisition Proposal or (ii)&nbsp;approve, recommend or declare advisable, or propose to approve, recommend or declare advisable,
or allow the Company to execute or enter into any Contract with respect to any Acquisition Proposal, or Contract that would require, or would reasonably be expected to cause, the Company to abandon, terminate, delay or fail to consummate, or that
would otherwise materially impede, interfere with or be inconsistent with, the Merger (other than an Acceptable Confidentiality Agreement) (any action described in <U>clauses (i)</U>&nbsp;or (ii) being referred to as a &#8220;<U>Company Adverse
Change Recommendation</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary contained in this Agreement, at any time prior to the <FONT
STYLE="white-space:nowrap">Cut-off</FONT> Time: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) if the Company has received a <I>bona fide</I> written Acquisition Proposal from any
Person that has not been withdrawn and after consultation with outside legal counsel, the Board of Directors shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer, (x)&nbsp;the Board of Directors may make a Company
Adverse Change Recommendation, or (y)&nbsp;if such Acquisition Proposal did not arise out of or result from a material breach of <U>Section</U><U></U><U>&nbsp;4.3</U> or this <U>Section</U><U></U><U>&nbsp;5.1</U> and the Company has complied in all
material respects with <U>Section</U><U></U><U>&nbsp;4.3</U> and this <U>Section</U><U></U><U>&nbsp;5.1</U>, the Company may terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(e)</U> to enter into a Specified Agreement with
respect to such Superior Offer, in each case under <U>(x)</U>&nbsp;or <U>(y)</U>, only if: (A)&nbsp;the Board of Directors determines in good faith, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
after consultation with the Company&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s
stockholders under applicable Legal Requirements; (B)&nbsp;the Company shall have given Parent prior written notice of its intention to consider making a Company Adverse Change Recommendation or terminating this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;7.1(e)</U> at least four (4)&nbsp;business days prior to making any such Company Adverse Change Recommendation or termination (a &#8220;<U>Determination Notice</U>&#8221;) (which notice shall not constitute a Company
Adverse Change Recommendation or termination) and, if desired by Parent, during such four (4)-business day period shall have negotiated in good faith with respect to any revisions to the terms of this Agreement or another proposal, to the extent
proposed by Parent, so that such Acquisition Proposal would cease to constitute a Superior Offer; and (C)&nbsp;(1) the Company shall have provided to Parent information with respect to such Acquisition Proposal in accordance with
<U>Section</U><U></U><U>&nbsp;4.3(d)</U>, (2) the Company shall have given Parent the four (4)-business day period after the Determination Notice to propose revisions to the terms of this Agreement or make another proposal so that such Acquisition
Proposal would cease to constitute a Superior Offer, and (3)&nbsp;after giving effect to the proposals made by Parent during such period, if any, after consultation with the Company&#8217;s outside legal counsel, the Board of Directors shall have
determined, in good faith, that such Acquisition Proposal is a Superior Offer and that the failure to make the Company Adverse Change Recommendation or terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(e)</U> would be
inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under applicable Legal Requirements. Issuance of any &#8220;stop, look and listen&#8221; communication by or on behalf of the Company pursuant to
Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> promulgated under the Exchange Act shall not be considered a Company Adverse Change Recommendation and shall not require the giving of a Determination Notice or compliance with the procedures set
forth in this <U>Section</U><U></U><U>&nbsp;5.1</U> if any such communication expressly reaffirms the Company Board Recommendation. The provisions of this <U>Section</U><U></U><U>&nbsp;5.1(b)(i)</U> shall also apply to any material amendment to any
Acquisition Proposal and shall require a new Determination Notice, except that the references to four (4)&nbsp;business days shall be deemed to be two (2)&nbsp;business days; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) other than in connection with an Acquisition Proposal, the Board of Directors may make a Company Adverse Change Recommendation only in
response to an Intervening Event and only if: (A)&nbsp;the Board of Directors determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary duties of
the Board of Directors to the Company&#8217;s stockholders under applicable Legal Requirements; (B)&nbsp;the Company shall have given Parent a Determination Notice at least four (4)&nbsp;business days prior to making any such Company Adverse Change
Recommendation and, if desired by Parent, during such four (4)-business day period shall have negotiated in good faith with respect to any revisions to the terms of this Agreement or another proposal to the extent proposed by Parent so that a
Company Adverse Change Recommendation would no longer be necessary; and (C)&nbsp;(1) the Company shall have specified in reasonable detail the facts and circumstances that render a Company Adverse Change Recommendation necessary, (2)&nbsp;the
Company shall have given Parent the four (4)-business day period after its receipt of the Determination Notice to propose revisions to the terms of this Agreement or make another proposal so that a Company Adverse Change Recommendation would no
longer be necessary, and (3)&nbsp;after giving effect to the proposals made by Parent during such period, if any, after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consultation with the Company&#8217;s outside legal counsel, the Board of Directors shall have determined, in good faith, that the failure to make the Company Adverse Change Recommendation would
be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under applicable Legal Requirements. The provisions of this <U>Section</U><U></U><U>&nbsp;5.1(b)(ii)</U> shall also apply to any material change
to the facts and circumstances relating to such Intervening Event, which shall require a new Determination Notice, except that the references to four (4)&nbsp;business days shall be deemed to be two (2)&nbsp;business days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Filings, Consents and Approvals</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Parties agree to use (and to cause their respective Affiliates to use) their respective reasonable best efforts to obtain promptly any
clearances required under the HSR Act or other applicable Antitrust Laws, so as to enable the Closing to occur as promptly as practicable, but in no case later than the End Date, including providing as promptly as reasonably practicable all
information required by any Governmental Body pursuant to its evaluation of the Transactions under the HSR Act or other applicable Antitrust Laws; <I>provided</I>, <I>however</I>, that notwithstanding anything to the contrary under this Agreement,
in no event shall Parent, Novo Holdings A/S, the Novo Nordisk Foundation, or any of their respective Affiliates be required to, either pursuant to the foregoing or in using its &#8220;reasonable best efforts&#8221;, nor be construed to be required
to, propose, negotiate, commit to or consent to any divestiture, sale, disposition, hold separate order or other structural or conduct relief, or other operational undertakings, in order to obtain clearance from any Governmental Body, or to avoid or
eliminate any impediment under any Legal Requirement that may be asserted by any Governmental Body or any other Person so as to enable the Parties to expeditiously consummate the Transactions. The Parties shall defend through litigation on the
merits any claim asserted in court by any party under Antitrust Laws in order to avoid entry of, or to have vacated or terminated, any decree, order or judgment (whether temporary, preliminary or permanent) that could restrain, delay or prevent the
Closing by the End Date. Neither Parent nor the Company shall (and neither shall permit any of its Affiliates, if applicable, to) commit to or agree with any Governmental Body to stay, toll or extend any applicable waiting period or withdraw its
filing under the HSR Act or any other applicable Antitrust Laws, or enter into any similar timing agreement, without the prior written consent of the other. Notwithstanding the foregoing, Parent may, without the consent of the Company, voluntarily
withdraw its notification under the HSR Act on one occasion; <I>provided</I>, that Parent will refile its HSR Act notification within two (2)&nbsp;business days after withdrawal unless otherwise agreed by the Parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to the terms and conditions of this Agreement, each of the Parties shall (and shall cause their respective Affiliates, if
applicable, to): (i) promptly, but in no event later than twenty (20)&nbsp;business days after the date hereof, make an appropriate filing of all notification and report forms as required by the HSR Act with respect to the Transactions and
(ii)&nbsp;cooperate with each other in promptly preparing and making any other filings, notifications or other consents that are advisable or required to be made with, or obtained from, any other Governmental Bodies in connection with the
Transactions under applicable Antitrust Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Without limiting the generality of anything contained in this
<U>Section</U><U></U><U>&nbsp;5.2</U>, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, each Party shall (i)&nbsp;give the other Parties prompt notice of the making or commencement of any request, inquiry, investigation, action
or Legal Proceeding brought by a Governmental Body or brought by a third party before any Governmental Body, in each case, with respect to the Transactions under the Antitrust Laws, (ii)&nbsp;keep the other Parties informed as to the status of any
such request, inquiry, investigation, action or Legal Proceeding, (iii)&nbsp;promptly inform the other Parties of, and wherever practicable give the other Parties reasonable advance notice of, and the opportunity to participate in, any communication
to or from the FTC, DOJ or any other Governmental Body in connection with any such request, inquiry, investigation, action or Legal Proceeding, (iv)&nbsp;promptly furnish to the other Parties, subject to an appropriate confidentiality agreement to
limit disclosure to counsel, including <FONT STYLE="white-space:nowrap">in-house</FONT> antitrust counsel, and outside consultants, copies of documents provided to or received from any Governmental Body in connection with any such request, inquiry,
investigation, action or Legal Proceeding (other than &#8220;Transaction-Related Documents&#8221; and &#8220;Plans and Reports&#8221; as those terms are used in the rules and regulations under the HSR Act, that contain valuation information (which
can be redacted)), (v) subject to an appropriate confidentiality agreement to limit disclosure to counsel, including <FONT STYLE="white-space:nowrap">in-house</FONT> antitrust counsel, and outside consultants, and to the extent reasonably
practicable, consult and cooperate with the other Parties and consider in good faith the views of the other Parties in connection with any analysis, appearance, presentation, memorandum, brief, argument, opinion or proposal made or submitted in
connection with any such request, inquiry, investigation, action or Legal Proceeding, and (vi)&nbsp;except as may be prohibited by any Governmental Body or by any Legal Requirement, in connection with any such request, inquiry, investigation, action
or Legal Proceeding in respect of the Transactions, give the other party reasonable advance notice of, and permit authorized Representatives of the other Party to be present at, each meeting or conference relating to such request, inquiry,
investigation, action or Legal Proceeding and to have access to and be consulted in connection with any argument, opinion or proposal made or submitted to any Governmental Body in connection with such request, inquiry, investigation, action or Legal
Proceeding. Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;5.2</U>, the Parties may redact materials provided to one another (A)&nbsp;to remove competitively sensitive information or information concerning valuation;
(B)&nbsp;as necessary to comply with Legal Requirements and Contracts; and (C)&nbsp;as necessary to address reasonable attorney-client privilege or other privilege or confidentiality concerns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Without limiting the obligations of Parent under <U>Section</U><U></U><U>&nbsp;5.2(a)</U>-<U>(c)</U>, Parent shall, on behalf of the
Parties, develop, determine and control (i)&nbsp;the strategy for obtaining any clearances or approvals under the HSR Act or any other Antitrust Laws, including Antitrust Laws in the Required Jurisdictions, or responding to any request from, inquiry
by, or investigation by (including directing the timing, nature, and substance of all such responses) any Governmental Body arising out of this Agreement and the Transactions, including the strategy, timing, form, and content of any remedial
undertakings made, or to be made, for the purpose of securing any required actions or nonactions, waivers, consents, clearances, decisions, declarations, approvals, and the lapse of waiting periods under any Antitrust Laws and (ii)&nbsp;the defense
or settlement of any action brought by or before any Governmental Body that has authority to enforce any Antitrust Laws; <I>provided</I>, that Parent will consider in good faith the views of the Company in respect of the matters described in the
foregoing <U>clauses (i)</U>-<U>(iii)</U>. The Company shall use reasonable best efforts to act consistently with such strategy as developed by Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>Employee Benefits</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For a period of one (1)&nbsp;year following the Closing Date (or if shorter, the applicable period that a Continuing Employee remains
employed with the Surviving Corporation or an Affiliate thereof), Parent shall provide, or cause to be provided, to each employee of the Company or its Subsidiary who is employed by an Acquired Corporation as of immediately prior to the Closing Date
and who continues to be employed by the Surviving Corporation (or any Affiliate thereof, including, for the avoidance of doubt, Parent and Parent&#8217;s Affiliates) during such one (1)-year period (each, a &#8220;<U>Continuing Employee</U>&#8221;)
with (i)&nbsp;a base salary or hourly wage rate (as applicable) and target annual or short-term cash incentive opportunities (excluding any <FONT STYLE="white-space:nowrap">one-time</FONT> bonus opportunities or transaction, change in control or
retention bonuses) that, in each case, are at least equal to the base salary or hourly wage rate (as applicable) and target annual or short-term cash incentive opportunities (excluding any <FONT STYLE="white-space:nowrap">one-time</FONT> bonus
opportunities or transaction, change in control or retention bonuses) provided to such Continuing Employee immediately prior to the Closing Date; (ii)&nbsp;the target long-term incentive compensation (in the form of cash or equity)&nbsp;(x) in an
amount at least equal to the aggregate target long-term equity incentive opportunity provided to such Continuing Employee immediately prior to the Closing Date and (y)&nbsp;with terms and conditions, including vesting terms, as provided to similarly
situated employees of Parent or its Affiliates (other than the Surviving Corporation); and (iii)&nbsp;other broad-based employee benefits (excluding any severance,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> or transaction-based payments, long-term incentives, nonqualified deferred compensation, retention, equity or equity-based compensation, defined
benefit arrangements and post-retirement or retiree medical or welfare benefits (the &#8220;<U>Excluded Benefits</U>&#8221;)) that are substantially similar in the aggregate to the broad based employee benefits (excluding any Excluded Benefits)
provided (A)&nbsp;by the Company or its Subsidiary to such Continuing Employee immediately prior to the Closing Date or (B)&nbsp;by Parent and its Affiliates (other than, following the Closing, the Surviving Corporation and its Subsidiary) to
similarly situated employees of Parent and its Affiliates, in the discretion of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For the one (1)-year period following the
Closing Date (or if shorter, the applicable period that a Continuing Employee remains employed with the Surviving Corporation or an Affiliate thereof), Parent shall, or shall cause its applicable Affiliate (including, following the Closing, the
Surviving Corporation and its Subsidiary) to, provide each Continuing Employee with severance benefits that are no less favorable than the severance benefits provided to similarly situated employees of Parent or its Affiliates (other than the
Surviving Corporation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent shall, or shall cause the Surviving Corporation or its Subsidiary to, use its commercially reasonable
efforts to give each Continuing Employee full credit for such Continuing Employee&#8217;s service with the Company and its Subsidiary (and any Affiliates or predecessors thereto) for purposes of eligibility to participate in and vesting under any
benefit plans maintained by Parent or any of its Affiliates (including the Surviving Corporation and its Subsidiary) in which the Continuing Employee participates to the same extent provided to similarly situated employees of Parent or any of its
Affiliates (other than the Surviving </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation); <I>provided, however</I>, (i)&nbsp;that such service shall not be recognized to the extent that such recognition would result in a duplication of benefits with respect to the same
period of service or for purposes of any Excluded Benefits and (ii)&nbsp;Continuing Employees will eligible for vacation and other paid time off in accordance with the policies of Parent or the applicable Affiliate thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Following the Closing Date, Parent or an Affiliate of Parent shall use its commercially reasonable efforts where administratively possible
and to the extent permitted by the terms of the applicable employee benefit plan to (i)&nbsp;waive any preexisting condition limitations otherwise applicable to Continuing Employees and their eligible dependents under any plan of Parent or an
Affiliate that provides health and welfare benefits in which Continuing Employees are eligible to participate following the Closing Date, and (ii)&nbsp;waive any waiting period limitation or evidence of insurability requirement that would otherwise
be applicable to a Continuing Employee and his or her eligible dependents on or after the Closing Date, in each case, to the extent such Continuing Employee or eligible dependent had satisfied any similar limitation or requirement under an analogous
Employee Plan prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Unless Parent notifies the Company otherwise in writing not later than five
(5)&nbsp;business days prior to the Closing Date, the Acquired Corporations shall adopt written resolutions of its Board of Directors necessary to terminate any and all Employee Plans that are intended to be qualified under Section&nbsp;401(a) of
the Code effective as of no later than the day immediately preceding the Closing Date (but contingent on the occurrence of the Closing), and to take all other actions in furtherance of terminating such Employee Plans as Parent may reasonably require
(including to make any employer matching and other contributions for the period up to and including the Closing Date). Prior to the Closing, the Company shall deliver to Parent reasonably satisfactory evidence of the Acquired Corporations&#8217;
actions with respect to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything to the contrary set forth in this Agreement, this
<U>Section</U><U></U><U>&nbsp;5.3</U> will not be deemed to: (i)&nbsp;create any rights to continued employment or service or guarantee employment for any period of time with Parent, the Acquired Corporations or any of their respective Affiliates,
or preclude the ability of Parent, Company or any of their respective Affiliates to terminate the employment or service of any employee or any other Person; (ii)&nbsp;create, terminate, modify or amend any Employee Plan or any other benefit or
compensation plan, program, agreement or arrangement, or limit the ability of the Parent, the Acquired Corporations or any of their respective Affiliates to amend, modify or terminate any benefit or compensation plan, program, policy, contract,
agreement or arrangement; (iii)&nbsp;alter or limit the ability of Parent or the Company or any of their respective Affiliates to amend, modify or terminate any benefit plan, program, agreement or arrangement at any time assumed, established,
sponsored or maintained by any of them; or (iv)&nbsp;create any third-party beneficiary rights in any employee or any other Person (or beneficiary or dependent thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4 Indemnification of Officers and Directors. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For a period of six (6)&nbsp;years from the Effective Time, Parent agrees that all rights to indemnification, advancement of expenses and
exculpation from liabilities for acts or omissions occurring at or prior to the Effective Time (whether asserted or claimed prior to, at or after the Effective Time) now existing in favor of the current or former directors or officers of any
Acquired Corporation (the &#8220;<U>Indemnified Persons</U>&#8221;) pursuant to the organizational documents thereof, and any indemnification or other similar agreements of any Acquired Corporation set forth in
<U>Section</U><U></U><U>&nbsp;5.4(a)</U> of the Company Disclosure Schedule, in each case as in effect on the date of this Agreement (except as set forth in Section&nbsp;5.4(a) of the Company Disclosure Schedule), shall continue in full force and
effect in accordance with their terms, and the Acquired Corporations shall perform their obligations thereunder. During the period commencing at the Effective Time and ending on the sixth anniversary of the Effective Time, Parent shall cause the
Surviving Corporation to comply with the obligations referenced in the preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For a period of six (6)&nbsp;years from
and after the Effective Time, Parent and the Surviving Corporation shall either cause to be maintained in effect the current policies of directors&#8217; and officers&#8217; insurance maintained by or for the benefit of the Acquired Corporations or
provide substitute policies for the Acquired Corporations and the Indemnified Persons who are currently covered by the directors&#8217; and officers&#8217; insurance coverage currently maintained by or for the benefit of the Acquired Corporations as
of the date of this Agreement, in either case, of not less than the existing coverage as of the date of this Agreement and having other terms that are in the aggregate not less favorable to the Indemnified Persons than the directors&#8217; and
officers&#8217; insurance coverage currently maintained by or for the benefit of the Acquired Corporations with respect to claims arising from facts or events that occurred at or before the Effective Time (with insurance carriers having at least an
&#8220;A&#8221; rating by A.M. Best with respect to directors&#8217; and officers&#8217; insurance), except that in no event shall Parent or the Surviving Corporation be required to pay with respect to such insurance policies more than 300% of the
aggregate annual premium most recently paid by the Acquired Corporations prior to the Closing Date (the &#8220;<U>Maximum Amount</U>&#8221;), and if the Surviving Corporation is unable to obtain the insurance required by this
<U>Section</U><U></U><U>&nbsp;5.4(b)</U> it shall obtain as much comparable insurance as possible for the years within such six (6)-year period for a premium equal to the Maximum Amount. In lieu of such insurance, prior to the Closing Date the
Company shall, if required by Parent, or may, at its option, purchase a &#8220;tail&#8221; directors&#8217; and officers&#8217; insurance policy for the Acquired Corporations and the Indemnified Persons who are currently covered by the
directors&#8217; and officers&#8217; insurance coverage currently maintained by or for the benefit of the Acquired Corporations, such tail to provide coverage in an amount substantially the same as the existing coverage and to have other terms
substantially the same to the insured persons than the directors&#8217; and officers&#8217; insurance coverage currently maintained by or for the benefit of the Acquired Corporations with respect to claims arising from facts or events that occurred
at or before the Effective Time; <I>provided</I> that in no event shall the cost of any such tail policy exceed the Maximum Amount. The Surviving Corporation shall not terminate any such &#8220;tail&#8221; policy during the six (6)-year period after
the Effective Time and shall perform its obligations under any such policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event that any Acquired Corporation or any of its
successors or assigns (i)&nbsp;consolidates with or merges into any other Person and is not the continuing or surviving corporation or Entity of such consolidation or merger or (ii)&nbsp;transfers or conveys all or substantially all of its
properties and assets to any Person, then, and in each such case, the Acquired Corporation, as applicable, shall cause proper provision to be made so that the successors and assigns of such Acquired Corporation assume the obligations set forth in
this <U>Section</U><U></U><U>&nbsp;5.4</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The provisions of this <U>Section</U><U></U><U>&nbsp;5.4</U> (i)&nbsp;shall survive the
Effective Time, (ii)&nbsp;are intended to be for the benefit of, and will be enforceable by, each indemnified or insured party (including the Indemnified Persons), his or her heirs, successors, assigns and representatives, and (iii)&nbsp;are in
addition to, and not in substitution for, any other rights to indemnification, advancement of expenses, exculpation or contribution that any such Person may have by contract or otherwise. Unless required by applicable Legal Requirement, this
<U>Section</U><U></U><U>&nbsp;5.4</U> may not be amended, altered or repealed after the Effective Time in such a manner as to adversely affect the rights of any Indemnified Person or any of their successors, assigns or heirs without the prior
written consent of the affected Indemnified Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B> <B>Stockholder Litigation</B>. The Company shall give Parent the
opportunity to participate in the Company&#8217;s defense, settlement or mooting disclosures relating to any litigation or threatened litigation against the Company and/or its directors or officers relating to the Transactions and shall give due
consideration to Parent&#8217;s advice with respect to such litigation, and no such settlement shall be agreed to without Parent&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed). The Company shall
promptly notify Parent of any such litigation and shall keep Parent reasonably and promptly informed with respect to the status thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B> <B>Additional Agreements</B>. Subject to the terms and conditions of this Agreement, including
<U>Section</U><U></U><U>&nbsp;5.2(a)</U>, (i) the Company shall deliver (x)&nbsp;the notices required pursuant to the terms of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants within five (5)&nbsp;days after the date hereof and
(y)&nbsp;copies of the Merger Proxy Statement to holders of the Hercules Warrants as required therein and (ii)&nbsp;Parent and the Company shall use reasonable best efforts to take, or cause to be taken, all actions necessary to consummate the
Merger and make effective the other Transactions. Without limiting the generality of the foregoing, subject to the terms and conditions of this Agreement, each Party to this Agreement shall use reasonable best efforts to (a)&nbsp;make all filings
(if any) and give all notices (if any) required to be made and given by such Party pursuant to any Material Contract in connection with the Merger and the other Transactions to the extent requested in writing by Parent, (b)&nbsp;seek each consent
(if any) required to be obtained pursuant to any Material Contract by such Party in connection with the Transactions to the extent requested in writing by Parent; <I>provided</I> that (i)&nbsp;without the prior written consent of Parent, the Company
shall not, and shall cause each of the other Acquired Corporations not to, pay or commit to pay to such Person that is not a Governmental Body whose approval or consent is being solicited any cash or other consideration, make any commitment or incur
any liability or other obligation due to such Person in order to obtain such approval or consent, and (ii)&nbsp;neither Parent nor any of its Affiliates shall be required to pay or commit to pay to any Person whose approval or consent is being
solicited pursuant to this <U>Section</U><U></U><U>&nbsp;5.6</U> any cash or other consideration, make any commitment or incur any liability or other obligation to any such Person in order to obtain such approval or consent; and (c)&nbsp;seek to
lift any restraint, injunction or other legal bar to the Merger brought by any third Person against such Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B> <B>Disclosure</B>. The initial press release relating to this Agreement shall be
a joint press release issued by the Company and Parent and thereafter Parent and the Company shall consult with each other before issuing any further press release(s) or otherwise making any public statement (to the extent not previously issued or
made in accordance with this Agreement) with respect to the Merger, this Agreement or any of the other Transactions and shall not issue any such press release or public statement without the other Party&#8217;s consent (such consent not to be
unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing: (a)&nbsp;each Party may, without such consultation or consent, make any public statement in response to questions from the press, analysts, investors or those attending
industry conferences, make internal announcements to employees and make disclosures in Company SEC Documents, so long as such statements are consistent with previous press releases, public disclosures or public statements made jointly by the Parties
(or individually, if approved by the other Party); (b) subject to <U>Section</U><U></U><U>&nbsp;5.1</U>, a Party may, without the prior consent of the other Party but subject to giving advance notice to the other Party as is feasible and giving the
other Party a right to review such press release or public announcement or statement, issue any such press release or make any such public announcement or statement as may be required by Legal Requirement; and (c)&nbsp;no Party needs to consult with
any other Party in connection with any portion of any press release, public statement or filing to be issued or made pursuant to <U>Section</U><U></U><U>&nbsp;4.3(e)</U> or with respect to any Acquisition Proposal or Company Adverse Change
Recommendation; <I>provided</I>, that that nothing in this <U>Section</U><U></U><U>&nbsp;5.7</U> shall limit the Company&#8217;s obligations under <U>Section</U><U></U><U>&nbsp;4.3</U> and <U>Section</U><U></U><U>&nbsp;5.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B> <B>Takeover Laws</B>. If any Takeover Law may become, or may purport to be, applicable to the Transactions, each of Parent, Merger
Sub and the Company and the members of their respective boards of directors shall use their respective reasonable best efforts to grant such approvals and take such actions as are necessary so that the Transactions may be consummated as promptly as
practicable on the terms and conditions contemplated hereby and otherwise act to lawfully eliminate the effect of any Takeover Law on any of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9</B> <B>CVR Agreement</B>. At or prior to the Effective Time, Parent shall authorize and duly adopt, execute and deliver, and will
ensure that CVR Parent and a duly qualified Rights Agent executes and delivers, the CVR Agreement, subject to any reasonable revisions to the CVR Agreement that are requested by such Rights Agent (<I>provided</I> that such revisions are not,
individually or in the aggregate, detrimental or adverse, taken as a whole, to any holder of a CVR). Parent and the Company shall cooperate, including by making changes to the form of CVR Agreement, as necessary to ensure that the CVRs are not
subject to registration under the Securities Act, the Exchange Act or any applicable state securities or &#8220;blue sky&#8221; laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10</B> <B></B><B>Section</B><B></B><B>&nbsp;16 Matters</B>. The Company, and the Board of Directors, shall, to the extent necessary, take
appropriate action, prior to or as of the Effective Time, to approve, for purposes of Section&nbsp;16(b) of the Exchange Act, the disposition and cancellation or deemed disposition and cancellation of Shares and Company Equity Awards in the Merger
by any officer or director of the Company who is subject to Section&nbsp;16 of the Exchange Act intended to cause such dispositions and/or cancellations to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the
Exchange Act.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.11</B> <B>Stock Exchange Delisting; Deregistration</B>. Prior to the Closing Date, the
Company shall cooperate with Parent and use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable Legal Requirements and
rules and policies of Nasdaq to enable the delisting by the Surviving Corporation of the Shares from Nasdaq and the deregistration of the Shares under the Exchange Act as promptly as practicable after the Effective Time. If the Surviving Corporation
is reasonably likely to be required to file any quarterly or annual periodic reports pursuant to the Exchange Act during the ten (10)&nbsp;days after the Closing Date, the Company will deliver to Parent at least five (5)&nbsp;business days prior to
the Closing a substantially final draft of any such quarterly or annual periodic report reasonably likely to be filed during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.12</B> <B>Notification of Certain Events</B>. Subject to applicable Legal Requirements, each of the Company and Parent shall promptly
notify the other of, and thereafter keep the other promptly informed of any material developments with respect to, (i)&nbsp;any notice or other communication received by such Party or, to such Party&#8217;s knowledge, any of its Affiliates, from any
Governmental Body in connection with this Agreement, the Merger or the other Transactions, or from any Person alleging that the consent of such Person is or may be required in connection with the Merger or the other Transactions; or (ii)&nbsp;any
Legal Proceeding commenced or, to such Party&#8217;s knowledge, threatened in writing against, such Party or any of its Affiliates or otherwise relating to, involving or affecting such Party or any of its Affiliates, in each case in connection with,
arising from or otherwise relating to the Merger or any other Transaction. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;6 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONDITIONS PRECEDENT TO THE MERGER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Parties to effect the Merger are subject to the satisfaction as of the Closing of each of the following conditions:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B>Conditions to Each Party</B><B>&#8217;</B><B>s Obligations to Effect the Merger</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company Stockholder Approval shall have been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) (i) Any waiting period (or any extension thereof) applicable to the Merger under the HSR Act shall have expired or been terminated and
(ii)&nbsp;any clearance or approval applicable to the Merger under Antitrust Laws in the Required Jurisdictions shall have been obtained, or deemed obtained unless waived, and any mandatory waiting period related thereto shall have expired or been
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There shall not have been issued by any Governmental Body of competent jurisdiction and remain in effect any temporary
restraining order, preliminary or permanent injunction or other order preventing the consummation of the Merger, nor shall any Legal Requirement have been promulgated, enacted, issued or deemed applicable to the Merger by any Governmental Body of
competent jurisdiction which prohibits or makes illegal the consummation of the Merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Conditions to Obligations of Parent and Merger Sub to Effect the Merger</B>.
The obligations of Parent and Merger Sub to effect the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Legal Requirements) on or prior to the
Closing Date of the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) the representations and warranties of the Company set forth in: the first two sentences
of <U>Section</U><U></U><U>&nbsp;2.1(a)</U> (Due Organization; Subsidiaries, Etc.), the first sentence of <U>Section</U><U></U><U>&nbsp;2.1(b)</U> (Due Organization; Subsidiaries, Etc.), <U>Section</U><U></U><U>&nbsp;2.2</U> (Certificate of
Incorporation and Bylaws), the first sentence of <U>Section</U><U></U><U>&nbsp;2.3(c)</U>, the first sentence of <U>Section</U><U></U><U>&nbsp;2.3(e)</U> (Capitalization, Etc.), <U>Section</U><U></U><U>&nbsp;2.3(f)</U> (Capitalization, Etc.),
<U>Section</U><U></U><U>&nbsp;2.21</U> (Authority; Binding Nature of Agreement), <U>Section</U><U></U><U>&nbsp;2.22</U> (Takeover Laws), the last sentence of <U>Section</U><U></U><U>&nbsp;2.23(b)</U>
<FONT STYLE="white-space:nowrap">(Non-Contravention;</FONT> Consents), <U>Section</U><U></U><U>&nbsp;2.24</U> (Opinion of Financial Advisor) and <U>Section</U><U></U><U>&nbsp;2.25</U> (Brokers and Other Advisors) of the Agreement shall be accurate
(without taking into account any &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such representations and warranties) in all material respects as of the date of the Agreement and at and as of the
Closing Date as if made on and as of such dates (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date or period); (ii) the representations and warranties of the
Company set forth in <U>Section</U><U></U><U>&nbsp;2.3(a)</U>, the last two sentences of <U>Section</U><U></U><U>&nbsp;2.3(c)</U>, <U>Section</U><U></U><U>&nbsp;2.3(d)</U>, <U>Section</U><U></U><U>&nbsp;2.3(g)</U> and
<U>Section</U><U></U><U>&nbsp;2.3(h)</U> (Capitalization, Etc.) shall be accurate (without taking into account any &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such representations and warranties)
except for <I>de minimis</I> inaccuracies as of the date of the Agreement and at and as of the Closing Date as if made on and as of such date (except to the extent any such representation or warranty expressly relates to an earlier date or period,
in which case as of such date or period); (iii) the representations and warranties of the Company set forth in <U>Section</U><U></U><U>&nbsp;2.5(b)</U> (No Material Adverse Effect) of the Agreement shall be accurate in all respects as of the date of
the Agreement and at and as of the Closing Date as if made on and as of such date with respect to the earlier period set forth in <U>Section</U><U></U><U>&nbsp;2.5(b)</U>; and (iv)&nbsp;the representations and warranties of the Company set forth in
the Agreement (other than those referred to in <U>Sections 6.2(a)(i)</U> through <U>(a)(iii)</U> above) shall be accurate (without taking into account any &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained
in such representations and warranties) as of the date of the Agreement and at and as of the Closing Date as if made on and as of such date (except to the extent any such representation or warranty expressly relates to an earlier date or period, in
which case as of such date or period), except where the failure of such representations and warranties to be so accurate has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Company shall have complied with or performed in all material respects the covenants and agreements it is required to comply with or
perform at or prior to the Closing Date (or any failure to comply or perform shall have been cured by such time); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) since the date of this Agreement, there shall not have occurred any Material Adverse
Effect which is continuing; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Parent and Merger Sub shall have received a certificate, dated the Closing Date, executed on behalf
of the Company by the Company&#8217;s Chief Executive Officer or Chief Financial Officer, certifying to the effect that the conditions set forth in <U>Sections 6.2(a)</U>, <U>6.2(b)</U> and <U>6.2(c)</U> have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B>Conditions to Obligations of the Company to Effect the Merger</B>. The obligations of the Company to effect the Merger are
further subject to the satisfaction (or waiver by the Company, to the extent permitted by applicable Legal Requirements) on or prior to the Closing Date of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) the representations and warranties of Parent and Merger Sub set forth in <U>Section</U><U></U><U>&nbsp;3.1</U> (Due Organization),
<U>Section</U><U></U><U>&nbsp;3.2</U> (Merger Sub) and <U>Section</U><U></U><U>&nbsp;3.3</U> (Authority; Binding Nature of Agreement) and <U>Section</U><U></U><U>&nbsp;3.10</U> (Brokers and Other Advisors) shall be accurate in all material respects
(without taking into account any &#8220;Parent Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such representations and warranties) as of the date of this Agreement and at and as of the Closing Date as if
made on and as of such date (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date or period); and (ii)&nbsp;the representations and warranties of Parent and Merger Sub
set forth in this Agreement, other than those referred to in <U>clause (i)</U>&nbsp;above, shall be accurate (without taking into account any &#8220;Parent Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such
representations and warranties) as of the date of this Agreement and at and as of the Closing Date as if made on and as of the Closing Date (except to the extent any such representation or warranty expressly relates to an earlier date or period, in
which case as of such date or period), except where the failure of such representations and warranties to be so true and correct has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent and Merger Sub shall have complied with or performed in all material respects the covenants and agreements they are
required to comply with or perform at or prior to the Closing Date (or any failure to comply or perform shall have been cured by such time); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent shall have delivered to the Company a certificate, dated the Closing Date and signed on its behalf by an officer of Parent,
certifying to the effect that the conditions set forth in <U>Sections 6.3(a)</U> and <U>6.3(b)</U> have been satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>CVR
Agreement</U>. The CVR Agreement shall be in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;7 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TERMINATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B>Termination</B>. This Agreement may be terminated prior to the Effective Time:</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of Parent and the Company at any time prior to the Closing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by either Parent or the Company, at any time prior to the Closing, if the Closing shall not have occurred on or prior to 11:59 p.m.
Eastern Time, on April&nbsp;9, 2026 (the &#8220;<U>End Date</U>&#8221;); <I>provided</I>, <I>however</I>, that in the case of this <U>Section</U><U></U><U>&nbsp;7.1(b)</U>, (x)&nbsp;if on the End Date all of the conditions set forth in
<U>Section</U><U></U><U>&nbsp;6</U>, other than <U>Sections 6.1(b)</U> and <U>6.1(c)</U> (solely in respect of Antitrust Laws) shall have been satisfied or waived by Parent or Merger Sub, to the extent waivable by Parent or Merger Sub (other than
conditions that by their nature are to be satisfied on the Closing Date, each of which is then capable of being satisfied), then the End Date shall automatically be extended to October&nbsp;9, 2026 (the &#8220;<U>Initial Extended End
Date</U>&#8221;) (and all references to the End Date herein shall be as so extended);<I> provided</I>, that, in the case of this <U>Section</U><U></U><U>&nbsp;7.1(b)</U>, if on the Initial Extended End Date all of the conditions set forth in
<U>Section</U><U></U><U>&nbsp;6</U>, other than <U>Sections 6.1(b)</U> and <U>6.1(c)</U> (solely in respect of Antitrust Laws) shall have been satisfied or waived by Parent or Merger Sub, to the extent waivable by Parent or Merger Sub (other than
conditions that by their nature are to be satisfied on the Closing Date, each of which is then capable of being satisfied), then the End Date may be extended by the Company (in its sole discretion) or Parent (in its sole discretion), in each case,
with prompt notice to the other Party, to April&nbsp;9, 2027 (and all references to the End Date herein shall be as so extended); and (y)&nbsp;the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(b)</U> shall not
be available to any Party whose material breach of this Agreement has caused or resulted in the Merger not being consummated by such date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by either Parent or the Company if a Governmental Body of competent jurisdiction shall have issued an order, decree or ruling, or shall
have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting or making illegal the consummation of the Merger, which order, decree, ruling or other action shall be final and nonappealable;
<I>provided</I>, <I>however</I>, that the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(c)</U> shall not be available to any Party whose material breach of this Agreement has caused or resulted in the issuance
of such final and nonappealable order, decree, ruling or other action or to any Party that has failed to comply with its obligations under <U>Sections 5.2</U> and <U>5.6</U> with respect to efforts to remove such order, decree, ruling or other
action; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by Parent at any time prior to the <FONT STYLE="white-space:nowrap">Cut-off</FONT> Time, if: (i)&nbsp;the Board of Directors
shall have failed to include the Company Board Recommendation in the Merger Proxy Statement when filed with the SEC or mailed, or shall have effected a Company Adverse Change Recommendation or shall have failed to file the preliminary Merger Proxy
Statement within the period set forth in <U>Section</U><U></U><U>&nbsp;4.4(a)</U>; (ii)&nbsp;in the case of a tender offer or exchange offer subject to Regulation 14D under the Exchange Act, the Board of Directors fails to recommend, in a
Solicitation/Recommendation Statement on Schedule <FONT STYLE="white-space:nowrap">14D-9,</FONT> rejection of such tender offer or exchange offer or fails to publicly reaffirm the Company Board Recommendation within ten (10)&nbsp;business days of
the commencement of such tender offer or exchange offer; (iii)&nbsp;after any public announcement of an Acquisition Proposal, the Board of Directors fails to publicly reaffirm the Company Board Recommendation within three (3)&nbsp;business days
after Parent so requests in writing (it being understood that the Company will have no obligation to make such reaffirmation on more than two (2)&nbsp;occasions with respect to any Acquisition Proposal); or (iv) the Company knowingly and
intentionally breaches its obligations pursuant to <U>Section</U><U></U><U>&nbsp;4.3</U> in any material respect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by the Company, at any time prior to the <FONT STYLE="white-space:nowrap">Cut-off</FONT>
Time, in order to accept a Superior Offer and substantially concurrently with such termination enter into a binding written definitive acquisition agreement providing for the consummation of a transaction which the Board of Directors shall have
determined, in good faith, constitutes a Superior Offer (a &#8220;<U>Specified Agreement</U>&#8221;); <I>provided</I>, that such termination shall be effective only if the Company shall have paid the Termination Fee immediately prior to or
substantially concurrently with such termination; <I>provided</I>, <I>further</I>, that no Acquired Corporation is in material breach of <U>Section</U><U></U><U>&nbsp;4.3</U> or <U>Section</U><U></U><U>&nbsp;5.1(b)(i)</U> in relation to such
Superior Offer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by either Parent or the Company if the Company Stockholder Approval shall not have been obtained at a duly convened
Company Stockholder Meeting (as such meeting may be adjourned or postponed) at which the vote was taken in respect of this Agreement and the Merger; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) by Parent at any time prior to the Closing, if a breach of any representation or warranty contained in this Agreement or failure to
perform any covenant or obligation in this Agreement on the part of the Company shall have occurred such that a condition set forth in <U>Section</U><U></U><U>&nbsp;6.2(a)</U> or <U>6.2(b)</U> would not be satisfied and cannot be cured by the
Company by the End Date, or if capable of being cured in such time period, shall not have been cured within thirty (30)&nbsp;days of the date Parent gives the Company written notice of such breach or failure to perform; <I>provided</I>,
<I>however</I>, that Parent shall not have the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(g)</U> if either Parent or Merger Sub is then in material breach of any representation, warranty, covenant or
obligation hereunder which breach would permit the Company to terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(h)</U>; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) by the Company at any time prior to the Closing, if a breach of any representation or warranty contained in this Agreement or failure to
perform any covenant or obligation in this Agreement on the part of Parent or Merger Sub shall have occurred such that a condition set forth in <U>Section</U><U></U><U>&nbsp;6.3(a)</U> or <U>6.3(b)</U> would not be satisfied and cannot be cured by
Parent or Merger Sub, as applicable, by the End Date, or if capable of being cured in such time period, shall not have been cured within thirty (30)&nbsp;days of the date the Company gives Parent written notice of such breach or failure to perform;
<I>provided</I>, <I>however</I>, that the Company shall not have the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(h)</U> if the Company is then in material breach of any representation, warranty, covenant or
obligation hereunder which breach would permit Parent to terminate this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1(g)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>Effect of Termination</B>. In the event of the termination of this Agreement as provided in
<U>Section</U><U></U><U>&nbsp;7.1</U>, written notice thereof shall be given to the other Party or Parties, specifying the provision hereof pursuant to which such termination is made, and this Agreement shall be of no further force or effect and
there shall be no liability on the part of Parent, Merger Sub or the Company or any of their respective former, current or future officers, directors, partners, stockholders, managers, members or Affiliates following any such termination;
<I>provided</I>, <I>however</I>, that (a)&nbsp;the final sentence of <U>Section</U><U></U><U>&nbsp;4.1</U>, this <U>Section</U><U></U><U>&nbsp;7.2</U>, <U>Section</U><U></U><U>&nbsp;7.3</U>, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;8</U> (other than <U>Section</U><U></U><U>&nbsp;8.5(b)</U>) and, solely to the extent applicable to the foregoing provisions, any definitions in <U>Exhibit A</U> or
elsewhere in this Agreement shall survive the termination of this Agreement and shall remain in full force and effect, (b)&nbsp;the Confidentiality Agreement shall survive the termination of this Agreement and shall remain in full force and effect
in accordance with its terms and (c)&nbsp;no such termination shall relieve any Party of any liability or damages (which, in the case of liabilities or damages payable by Parent and Merger Sub, the Parties acknowledge and agree shall include, to the
fullest extent permitted by Section&nbsp;261(a)(1) of the DGCL, amounts representing, or based on the loss of, any premium or other economic entitlement the Company&#8217;s stockholders would be entitled to receive under this Agreement if the
Closing were to occur in accordance with the terms of this Agreement, which shall be deemed in such event to be damages of the Company) resulting from any fraud or willful and material breach of this Agreement prior to such termination;
<I>provided</I>, <I>however</I>, that if the Termination Fee or the Reverse Termination Fee, as applicable, is payable and paid in accordance with <U>Section</U><U></U><U>&nbsp;7.3</U>, this <U>clause (c)</U>&nbsp;shall not apply to such
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Expenses; Termination Fees</B>.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as set forth in this <U>Section</U><U></U><U>&nbsp;7.3</U>, all fees and expenses incurred in connection with this Agreement and
the Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) this Agreement is terminated by the Company pursuant to <U>Section</U><U></U><U>&nbsp;7.1(e)</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) this Agreement is terminated by Parent pursuant to <U>Section</U><U></U><U>&nbsp;7.1(d)</U>; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) each of the following <U>clauses (A)</U>, <U>(B)</U> and <U>(C)</U>&nbsp;are satisfied: (A)&nbsp;this Agreement is terminated by Parent
or the Company pursuant to <U>Section</U><U></U><U>&nbsp;7.1(b)</U> (but in the case of a termination by the Company, only if at such time Parent would not be prohibited from terminating this Agreement pursuant to proviso <U>(y)</U>&nbsp;to
<U>Section</U><U></U><U>&nbsp;7.1(b)</U>) or by Parent pursuant to <U>Section</U><U></U><U>&nbsp;7.1(f)</U> or <U>Section</U><U></U><U>&nbsp;7.1(g)</U>, (B)&nbsp;any Person shall have communicated to the Board of Directors or publicly disclosed a
<I>bona fide</I> Acquisition Proposal after the date hereof and prior to such termination and such Acquisition Proposal has not been publicly withdrawn prior to such termination and (C)&nbsp;within twelve (12)&nbsp;months of such termination the
Company shall have entered into a definitive agreement with respect to, or consummated, an Acquisition Proposal; <I>provided</I> that for purposes of <U>clauses (B)</U>&nbsp;and <U>(C)</U> the references to &#8220;20%&#8221; in the definition of
&#8220;Acquisition Proposal&#8221; shall be deemed to be references to &#8220;50%&#8221;; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, in any such event under <U>clause (i)</U>, <U>(ii)</U> or
<U>(iii)</U>&nbsp;of this <U>Section</U><U></U><U>&nbsp;7.3(b)</U>, the Company shall pay to Parent or its designee the Termination Fee by wire transfer of same day funds (x)&nbsp;in the case of <U>Section</U><U></U><U>&nbsp;7.3(b)(i)</U>, on the
date that the Specified Agreement is executed (or if the Specified Agreement is executed on a day that is not a business day, the next business day), (y) in the case of <U>Section</U><U></U><U>&nbsp;7.3(b)(ii)</U>, within three (3)&nbsp;business
days after such termination or (z)&nbsp;in the case of <U>Section</U><U></U><U>&nbsp;7.3(b)(iii)</U>, on the date that the definitive agreement for the Acquisition Proposal referred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to in <U>clause (C)</U>&nbsp;of <U>Section</U><U></U><U>&nbsp;7.3(b)(iii)</U> is executed by the parties thereto (or the earlier consummation of the Acquisition Proposal) (or if the execution (or
earlier consummation) occurs on a day that is not a business day, the next business day); it being understood that in no event shall the Company be required to pay the Termination Fee on more than one occasion. As used herein, &#8220;<U>Termination
Fee</U>&#8221; shall mean a cash amount equal to $165,000,000. Payment of the Termination Fee pursuant to this <U>Section</U><U></U><U>&nbsp;7.3(b)</U> together with any amounts to which the Parent is entitled pursuant to
<U>Section</U><U></U><U>&nbsp;7.3(d)</U> in a situation where the Termination Fee is due and payable shall be deemed to be liquidated damages for, and the sole and exclusive remedy of Parent, Merger Sub and any of their respective Affiliates with
respect to, any and all losses or damages suffered or incurred by Parent, Merger Sub, any of their respective Affiliates or any other Person in connection with this Agreement (and any breach or failure to perform hereunder or the termination
hereof), the Transactions (and the abandonment thereof) or any matter forming the basis for such termination, and none of Parent, Merger Sub or any of their respective Affiliates shall be entitled to bring or maintain any claim, action or proceeding
against the Acquired Corporations and any of their respective former, current or future officers, directors, partners, stockholders, managers, members or other Affiliates (the &#8220;<U>Company Related Parties</U>&#8221;) arising out of or in
connection with this Agreement, any of the Transactions or any matters forming the basis for such termination, and upon payment of such amount(s), none of the Company Related Parties shall have any further liability or obligations relating to or
arising out of this Agreement or the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event that (i)&nbsp;this Agreement is terminated by either Parent or the
Company pursuant to <U>Section</U><U></U><U>&nbsp;7.1(c)</U> as a result of a final and nonappealable order, decree, ruling or other action by a court of competent jurisdiction or any other Governmental Body of competent jurisdiction and solely to
the extent arising under Antitrust Laws or (ii)&nbsp;each of the following <U>clauses (A)</U>, <U>(B)</U> <U>(C)</U>, and <U>(D)</U>&nbsp;are satisfied: (A)&nbsp;this Agreement is terminated by either Parent or the Company pursuant to
<U>Section</U><U></U><U>&nbsp;7.1(b)</U>, (B) any of the conditions set forth in <U>Sections 6.1(b)</U> and <U>6.1(c)</U> (solely in respect of Antitrust Laws) have not been satisfied, (C)&nbsp;all of the conditions set forth in
<U>Section</U><U></U><U>&nbsp;6.1</U>, other than any of the conditions set forth in <U>Sections 6.1(b)</U> or <U>6.1(c)</U> (solely in respect of Antitrust Laws), and in <U>Section</U><U></U><U>&nbsp;6.2</U> shall have been satisfied or waived by
Parent or Merger Sub, to the extent waivable by Parent or Merger Sub (other than conditions that by their nature are to be satisfied at the Closing, each of which is then capable of being satisfied), and (D)&nbsp;no breach by the Company of its
obligations in <U>Section</U><U></U><U>&nbsp;5.2</U> has contributed materially to the applicable order, decree, ruling or other action that gives rise to the termination right pursuant to <U>Section</U><U></U><U>&nbsp;7.1(c)</U> or the failure of
any of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6.1(b)</U> or <U>Section</U><U></U><U>&nbsp;6.1(c)</U> to be satisfied; then Parent will promptly, but in no event later than three (3)&nbsp;business days after such termination, pay
or cause to be paid to the Company a termination fee (the &#8220;<U>Reverse Termination Fee</U>&#8221;) of $185,000,000 in cash. Parent will not be required to pay the Reverse Termination Fee pursuant to this <U>Section</U><U></U><U>&nbsp;7.3(c)</U>
more than once. Payment of the Reverse Termination Fee pursuant to this <U>Section</U><U></U><U>&nbsp;7.3(c)</U> together with any amounts to which the Company is entitled pursuant to <U>Section</U><U></U><U>&nbsp;7.3(d)</U> in a situation where the
Reverse Termination Fee is due and payable shall be deemed to be liquidated damages for, and the sole and exclusive remedy of the Company Related Parties with respect to, any and all losses or damages suffered or incurred by any Company Related
Party or any other Person in connection with this Agreement (and any breach or failure to perform hereunder or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination hereof), the Transactions (and the abandonment thereof) or any matter forming the basis for such termination, and no Company Related Party shall be entitled to bring or maintain any
claim, action or proceeding against Parent, Merger Sub, Novo Holdings A/S, the Novo Nordisk Foundation, or any of their respective former, current or future officers, directors, partners, stockholders, managers, members or other Affiliates
(collectively, &#8220;<U>Parent Related Parties</U>&#8221;) arising out of or in connection with this Agreement, any of the Transactions or any matters forming the basis for such termination, and upon payment of such amount(s), none of the Parent
Related Parties shall have any further liability or obligations relating to or arising out of this Agreement or the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The
Parties acknowledge that the agreements contained in this <U>Section</U><U></U><U>&nbsp;7.3</U> are an integral part of the Transactions and that, without these agreements, the Parties would not enter into this Agreement; accordingly, if the Company
fails to timely pay any amount due pursuant to <U>Section</U><U></U><U>&nbsp;7.3(b)</U>, or Parent fails to timely pay any amount due pursuant to <U>Section</U><U></U><U>&nbsp;7.3(c)</U> and, in order to obtain the payment, the Party to whom payment
is due commences a Legal Proceeding which results in a judgment against the other Party, the other Party shall pay the Party to whom payment is due its reasonable and documented costs and expenses (including reasonable and documented
attorneys&#8217; fees) in connection with such suit, not to exceed $20,000,000 together with interest on such amount at the prime rate as published in the Wall Street Journal in effect on the date such payment was required to be made through the
date such payment was actually received. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION&nbsp;8 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MISCELLANEOUS PROVISIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B>Amendment</B>. Subject to applicable Legal Requirements and as otherwise provided in this Agreement, this Agreement may be
amended, modified or supplemented by written agreement of the Parties. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B>Waiver</B>. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or
remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. At any time prior to the Effective Time, Parent and Merger Sub, on the one hand, and the Company, on the other hand, may, to the extent
permissible under applicable Legal Requirements, (a)&nbsp;extend the time for the performance of any of the obligations or other acts of the other, (b)&nbsp;waive any breach of the representations and warranties of the other contained herein or in
any document delivered pursuant hereto or (c)&nbsp;waive compliance by the other with any of the agreements or covenants contained herein. Any such extension or waiver shall be valid only if is expressly set forth in a written instrument duly
executed and delivered on behalf of the Party or Parties to be bound thereby, but such extension or waiver or failure to insist on strict compliance with an obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel
with respect to, any subsequent or other failure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B>No Survival of Representations and Warranties</B>. None of the representations
and warranties contained in this Agreement, the Company Disclosure Schedule or in any certificate or schedule or other document delivered by any Person pursuant to this Agreement shall survive the Effective Time.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B> <B>Entire Agreement; Counterparts</B>. This Agreement (including its Exhibits, Annexes and the Company Disclosure Schedule), the
CVR Agreement (including any annexes, schedules and exhibits thereto) and the Confidentiality Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties
and their respective Affiliates, with respect to the subject matter hereof and thereof. This Agreement may be executed in one or more counterparts, including by facsimile or by email with .pdf attachments, all of which shall be considered one and
the same agreement, and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5</B> <B>Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement, the Transactions and any other matters or disputes relating thereto shall be governed by, and construed in accordance
with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. In any action or proceeding arising out of or relating to this Agreement or any of the
Transactions: (i)&nbsp;each of the Parties irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of: (A)&nbsp;the Chancery Court of the State of Delaware and any state appellate court therefrom, (B)&nbsp;if
(but only if) the court in <U>clause (A)</U>&nbsp;lacks subject matter jurisdiction, the Superior Court of the State of Delaware sitting in New Castle County and any state appellate court therefrom or (C)&nbsp;if (but only if) the courts in
<U>clauses (A)</U>&nbsp;and <U>(B)</U> lack subject matter jurisdiction, the United States District Court in the State of Delaware and any appellate court therefrom (collectively, the courts described in <U>clauses (A)</U>&nbsp;through <U>(C)</U>,
the &#8220;<U>Delaware Courts</U>&#8221;); and (ii)&nbsp;each of the Parties irrevocably consents to service of process by first class certified mail, return receipt requested, postage prepaid, to the address at which such Party is to receive notice
in accordance with <U>Section</U><U></U><U>&nbsp;8.8</U>. Each of the Parties irrevocably and unconditionally (1)&nbsp;agrees not to commence any such action or proceeding except in the Delaware Courts, (2)&nbsp;agrees that any claim in respect of
any such action or proceeding may be heard and determined in the Delaware Courts, (3)&nbsp;waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the jurisdiction or laying of venue of
any such action or proceeding in the Delaware Courts and (4)&nbsp;waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in the Delaware Courts. The Parties agree that a
final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable Legal Requirements; <I>provided</I>,<I> however</I>, that nothing in
the foregoing shall restrict any Party&#8217;s rights to seek any post-judgment relief regarding, or any appeal from, such final trial court judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Parties agree that irreparable damage for which monetary damages, even if available,
would not be an adequate remedy, would occur in the event that the Parties do not perform their obligations under the provisions of this Agreement in accordance with its specified terms or otherwise breach such provisions. The Parties acknowledge
and agree that (i)&nbsp;the Parties shall be entitled to an injunction or injunctions, specific performance, or other equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the courts
described in <U>Section</U><U></U><U>&nbsp;8.5(a)</U> without proof of damages or otherwise, this being in addition to any other remedy to which they are entitled under this Agreement, and (ii)&nbsp;the right of specific performance is an integral
part of the Transactions and without that right, neither the Company nor Parent would have entered into this Agreement. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief
on the basis that the other Parties have an adequate remedy at law or that an award of specific performance is not an appropriate remedy for any reason at law or equity. The Parties acknowledge and agree that any Party seeking an injunction or
injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this <U>Section</U><U></U><U>&nbsp;8.5(b)</U> shall not be required to provide any bond or other security in
connection with any such order or injunction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) EACH OF THE PARTIES IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING BETWEEN THE PARTIES (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE), INCLUDING ANY COUNTERCLAIM, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION,
ADMINISTRATION, PERFORMANCE AND ENFORCEMENT THEREOF. EACH PARTY (I)&nbsp;MAKES THIS WAIVER VOLUNTARILY AND (II)&nbsp;ACKNOWLEDGES THAT SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS CONTAINED IN
THIS <U>SECTION 8.5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6</B> <B>Assignability</B>. This Agreement shall be binding upon, and shall be enforceable by and inure
solely to the benefit of, the Parties and their respective successors and permitted assigns; <I>provided</I>,<I> however</I>, that neither this Agreement nor any of the rights hereunder may be assigned by a Party without the prior written consent of
the other Parties, and any attempted assignment of this Agreement or any of such rights without such consent shall be void and of no effect, except that Parent and Merger Sub may assign all or any of their rights and obligations under this Agreement
to any controlled Affiliate of Parent (an &#8220;<U>Assignee</U>&#8221;). Any such Assignee may thereafter assign all or any of its rights and obligations under this Agreement to one or more additional Assignees; <I>provided</I>, <I>however</I>,
that in connection with any assignment to an Assignee, Parent and Merger Sub (and such assignor, if applicable) will remain liable for performance by Parent and Merger Sub (and such assignor, if applicable) of their obligations
hereunder.<I>&nbsp;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.7</B> <B>No Third Party Beneficiaries</B>. Nothing in this Agreement, express or implied, is intended to or
shall confer upon any Person (other than the Parties) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement; except for: (a)&nbsp;if the Effective Time occurs, (i)&nbsp;the right of the Company&#8217;s
stockholders to receive the Merger Consideration pursuant to <U>Section</U><U></U><U>&nbsp;1</U> following the Effective Time in accordance with the terms of this Agreement, and (ii)&nbsp;the right of the holders of Company Equity Awards to receive
the Merger Consideration pursuant to <U>Section</U><U></U><U>&nbsp;1.8</U> following the Effective Time in accordance with the terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this Agreement; (b)&nbsp;the provisions set forth in <U>Section</U><U></U><U>&nbsp;5.4</U> of this Agreement; (c)&nbsp;the limitations on liability of the Company Related Parties set forth in
<U>Section</U><U></U><U>&nbsp;7.3(b)</U>; and (d)&nbsp;the limitations on liability of the Parent Related Parties set forth in <U>Section</U><U></U><U>&nbsp;7.3(c)</U>. The Parties hereby agree that the Company shall have the right, on its own
behalf and, in accordance with and to the fullest extent permitted by Section&nbsp;261(a)(2)&nbsp;of the DGCL, as representative on behalf of the Company&#8217;s stockholders and the holders of Company Equity Awards to pursue specific performance as
set forth in <U>Section</U><U></U><U>&nbsp;8.5(b)</U> or damages to the fullest extent permitted by Section&nbsp;261(a)(1) of the DGCL. For the avoidance of doubt, (i)&nbsp;only the Company (and not the Company&#8217;s stockholders or the holders of
Company Equity Awards) may bring an action pursuing liability for such damages and (ii)&nbsp;the Company may retain, without distribution to the Company&#8217;s stockholders or the holders of Company Equity Awards, any damages received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.8</B> <B>Notices</B>. All notices and other communications required or permitted to be given to any Party hereunder shall be in writing
and shall be deemed properly delivered on (a)&nbsp;the date and time of delivery if delivered personally, (b)&nbsp;the date and time of transmittal if delivered by email (<I>provided</I>, no &#8220;bounce back&#8221; or similar message of <FONT
STYLE="white-space:nowrap">non-delivery</FONT> is received with respect thereto), (c) the first business day following the date of dispatch if delivered utilizing a <FONT STYLE="white-space:nowrap">next-day</FONT> service by a recognized <FONT
STYLE="white-space:nowrap">next-day</FONT> courier or (d)&nbsp;upon confirmed receipt if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices or other communications hereunder shall be delivered to the
addresses or email addresses set forth below, or pursuant to such other instructions as the Party to receive such notice or communication shall have specified in a written notice given to the other Parties:<I>&nbsp;</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to Parent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Novo Nordisk A/S
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Novo All&eacute; 1 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">2880
Bagsvaerd </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Denmark </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: John Kuckelman, General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy
(which shall not constitute notice) to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Ropes&nbsp;&amp; Gray LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">800 Boylston Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston, MA
02110 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:&#8195;&#8195;Emily J. Oldshue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;Christopher D. Comeau </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8201;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to Merger Sub (or following the Effective Time, the Surviving Corporation): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">800 Scudders Mill Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Plainsboro, NJ 08536 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Daniel Bohsen, Senior Vice President of Finance and Operations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy
(which shall not constitute notice) to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Ropes&nbsp;&amp; Gray LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">800 Boylston Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston, MA
02110 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:&#8195;&#8195;Emily J. Oldshue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;Christopher D. Comeau </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8201;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to the Company (prior to the Effective Time): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Akero Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">601
Gateway Boulevard, Suite 350 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Andrew Cheng, President and Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy
(which shall not constitute notice) to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Clarendon Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston,
Massachusetts 02116 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:&#8195;&#8195;Graham Robinson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;Laura Knoll </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;Benjamin Jiang </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8201;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.9</B> <B>Severability</B>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction
shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of
a court of competent jurisdiction declares that any term or provision of this Agreement is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such
term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the
event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible,
the economic, business and other purposes of such invalid or unenforceable term or provision.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.10</B> <B>Obligation of Parent</B>.
Parent shall ensure that Merger Sub (and, following the Effective Time, the Surviving Corporation) duly performs, satisfies and discharges on a timely basis each of the covenants, obligations and liabilities applicable to Merger Sub or the Surviving
Corporation, as applicable, under this Agreement, and Parent shall be jointly and severally liable with Merger Sub or the Surviving Corporation, as applicable, for the due and timely performance and satisfaction of each of said covenants,
obligations and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.11</B> <B>Construction</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine
gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be
applied in the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All references to days or months shall be deemed references to
calendar days or months unless otherwise specified herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As used in this Agreement, the word &#8220;including&#8221; and words of
similar import shall mean including without limiting the generality of any description preceding such term, unless otherwise specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As used in this Agreement, the phrase &#8220;to the extent&#8221; shall mean the degree to which a subject or other thing extends and
shall not simply mean &#8220;if.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221;
&#8220;Exhibits&#8221; or &#8220;Annexes&#8221; are intended to refer to Sections of this Agreement and Exhibits or Annexes to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this
Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The term
&#8220;dollars&#8221; and character &#8220;$&#8221; shall mean United States dollars. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Any reference to (i)&nbsp;any Governmental Body includes any successor to that
Governmental Body; and (ii)&nbsp;any applicable Legal Requirement refers to such applicable Legal Requirement as amended, modified, supplemented, or replaced from time to time (and, in the case of statutes, include any rule and regulation
promulgated under such statute) and references to any section of any applicable Legal Requirement includes any successor to such section (<I>provided</I> that, for purposes of any representation and warranty in this Agreement that is made as of a
specific date, references to any Legal Requirement or Contract shall be deemed to refer to such Legal Requirement or Contract, as amended, and to any rule or regulation promulgated thereunder, in each case, as of such date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Documents or other information or materials will be deemed to have been &#8220;made available,&#8221; &#8220;furnished,&#8221;
&#8220;provided,&#8221; or &#8220;delivered&#8221; by the Company if such documents, information or materials have been physically or electronically delivered, in unredacted form, to Parent at least forty-eight (48)&nbsp;hours prior to the execution
and delivery of this Agreement, including by being posted to the virtual data room managed by the Company and hosted by Donnelley Financial Solutions (the &#8220;<U>Data Room</U>&#8221;), available to Parent on the Company&#8217;s designated file
server on Egnyte, or filed with or furnished to the SEC and available on EDGAR at least 48 hours prior to the execution and delivery of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature page follows] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have caused this Agreement to be executed as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Akero Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andrew Cheng</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Andrew Cheng, M.D., Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Novo Nordisk A/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Karsten Munk Knudsen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Karsten Munk Knudsen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Executive Vice President &amp; Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Novo Nordisk A/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mike Doustdar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Mike Doustdar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President &amp; Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NN Invest Sub, Inc</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Daniel Bohsen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Daniel Bohsen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President &amp; Treasurer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Agreement and Plan of Merger] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
purposes of the Agreement (including this <B><U>Exhibit A</U></B>): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Acceptable Confidentiality Agreement</B>. &#8220;<U>Acceptable
Confidentiality Agreement</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;4.3(a)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Acquired
Corporations</B>. &#8220;<U>Acquired Corporations</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.1(a)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Acquisition Proposal</B>. &#8220;<U>Acquisition Proposal</U>&#8221; shall mean any proposal or offer from any Person (other than Parent and
its Affiliates) or &#8220;group&#8221;, within the meaning of Section&nbsp;13(d) of the Exchange Act, relating to, in a single transaction or series of related transactions, any (A)&nbsp;acquisition or exclusive license of assets of the Company
equal to 20% or more of the Company&#8217;s consolidated assets (determined by value) attributable, (B)&nbsp;issuance or acquisition of 20% or more of the outstanding Company Common Stock, (C)&nbsp;recapitalization, tender offer or exchange offer
that if consummated would result in any Person or group beneficially owning 20% or more of the outstanding Company Common Stock or (D)&nbsp;merger, consolidation, amalgamation, share exchange, business combination, recapitalization, liquidation,
dissolution or similar transaction involving the Company that if consummated would result in any Person or group beneficially owning 20% or more of the outstanding Company Common Stock, in each case <U>(A)</U>&nbsp;through <U>(D)</U> other than the
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Affiliate</B>. &#8220;<U>Affiliate</U>&#8221; shall mean, as to any Person, any other Person that, directly or
indirectly, controls, or is controlled by, or is under common control with, such Person. For this purpose, &#8220;control&#8221; (including, with its correlative meanings, &#8220;controlled by&#8221; and &#8220;under common control with&#8221;)
shall mean the possession, directly or indirectly, of the power to direct or cause the direction of management or policies of a Person, whether through the ownership of securities or partnership or other ownership interests, by Contract or
otherwise. Notwithstanding anything to the contrary set forth in the preceding sentence, other than for purposes of <U>Sections 2.26</U>, <U>5.12</U>, <U>7.2</U>, and <U>7.3(b)</U>, Novo Holdings A/S, the Novo Nordisk Foundation and their respective
Affiliates (other than Parent and its Subsidiaries and any Person that controls the foregoing other than Novo Holdings A/S or the Novo Nordisk Foundation) will not be considered Affiliates of Parent or Merger Sub hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Agreement</B>. &#8220;<U>Agreement</U>&#8221; is defined in the preamble to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Anti-Corruption Laws</B>. &#8220;<U>Anti-Corruption Laws</U>&#8221; shall mean the Foreign Corrupt Practices Act of 1977, the Anti-Kickback
Act of 1986, the UK Bribery Act of 2010, and the Anti-Bribery Laws of the People&#8217;s Republic of China or any applicable Legal Requirements of similar effect, and the related regulations and published interpretations thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Antitrust Laws</B>. &#8220;<U>Antitrust Laws</U>&#8221; shall mean the Sherman Act, the
Clayton Act, the HSR Act, the Federal Trade Commission Act, all applicable foreign antitrust laws and foreign direct investment laws and all other applicable Legal Requirements issued by a Governmental Body that are designed or intended to prohibit,
restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening of competition or that provide for national security and public order reviews in connection with the cross-border acquisition of any
interest or assets of a business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Assignee</B>. &#8220;<U>Assignee</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;8.6</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B>. &#8220;<U>Board of Directors</U>&#8221; is defined in the Introduction to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Shares</B>. &#8220;<U>Book-Entry Shares</U>&#8221; shall mean <FONT STYLE="white-space:nowrap">non-certificated</FONT> Shares
represented by book-entry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>business day</B>. &#8220;<U>business day</U>&#8221; shall mean a day except a Saturday, a Sunday or other
day on which banks in either the City of New York, NY or Copenhagen, Denmark are authorized or required by Legal Requirements to be closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Certificated Shares</B>. &#8220;<U>Certificated Shares</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.6(b)</U> of the Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Certificates</B>. &#8220;<U>Certificates</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.6(b)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Change of Control Payment</B>. &#8220;<U>Change of Control Payment</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.9(a)(vii)</U>
of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Closing</B>. &#8220;<U>Closing</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.3(a)</U> of the Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Closing Consideration</B>. &#8220;<U>Closing Consideration</U>&#8221; is defined in Introduction to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Closing Date</B>. &#8220;<U>Closing Date</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.3(a)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Code</B>. &#8220;<U>Code</U>&#8221; shall mean the Internal Revenue Code of 1986. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company</B>. &#8220;<U>Company</U>&#8221; is defined in the preamble to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Adverse Change Recommendation</B>. &#8220;<U>Company Adverse Change Recommendation</U>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;5.1(a)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Board Recommendation</B>. &#8220;<U>Company Board
Recommendation</U>&#8221; is defined in the Introduction to the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Common Stock</B>. &#8220;<U>Company Common
Stock</U>&#8221; shall mean the common stock, $0.0001 par value per share, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Disclosure Schedule</B>.
&#8220;<U>Company Disclosure Schedule</U>&#8221; shall mean the disclosure schedule that has been prepared by the Company in accordance with the requirements of the Agreement and that has been delivered by the Company to Parent on the date of the
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Equity Award</B>. &#8220;<U>Company Equity Award</U>&#8221; shall mean each
Company Option and Company RSU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Equity Plans</B>. &#8220;<U>Company Equity Plans</U>&#8221; shall mean the Company&#8217;s
2019 Stock Option and Incentive Plan and the Company&#8217;s 2018 Stock Option and Grant Plan, in each case, as may be further amended, restated, modified or supplemented from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company ESPP</B>. &#8220;<U>Company ESPP</U>&#8221; shall mean the Company&#8217;s 2019 Employee Stock Purchase Plan, as may be further
amended, restated, modified or supplemented from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP</B>.
&#8220;<U>Company <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP</U>&#8221; shall mean all Intellectual Property Rights owned or purported to be owned by a third party, solely or jointly, and licensed to any of the Acquired Corporations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company IP</B>. &#8220;<U>Company IP</U>&#8221; shall mean, collectively, (a)&nbsp;the Company Owned IP and (b)&nbsp;the Company <FONT
STYLE="white-space:nowrap">In-Licensed</FONT> IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company IT Assets</B>. &#8220;<U>Company IT Assets</U>&#8221; shall mean computers,
computer software, firmware, middleware, servers, workstations, routers, hubs, switches, data communications lines and all other information technology equipment, and all associated documentation owned by the Company or the Acquired Corporations, or
licensed or leased to the Company or the Acquired Corporations pursuant to written agreements (excluding any public networks). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company
Options</B>. &#8220;<U>Company Options</U>&#8221; shall mean all compensatory options to purchase Shares granted under any Company Equity Plan. A purchase right under the Company ESPP is not considered to be a Company Option for purposes of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Owned IP</B>. &#8220;<U>Company Owned IP</U>&#8221; shall mean all Intellectual Property Rights that are owned or
purported to be owned, solely or jointly, by any of the Acquired Corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Preferred Stock</B>. &#8220;<U>Company
Preferred Stock</U>&#8221; shall mean the preferred stock, $0.0001 par value per share, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Registered IP</B>.
&#8220;<U>Company Registered IP</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.8(a)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Related
Parties</B>. &#8220;<U>Company Related Parties</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.3(b)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Returns</B>. &#8220;<U>Company Returns</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.15(a)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company RSUs</B>. &#8220;<U>Company RSUs</U>&#8221; shall mean all restricted stock units granted under any Company Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company SEC Documents</B>. &#8220;<U>Company SEC Documents</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.4(a)</U> of the
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Securities</B>. &#8220;<U>Company Securities</U>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;2.3(h)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Stockholder Approval</B>. &#8220;<U>Company Stockholder
Approval</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.21</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company Stockholder Meeting</B>.
&#8220;<U>Company Stockholder Meeting</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;4.4(b)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Company
Warrants</B>. &#8220;<U>Company Warrants</U>&#8221; shall mean all warrants to purchase Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Confidentiality Agreement</B>.
&#8220;<U>Confidentiality Agreement</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;4.1</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Consent</B>.
&#8220;<U>Consent</U>&#8221; shall mean any approval, consent, ratification, permission, waiver or authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Continuing
Employee</B>. &#8220;<U>Continuing Employee</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.3(a)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Contract</B>. &#8220;<U>Contract</U>&#8221; shall mean any legally binding agreement, contract, subcontract, lease, understanding,
instrument, bond, debenture, note, option, warrant, license, sublicense, purchase order, sales order, commitment or undertaking. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Copyrights</B>. &#8220;<U>Copyrights</U>&#8221; is defined in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Cut-off</FONT> Time</B>. &#8220;<U><FONT STYLE="white-space:nowrap">Cut-off</FONT> Time</U>&#8221; is
defined in <U>Section</U><U></U><U>&nbsp;4.3(c)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVR Agreement</B>. &#8220;CVR Agreement&#8221; is defined in the
Introduction to the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>CVR Parent</B>. &#8220;CVR Parent&#8221; is defined in the Introduction to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Data Protection and Security Requirements</B>. &#8220;<U>Data Protection and Security Requirements</U>&#8221; shall mean, as applicable
(a)&nbsp;all state, federal, local, or other domestic or foreign laws relating to the Processing of Personal Data, data privacy, data or cyber security, breach notification, or data localization, including HIPAA, Regulation (EU) 2016/679 (General
Data Protection Regulation or &#8220;<U>GDPR</U>&#8221;), the United Kingdom Data Protection Act 2018, and comparable foreign or state laws regulating the privacy and security of Personal Data; (b)&nbsp;all regulatory guidelines and published
interpretations by Governmental Bodies of such laws; (c)&nbsp;all policies and notices of the Company relating to the Processing of Personal Data; and (d)&nbsp;Executive Order 14117 of February&nbsp;28, 2024 (Preventing Access to Americans&#8217;
Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern) and the U.S. Department of Justice Final Rule entitled &#8220;Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern
or Covered Persons,&#8221; 28 C.F.R. Part 202 (the &#8220;<U>DOJ Data Security Program</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Data Room</B>. &#8220;<U>Data
Room</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;8.11(j)</U> of the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Delaware Courts</B>. &#8220;<U>Delaware Courts</U>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;8.5(a)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Determination Notice</B>. &#8220;<U>Determination Notice</U>&#8221; is
defined in <U>Section</U><U></U><U>&nbsp;5.1(b)(i)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Development Plan. </B>&#8220;Development Plan&#8221; shall
mean the development plan set forth on Schedule 4.2(a), as it may be amended, modified or supplemented by written agreement of the Parties from time to time, by an instrument in writing signed on behalf of each of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DGCL</B>. &#8220;<U>DGCL</U>&#8221; shall mean the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Dissenting Shares</B>. &#8220;<U>Dissenting Shares</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.7</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOJ</B>. &#8220;<U>DOJ</U>&#8221; shall mean the U.S. Department of Justice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOJ Data Security Program</B>. &#8220;<U>DOJ Data Security Program</U>&#8221; is defined in the definition for &#8220;Data Protection and
Security Requirements&#8221;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>EDGAR</B>. &#8220;<U>EDGAR</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.9(b)</U> of the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Effective Time</B>. &#8220;<U>Effective Time</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.3(b)</U> of the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Employee Plan</B>. &#8220;<U>Employee Plan</U>&#8221; shall mean any &#8220;employee benefit plan&#8221; within the meaning
of Section&nbsp;3(3) of ERISA, and any other plan, program, policy, practice, contract, agreement or arrangement providing for compensation or benefits, whether or not subject to ERISA, whether or not reduced to writing, and whether covering a
single individual or group of individuals, including any bonus, commission, change in control, retention, transaction, deferred compensation, incentive compensation, stock purchase, stock option, other equity or equity-based award, severance pay,
termination pay, death and disability benefits, hospitalization, medical, life or other insurance, health and welfare, flexible benefits, fringe benefit, <FONT STYLE="white-space:nowrap">gross-up,</FONT> profit-sharing, pension or retirement,
employment, individual consulting or other compensation or employee benefit plan, policy, practice, program, contract, agreement or arrangement, in each case that is (i)&nbsp;sponsored, maintained, contributed to or required to be contributed to by
an Acquired Corporation for the benefit of any current or former employee, director, officer, independent contractor or other individual service provider of an Acquired Corporation, (ii)&nbsp;with respect to which an Acquired Corporation has any
liability or (iii)&nbsp;to which an Acquired Corporation is a party, in each case, excluding any plan or arrangement that is maintained because it is required by, or to which contributions are required by, a Governmental Body or applicable Legal
Requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Encumbrance</B>. &#8220;<U>Encumbrance</U>&#8221; shall mean any lien, pledge, hypothecation, mortgage, security
interest, encumbrance, right of first refusal, preemptive right, claim, charge or similar restriction of any nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>End Date</B>.
&#8220;<U>End Date</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.1(b)</U> of the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Entity</B>. &#8220;<U>Entity</U>&#8221; shall mean any corporation (including any <FONT
STYLE="white-space:nowrap">non-profit</FONT> corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint
stock company), firm, society or other enterprise, association, organization or entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Environmental Law</B>. &#8220;<U>Environmental
Law</U>&#8221; shall mean any federal, state, local or foreign Legal Requirement relating to pollution or protection of human health, worker health or the environment (including ambient air, surface water, ground water, land surface or subsurface
strata), including any law or regulation relating to emissions, discharges, Releases or threatened Releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or
handling of Hazardous Materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ERISA</B>. &#8220;<U>ERISA</U>&#8221; shall mean the Employee Retirement Income Security Act of 1974,
as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Exchange Act</B>. &#8220;<U>Exchange Act</U>&#8221; shall mean the Securities Exchange Act of 1934, and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Excluded Benefits</B>. &#8220;<U>Excluded Benefits</U>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;5.3(a)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Excluded Shares</B>. &#8220;<U>Excluded Shares</U>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;1.5(a)(ii)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FDA</B>. &#8220;<U>FDA</U>&#8221; shall mean the United States Food and
Drug Administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FDCA</B>. &#8220;<U>FDCA</U>&#8221; shall mean the Federal Food, Drug and Cosmetic Act, (21 U.S.C. &#167; 301 et.
seq.) and all regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FTC</B>. &#8220;<U>FTC</U>&#8221; shall mean the U.S. Federal Trade Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>GAAP</B>. &#8220;<U>GAAP</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.4(b)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Global Trade Laws</B>. &#8220;<U>Global Trade Laws</U>&#8221; shall mean (a)&nbsp;the trade, sanctions, export control, import, and
anti-boycott Legal Requirements imposed, administered, or enforced by the U.S. government, including the Export Administration Regulations, the International Traffic in Arms Regulations, the customs and import Legal Requirements administered by U.S.
Customs and Border Protection, the Foreign Trade Regulations, and the economic and trade sanctions administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control or the U.S. Department of State; and (b)&nbsp;other trade,
sanctions, export control, import, and anti-boycott Legal Requirements applicable to any Acquired Corporation (except to the extent inconsistent with U.S. Legal Requirements). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Governmental Authorization</B>. &#8220;<U>Governmental Authorization</U>&#8221; shall mean any: permit, license, certificate, franchise,
permission, approval, clearance, registration, qualification, grant, accreditation, waiver or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Legal Requirement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Governmental Body</B>. &#8220;<U>Governmental Body</U>&#8221; shall mean any:
(a)&nbsp;nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; or (c)&nbsp;governmental or quasi-governmental
authority of any nature including any governmental division, department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit or body and any court, arbitrator, mediator or other tribunal, with
respect to <U>(a)</U>-<U>(c)</U>, including the U.S. Patent and Trademark Office, U.S. Copyright Office and any similar office or agency anywhere in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Hazardous Materials</B>. &#8220;<U>Hazardous Materials</U>&#8221; shall mean any waste, material, or substance that is listed, regulated or
defined under any Environmental Law and includes any pollutant, chemical substance, hazardous substance, hazardous waste, special waste, solid waste, asbestos, mold, radioactive material, polychlorinated biphenyls, petroleum or petroleum-derived
substance or waste. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Health Care Laws</B>. &#8220;<U>Health Care Laws</U>&#8221; shall mean all applicable Legal Requirements governing
the research, development, design, manufacturing, packaging, labeling, quality, safety, import, export, commercialization, marketing, promotion, sale, and distribution of biologics, including the FDCA and the Public Health Services Act (42 U.S.C.
&#167; 262); the federal Anti-kickback Statute (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b));</FONT> the Beneficiary Inducement Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a(a)(5));</FONT> the civil False Claims
Act (31 U.S.C. &#167;&#167; 3729 et seq.); the criminal False Claims Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a));</FONT> the Exclusion Laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7);</FONT> the Animal
Welfare Act (7 U.S.C. &#167;&#167; 2131&#8211;2159) and the National Institutes of Health (&#8220;<U>NIH</U>&#8221;) Office of Laboratory Animal Welfare standards for animal use in research; the Association for Assessment and Accreditation of
Laboratory Animal Care standards to evaluate animal care and use programs; any other applicable state, federal, local, or other domestic or foreign law or regulation related to animal research; the NIH Guidelines for Research Involving Recombinant
or Synthetic Nucleic Acid Molecules; the European Union Clinical Trials Regulation (Regulation (EU) No.&nbsp;536/2014); any related or analogous applicable Legal Requirement, whether of the United States or any other applicable jurisdiction; and any
applicable rules, regulations, and legally binding directives, policy statements, or guidance promulgated or issued pursuant to such Legal Requirements, as each of the foregoing may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Hercules Loan Agreement</B>. &#8220;<U>Hercules Loan Agreement</U>&#8221; shall mean that certain Loan and Security Agreement, dated as of
June&nbsp;15, 2022 (as amended, restated, supplemented or otherwise modified from time to time) by and among the Company and each of the Company&#8217;s subsidiaries from time to time party thereto, as borrower, the several banks and other financial
institutions or entities from time to time party thereto and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the lenders party thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Hercules Warrant</B>. &#8220;<U>Hercules Warrant</U>&#8221; shall mean a warrant issued by the Company pursuant to the Hercules Loan
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>HIPAA</B>. &#8220;<U>HIPAA</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.12(j)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>HSR Act</B>. &#8220;<U>HSR Act</U>&#8221; shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In the Money Option</B>. &#8220;<U>In the Money Option</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.8(a)</U> of the Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">In-bound</FONT> License</B>.<B> </B>&#8220;<U><FONT
STYLE="white-space:nowrap">In-bound</FONT> License</U>&#8221;<B> </B>is defined in <U>Section</U><U></U><U>&nbsp;2.9(a)(ix)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Indebtedness</B>. &#8220;<U>Indebtedness</U>&#8221; shall mean, without duplication, the outstanding principal amount of, and all interest,
fees and other amounts accrued in respect of and all amounts and premiums payable at retirement (including prepayment penalties) of, (i)&nbsp;any indebtedness for borrowed money (including the issuance of any debt security) to any Person, including
that portion of obligations with respect to any capital or finance leases that is classified as a liability on a balance sheet in conformity with GAAP, (ii)&nbsp;any obligations evidenced by notes, bonds, debentures or similar Contracts owing to any
Person other than an Acquired Corporation, (iii)&nbsp;any reimbursement obligations in respect of all drawn amounts under letters of credit, surety and performance bonds, bankers&#8217; acceptances or similar facilities, (iv)&nbsp;all indebtedness
created or arising under any conditional sale or other title retention agreement with respect to property acquired, (v)&nbsp;interest rate swap, forward contract, currency or other hedging arrangements or derivative instruments, (vi)&nbsp;any
dividends or distributions or (vii)&nbsp;any guaranty of any such obligations described in <U>clauses (i)</U>&nbsp;through <U>(vi)</U> of any Person other than an Acquired Corporation (other than, in any case, accounts payable to trade creditors and
accrued expenses, in each case, arising in the ordinary course of business consistent with past practice). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Indemnified Persons</B>.
&#8220;<U>Indemnified Persons</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;5.4(a)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Initial Extended End
Date</B>. &#8220;<U>Initial Extended </U><U>End Date</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.1(b)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property Rights</B>. &#8220;<U>Intellectual Property Rights</U>&#8221; shall mean all intellectual property and industrial
property rights of every kind and description throughout the world, including all U.S. and foreign (i)&nbsp;patents, patent applications, invention disclosures, and all related provisionals, <FONT STYLE="white-space:nowrap">non-provisionals,</FONT>
continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisionals, reissues, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> substitutions, and extensions thereof
(&#8220;<U>Patents</U>&#8221;), (ii)&nbsp;trademarks, service marks, names, corporate names, trade names, Internet domain names, logos, slogans, trade dress, design rights, and other similar designations of source or origin, together with all
goodwill associated with the foregoing (&#8220;<U>Trademarks</U>&#8221;), (iii)&nbsp;works of authorship, whether or not copyrightable, copyrights and copyrightable subject matter (&#8220;<U>Copyrights</U>&#8221;), and (iv)&nbsp;trade secrets and
other confidential and proprietary ideas, <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, processes, formulae, models, and methodologies, specifications, assays, manuals, drawings, standard operating procedures, regulatory, chemical,
pharmacological, toxicological, pharmaceutical, physical and analytical, safety, quality assurance, quality control and clinical data and similar data and information (&#8220;<U>Trade Secrets</U>&#8221;), with respect to <U>(i)</U>-<U>(iv)</U>,
whether registered or unregistered, issued or unissued, and including all applications therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Intervening Event</B>.
&#8220;<U>Intervening Event</U>&#8221; shall mean any material event, fact, development or occurrence that affects the business, assets or operations of the Company that is unknown to, and not reasonably foreseeable by, the Board of Directors as of
the date of this Agreement, or if known to the Board of Directors as of the date of this Agreement, the material consequences of which were not known to, and not reasonably foreseeable by, the Board of Directors as of the date of this Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IRS</B>. &#8220;<U>IRS</U>&#8221; shall mean the U.S. Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>knowledge</B>. &#8220;<U>knowledge</U>&#8221; with respect to an Entity shall mean with respect to any matter in question the actual
knowledge, after reasonable inquiry, of such Entity&#8217;s executive officers; <I>provided</I> that the foregoing shall not require any freedom to operate or other analysis with respect to validity or
<FONT STYLE="white-space:nowrap">non-infringement</FONT> of Intellectual Property Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Leased Real Property</B>. &#8220;<U>Leased
Real Property</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.7(b)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Legal Proceeding</B>.
&#8220;<U>Legal Proceeding</U>&#8221; shall mean any action, claim, charge, audit, suit, complaint, litigation, arbitration, mediation proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing or
investigation commenced, brought, conducted or heard by or before any Governmental Body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Legal Requirement</B>. &#8220;<U>Legal
Requirement</U>&#8221; shall mean any federal, state, local, municipal, foreign or other law, statute, constitution, resolution, ordinance, common law, act, injunction, award, code, decree, rule, regulation, order, ruling or requirement issued,
enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of Nasdaq or another stock exchange). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Material Adverse Effect</B>. &#8220;<U>Material Adverse Effect</U>&#8221; shall mean any event, occurrence, circumstance, change or effect
which, individually or when taken together with all other events, occurrences, circumstances, changes or effects which have occurred in the applicable determination period for a Material Adverse Effect, has had or would reasonably be expected to
have a material adverse effect on (a)&nbsp;the ability of the Company to consummate the Transactions on or before the End Date or (b)&nbsp;the business, assets, financial condition or results of operations of the Acquired Corporations, taken as a
whole; <I>provided</I>,<I> however</I>, that none of the following shall be deemed to constitute or be taken into account in determining whether there is, or would reasonably be expected to be, a Material Adverse Effect for purposes of <U>clause
(b)</U>&nbsp;above: (i)&nbsp;any change in the market price or trading volume of the Company&#8217;s stock or change in the Company&#8217;s credit ratings; <I>provided</I> that the underlying causes of any such change may be considered in
determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by another exception herein; (ii)&nbsp;any event, occurrence, circumstance, change or effect resulting from the announcement, pendency or performance of
the Transactions (other than with respect to any representation or warranty the purpose of which is to address the consequences of the execution and delivery of this Agreement or the consummation of the Transactions of the performance of obligations
of the Company hereunder); (iii)&nbsp;any event, occurrence, circumstance, change or effect generally affecting the industries in which the Acquired Corporations operate or in the economy generally or other general business, financial or market
conditions; (iv)&nbsp;any event, occurrence, circumstance, change or effect arising directly or indirectly from or otherwise relating to fluctuations in the value of any currency or interest rates; (v)&nbsp;any event, occurrence, circumstance,
change or effect arising directly or indirectly from or otherwise relating to any act of terrorism, war, national or international calamity, natural disaster, acts of god, epidemic, pandemic, trade wars or any other similar event; (vi)&nbsp;the
failure of the Company to meet internal or analysts&#8217; expectations or projections; <I>provided</I> that the underlying causes of such failure may be considered in determining whether a Material Adverse
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Effect has occurred to the extent not otherwise excluded by another exception herein; (vii)&nbsp;any adverse effect arising directly from or otherwise directly relating to any action taken by an
Acquired Corporation at the written direction of Parent or any action specifically required to be taken by an Acquired Corporation under this Agreement; (viii)&nbsp;any event, occurrence, circumstance, change or effect resulting or arising from the
identity of, or any facts or circumstances relating to, Parent, Merger Sub or any of their respective Affiliates; (ix)&nbsp;any event, occurrence, circumstance, change or effect arising directly or indirectly from or otherwise relating to any change
in, or any compliance with or action taken for the purpose of complying with any change in, any Legal Requirement or GAAP (or interpretations of any Legal Requirement or GAAP); (x)&nbsp;any Legal Proceeding described in
<U>Section</U><U></U><U>&nbsp;1.7</U> or <U>Section</U><U></U><U>&nbsp;5.5</U>; (xi) the availability of or cost of equity, debt or other financing to Parent or Merger Sub; or (xii)&nbsp;any event, occurrence, circumstance, change or effect
proximately resulting or arising from Parent&#8217;s or Merger Sub&#8217;s material breach of this Agreement; <I>provided</I> that any event, occurrence, circumstance, change or effect referred to in the foregoing <U>clauses (iii)</U>, <U>(iv)</U>,
<U>(v)</U> and <U>(ix)</U>&nbsp;may be taken into account in determining whether there is, or would be reasonably expected to be, a Material Adverse Effect solely to the extent such event, occurrence, circumstance, change or effect
disproportionately affects the Acquired Corporations relative to other participants in the industries in which the Acquired Corporations operate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Material Contract</B>. &#8220;<U>Material Contract</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.9(a)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Merger</B>. &#8220;<U>Merger</U>&#8221; is defined in the Introduction to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Merger Consideration</B>. &#8220;<U>Merger Consideration</U>&#8221; is defined in the Introduction to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Merger Proxy Statement</B>. &#8220;<U>Merger Proxy Statement</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;4.4(a)</U> of the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Merger Sub</B>. &#8220;<U>Merger Sub</U>&#8221; is defined in the preamble to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq</B>. &#8220;<U>Nasdaq</U>&#8221; shall mean The Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Employees</B>. &#8220;<U><FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Employees</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.17(a)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Out of the Money Option</B>. &#8220;Out
of the Money Option&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.8(b)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Out-bound</FONT> License</B>.<B> </B>&#8220;<U><FONT STYLE="white-space:nowrap">Out-bound</FONT>
License</U>&#8221;<B> </B>is defined in <U>Section</U><U></U><U>&nbsp;2.9(a)(ix)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Parent</B>.
&#8220;<U>Parent</U>&#8221;<B><I> </I></B>is defined in the preamble to the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Parent Material Adverse Effect</B>.
&#8220;<U>Parent Material Adverse Effect</U>&#8221; shall mean any effect, change, event or occurrence that would or would reasonably be expected to, individually or in the aggregate, materially impair, prevent or materially delay Parent&#8217;s or
Merger Sub&#8217;s ability to consummate the Transactions in a timely manner on the terms set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Parent Related Parties</B>. &#8220;<U>Parent Related Parties</U>&#8221; is defined in
<U>Section</U><U></U><U>&nbsp;7.3(c)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Parties</B>. &#8220;<U>Parties</U>&#8221; shall mean Parent, Merger Sub,
and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Paying Agent</B>. &#8220;<U>Paying Agent</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.6(a)</U> of the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Payment Fund</B>. &#8220;<U>Payment Fund</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;1.6(a)</U> of the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Permitted Encumbrance</B>. &#8220;<U>Permitted Encumbrance</U>&#8221; shall mean (a)&nbsp;any Encumbrance for Taxes
(i)&nbsp;that are not due and payable or (ii)&nbsp;the validity of which is being contested in good faith by appropriate proceedings and for which a reserve has been established in accordance with GAAP in the financial statements included in the
Company SEC Documents filed prior to the date of this Agreement, (b)&nbsp;any Encumbrance representing the rights of customers, suppliers and subcontractors in the ordinary course of business consistent with past practice under the terms of any
Contracts to which the relevant Party is a party or under general principles of commercial or government contract law (including mechanics&#8217;, materialmen&#8217;s, carriers&#8217;, workmen&#8217;s, warehouseman&#8217;s, repairmen&#8217;s,
landlords&#8217; and similar liens granted or which arise in the ordinary course of business consistent with past practice), (c) any interest or title of a lessor under leases (other than capital leases) entered into by the Company or its Subsidiary
in the ordinary course of business, and any Encumbrance related thereto, (d)&nbsp;in the case of any Contract, Encumbrances that are restrictions against the transfer or assignment thereof that are included in the terms of such Contract, <FONT
STYLE="white-space:nowrap">(e)&nbsp;non-exclusive</FONT> licenses of Intellectual Property Rights granted in the ordinary course of business consistent with past practice and (f)&nbsp;in the case of real property, Encumbrances that are easements, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rights-of-way,</FONT></FONT> encroachments, restrictions, conditions and other similar Encumbrances incurred or suffered in the ordinary course of business consistent with past practice and
which, individually or in the aggregate, do not and would not materially impair the use (or contemplated use), utility or value of the applicable real property or otherwise materially impair the present or contemplated business operations at such
location, or zoning, entitlement, building and other land use regulations imposed by Governmental Bodies having jurisdiction over such real property or that are otherwise set forth on a title report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Person</B>. &#8220;<U>Person</U>&#8221; shall mean any individual, Entity or Governmental Body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Personal Data</B>. &#8220;<U>Personal Data</U>&#8221; shall mean all data or information in any medium that alone or in combination with
other information allows the identification of an individual or that otherwise constitutes personal data or personal information under any applicable Data Protection and Security Requirements, including any financial, credit, transactional, medical
or other information, names, addresses, social security or insurance numbers, telephone numbers, facsimile numbers, email addresses or other contact information, or any personal or device identifier. Personal Data shall include &#8220;Protected
Health Information,&#8221; as that term is defined at 45 C.F.R. &#167; 160.103 for purposes of HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period</B>. &#8220;<U><FONT STYLE="white-space:nowrap">Pre-Closing</FONT>
Period</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;4.1</U> of the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant</B>. &#8220;<U><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant</U>&#8221; shall mean a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant issued pursuant to the Underwriting Agreement, dated as of January&nbsp;28, 2025, among the Company and J.P.
Morgan Securities LLC, Morgan Stanley&nbsp;&amp; Co. LLC and Jefferies LLC, as representatives of the several underwriters named therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Processing</B>. &#8220;<U>Processing</U>&#8221; shall mean the collection, use, storage, processing, recording, distribution, transfer,
import, export, protection (including security measures), disposal, disclosure or other activity regarding data (whether electronically or in any other form or medium). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Reference Date</B>. &#8220;<U>Reference Date</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;2.3(a)</U> of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Regulatory Permit</B>. &#8220;<U>Regulatory Permit</U>&#8221; shall mean all Governmental Authorizations granted or issued by FDA or other
Governmental Body required to operate the business of the Acquired Corporations with respect to any Health Care Laws, including any investigational new drug applications, biologics license applications, clinical trial applications, marketing
authorization applications, establishment registrations and drug listings (as defined in 21 C.F.R. Part 207), all supplements or amendments thereto, and all comparable Governmental Authorizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Release</B>. &#8220;<U>Release</U>&#8221; shall mean any presence, emission, spill, seepage, leak, escape, leaching, discharge, injection,
pumping, pouring, emptying, dumping, disposal, migration, or release of Hazardous Materials from any source into or upon the environment, including the air, soil, improvements, surface water, groundwater, the sewer, septic system, storm drain,
publicly owned treatment works, or waste treatment, storage, or disposal systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Representatives</B>.
&#8220;<U>Representatives</U>&#8221; shall mean officers, directors, employees, attorneys, accountants, investment bankers, consultants, agents, financial advisors, other advisors and other representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Required Jurisdiction</B>. &#8220;<U>Required Jurisdiction</U>&#8221; means each of the jurisdictions set forth on Schedule 5.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Reverse Termination Fee</B>. &#8220;<U>Reverse Termination Fee</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.3(c)</U> of the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Rights Agent</B>. &#8220;<U>Rights Agent</U>&#8221; is defined in the Introduction to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Sarbanes-Oxley Act</B>. &#8220;<U>Sarbanes-Oxley Act</U>&#8221; means the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SEC</B>. &#8220;<U>SEC</U>&#8221; shall mean the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SEC Clearance Date</B>. &#8220;<U>SEC Clearance Date</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;4.4(b)</U> of the Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Securities Act</B>. &#8220;<U>Securities Act</U>&#8221; shall mean the Securities Act of 1933. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Security Incident</B>. &#8220;<U>Security Incident</U>&#8221; shall mean any
(a)&nbsp;unauthorized access, acquisition, interruption, alteration or modification, loss, theft, corruption or other unauthorized Processing or Misuse of Personal Data or other business data, (b)&nbsp;inadvertent, unauthorized or unlawful sale, or
rental of, Personal Data or other business data, or (c)&nbsp;other unauthorized access to or use of the information technology systems of any member of the Company. &#8220;Security Incident&#8221; includes any &#8220;breach&#8221; or &#8220;security
incident&#8221; as defined under HIPAA and any &#8220;personal data breach&#8221; as defined under GDPR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Shares</B>.
&#8220;<U>Shares</U>&#8221; is defined in the Introduction to the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Specified Agreement</B>. &#8220;<U>Specified
Agreement</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.1(e)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Subsidiary</B>. An Entity shall be
deemed to be a &#8220;<U>Subsidiary</U>&#8221; of another Person if such Person directly or indirectly owns, beneficially or of record, (a)&nbsp;an amount of voting securities or other interests in such Entity that is sufficient to enable such
Person to elect at least a majority of the members of such Entity&#8217;s board of directors or other governing body, or (b)&nbsp;at least 50% of the outstanding equity or financial interests of such Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Superior Offer</B>. &#8220;<U>Superior Offer</U>&#8221; shall mean a <I>bona fide</I> written Acquisition Proposal that the Board of
Directors determines, in its good faith judgment, after consultation with the Company&#8217;s outside legal counsel and financial advisors, is reasonably likely to be consummated in accordance with its terms, taking into account all legal,
regulatory and financing aspects (including certainty of closing) of the proposal and the Person making the proposal and other aspects of the Acquisition Proposal that the Board of Directors deems relevant, and if consummated, would result in a
transaction more favorable to the Company&#8217;s stockholders (solely in their capacity as such) from a financial point of view than the Transactions (including after giving effect to proposals, if any, made by Parent pursuant to
<U>Section</U><U></U><U>&nbsp;5.1(b)(i)</U>); <I>provided</I> that for purposes of the definition of &#8220;Superior Offer,&#8221; the references to &#8220;20%&#8221; in the definition of Acquisition Proposal shall be deemed to be references to
&#8220;50%.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Surviving Corporation</B>. &#8220;<U>Surviving Corporation</U>&#8221; is defined in the Introduction to the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Takeover Laws</B>. &#8220;<U>Takeover Laws</U>&#8221; shall mean any &#8220;moratorium,&#8221; &#8220;control share
acquisition,&#8221; &#8220;fair price,&#8221; &#8220;supermajority,&#8221; &#8220;affiliate transactions,&#8221; or &#8220;business combination statute or regulation&#8221; or other similar state anti-takeover laws and regulations (including, for
the avoidance of doubt, Section&nbsp;203 of the DGCL). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Tax</B>. &#8220;<U>Tax</U>&#8221; shall mean any and all U.S. federal, state or
local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, including any net income, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT> minimum, gross income, gross receipts, sales, use, ad valorem, value added, transfer, franchise,
profits, license, registration, recording, documentary, gains, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, environmental or windfall profit, custom duty, estimated or other tax or similar levy,
assessment, or other charge in the nature of a tax, together with any interest, penalty, or addition thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Tax Return</B>. &#8220;<U>Tax Return</U>&#8221; shall mean any return (including any
information return), report, statement, declaration, estimate, schedule, form, election, certificate or other document or information filed or required to be filed with any Governmental Body in connection with the determination, assessment,
collection or payment of any Tax and any attachments thereto or amendments thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Termination Fee</B>. &#8220;<U>Termination
Fee</U>&#8221; is defined in <U>Section</U><U></U><U>&nbsp;7.3(b)</U> of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Trademarks</B>.
&#8220;<U>Trademarks</U>&#8221; is defined in the definition of Intellectual Property Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Trade Secrets</B>. &#8220;<U>Trade
Secrets</U>&#8221; is defined in the definition of Intellectual Property Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Transactions</B>. &#8220;<U>Transactions</U>&#8221;
shall mean (a)&nbsp;the execution and delivery of the Agreement and (b)&nbsp;all of the transactions contemplated by the Agreement, including the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>willful and material breach</B>. &#8220;<U>willful and material breach</U>&#8221; shall mean a breach that is a consequence of an act or
omission undertaken by the breaching party with the knowledge that the taking of, or failure to take, such act would, or would reasonably be expected to, cause or constitute a material breach of the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX I </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVR AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF CONTINGENT VALUE RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [&#149;] (this &#8220;<U>Agreement</U>&#8221;), is entered into by and between [&#149;], a
[Delaware corporation] and wholly owned subsidiary of Ultimate Parent (as defined below) (&#8220;<U>Parent</U>&#8221;), [&#149;] as the Rights Agent (as hereinafter defined) and, solely with respect to <U>Section</U><U></U><U>&nbsp;6.11</U>, Novo
Nordisk A/S, a Danish<I>&nbsp;aktieselska</I>b (&#8220;<U>Ultimate Parent</U>&#8221;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this Agreement is entered into pursuant to the Agreement and Plan of Merger, dated as of October 9, 2025 (the &#8220;<U>Merger
Agreement</U>&#8221;), by and among Ultimate Parent, NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholly owned subsidiary of Ultimate Parent (&#8220;<U>Merger Sub</U>&#8221;) and Akero Therapeutics, Inc., a Delaware
corporation (&#8220;<U>Akero</U>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Merger Agreement, Akero shall merge with and into Merger Sub, with
Akero surviving such merger (the &#8220;<U>Merger</U>&#8221;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Merger Agreement, Ultimate Parent has agreed
to provide to Akero&#8217;s stockholders and certain of Akero&#8217;s other equity holders the right to receive the CVRs as hereinafter described. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the consummation of the transactions referred to above, Parent, Ultimate Parent and the
Rights Agent agree, for the equal and proportionate benefit of all Holders (as hereinafter defined), as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. DEFINITIONS; CERTAIN RULES OF
CONSTRUCTION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.1. <U>Definitions</U>. Capitalized terms used but not otherwise defined herein will have the meanings ascribed to them in the Merger
Agreement. As used in this Agreement, the following terms will have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Akero</U>&#8221; shall have the
meaning set forth in the Recitals of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Agreement</U>&#8221; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Approval Milestone</U>&#8221; means receipt by Parent or one of its Affiliates or Assignees, prior to the Termination Date, of FDA
Approval for the Product (whether alone or in combination with another product) for the treatment of patients with compensated cirrhosis (consistent with stage F4c fibrosis) due to metabolic dysfunction-associated steatohepatitis, and which
expressly sets forth the foregoing as an indication in the indications and usage section of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> prescribing information for the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Approval Milestone Payment</U>&#8221; means $6.00 per CVR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Approval Milestone Payment Date</U>&#8221; means a date selected by Parent that is not more than thirty (30)&nbsp;Business Days
following the date of the achievement of the Approval Milestone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Assignee</U>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.3</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Business Day</U>&#8221; means a day except a Saturday, a Sunday or other day on
which banks in either New York City, NY or Copenhagen, Denmark are authorized or required by Legal Requirements to be closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Commercially Reasonable Efforts</U>&#8221; means, with respect to any activities or decision-making by Parent pursuant to
<U>Section</U><U></U><U>&nbsp;2.6</U>, those efforts that are commensurate with the efforts of a pharmaceutical company similarly situated to Parent to develop a program or product of similar potential, market potential, and profit potential (taking
into account payments under this Agreement) and at a similar stage of product life, based on conditions then prevailing and taking into account Parent&#8217;s and its Affiliates&#8217; other products, taking into account, without limitation
(a)&nbsp;issues of efficacy, safety, and expected and actual approved labeling, as well as all other related commercial and scientific advantages and disadvantages, in each case, based on Parent&#8217;s evaluation thereof, (b)&nbsp;the expected and
actual competitiveness of alternative products (including the development of other internal product candidates), (c) the expected and actual product profile of the Product, including product usage convenience and usage convenience of other products,
(d)&nbsp;the expected and actual patent and other proprietary position of the Product, and the expected and actual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">freedom-to-operate</FONT></FONT> landscape therefor, (e)&nbsp;the
likelihood of, and timelines for, FDA Approval or pricing and reimbursement approval given the regulatory structure involved, including timing of entry to market and regulatory or data exclusivity, and other matters related to FDA Approval, pricing
and reimbursement approval, and timing for development and commercialization, (f)&nbsp;supply chain management considerations, including manufacturing capabilities, availabilities, and timelines, (g)&nbsp;the expected and actual profitability and
return on investment of the Product, taking into consideration, among other factors, expected and actual (i)&nbsp;third party expenses, (ii)&nbsp;royalty, milestone, and other payments to third parties or required under this Agreement,
(iii)&nbsp;the pricing and reimbursement relating to the Product, and (iv)&nbsp;costs of exploitation of the Product, (h)&nbsp;any delays or pauses in any development or regulatory activities related to the Product relating to external factors
(including pandemic, natural disaster, government shutdown, war, terrorist attack and cyber-attack, and actions, inactions, or requirements of, or as a result of, regulatory authorities or changes in law or regulation), and (i)&nbsp;all other
relevant technical, legal, scientific, financial, commercial, medical, and other factors, including the effect that activities in one market may have on activities in another market. Rights Agent expressly understands and agrees that the use of
Commercially Reasonable Efforts may result in Parent or its Affiliates ceasing to develop, seek or obtain FDA Approval for, or commercialize the Product (in whole or in part), and that once such activities for the Product have ceased in compliance
with this definition of Commercially Reasonable Efforts, Commercially Reasonable Efforts do not require the continued <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of whether such activities must be
<FONT STYLE="white-space:nowrap">re-initiated</FONT> for the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Company Common Stock</U>&#8221; means the common stock,
$0.0001 par value per share, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>CVR Register</U>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.3(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>CVRs</U>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Delaware Courts</U>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.5</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>DTC</U>&#8221; means The Depository Trust Company or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Equity Award CVR</U>&#8221; means a CVR received by a Holder in respect of Company Options or Company RSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>FDA Approval</U>&#8221; means the full approval by the U.S. Food and Drug Administration (&#8220;<U>FDA</U>&#8221;) of a biologics
license application (&#8220;<U>BLA</U>&#8221;) to market the Product under 42 U.S.C. &#167; 262(a), either alone or in combination with another active pharmaceutical ingredient, as evidenced by the receipt by the Company of a &#8220;BLA
Approval&#8221; letter from the FDA <U>and</U> such approval (a)&nbsp;does not require the inclusion of a &#8220;boxed warning&#8221; (as defined in 21 CFR &#167; 201.57(c)(1)) in the product labeling and (b)&nbsp;does not require the implementation
of a risk evaluation and mitigation strategy required by the FDA under the authority granted to it in 21 U.S.C &#167; <FONT STYLE="white-space:nowrap">355-1,</FONT> <I>unless </I>such approval includes a combination with another active
pharmaceutical ingredient and any such &#8220;boxed warning&#8221; or implementation of a risk evaluation and mitigation strategy is not due to the Product. For the avoidance of doubt, FDA Approval does not include an accelerated approval of a BLA
pursuant to 21 U.S.C. &#167; 356(c) or 21 C.F.R. Part 601, Subpart E. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Holder</U>&#8221; means a Person in whose name a CVR is
registered in the CVR Register at the applicable time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Merger</U>&#8221; shall have the meaning set forth in the Recitals of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Merger Agreement</U>&#8221; shall have the meaning set forth in the Recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Merger Sub</U>&#8221; shall have the meaning set forth in the Recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Officer&#8217;s Certificate</U>&#8221; when used with respect to Parent means a certificate signed by the Chief Executive Officer,
the Chief Financial Officer, a Vice President or any other person duly authorized to act on behalf of Parent for such purpose or for any general purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Parent</U>&#8221; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Permitted Transfer</U>&#8221; means a transfer of CVRs (a)&nbsp;upon death of a Holder by will or intestacy; (b)&nbsp;pursuant to a
court order; (c)&nbsp;by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; or
(d)&nbsp;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, to the extent allowable by DTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Product</U>&#8221; means the efruxifermin for subcutaneous injection candidate that is being studied in the SYNCHRONY Histology
clinical trial and the SYNCHRONY Outcomes clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Rights Agent</U>&#8221; means the Rights Agent named in the first
paragraph of this Agreement, until a successor Rights Agent will have become such pursuant to the applicable provisions of this Agreement, and thereafter &#8220;Rights Agent&#8221; will mean such successor Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Termination Date</U>&#8221; means June&nbsp;30, 2031. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2. <U>Rules of Construction</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine
gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) The parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be
applied in the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) All references to days or months shall be deemed references to
calendar days or months unless otherwise specified herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) As used in this Agreement, the word &#8220;including&#8221; and words of
similar import shall mean including without limiting the generality of any description preceding such term, unless otherwise specified. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e) As used in this Agreement, the phrase &#8220;to the extent&#8221; shall mean the degree to which a subject or other thing extends and shall
not simply mean &#8220;if.&#8221; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f) Except as otherwise indicated, all references in this Agreement to &#8220;Sections&#8221; or
&#8220;Annexes&#8221; are intended to refer to Sections of this Agreement and Annexes to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g) The section headings
contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(h) The term &#8220;dollars&#8221; and character &#8220;$&#8221; shall mean United States dollars. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) Any reference to (i)&nbsp;any Governmental Body includes any successor to that Governmental Body; and (ii)&nbsp;any applicable Legal
Requirement refers to such applicable Legal Requirement as amended, modified, supplemented, or replaced from time to time (and, in the case of statutes, include any rule and regulation promulgated under such statute) and references to any section of
any applicable Legal Requirement includes any successor to such section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. CONTINGENT VALUE RIGHTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1. <U>CVRs</U>. The contingent value rights represent the rights of Holders to receive contingent cash payments pursuant to this Agreement
(&#8220;<U>CVRs</U>&#8221;). The initial Holders will be determined pursuant to the terms of the Merger Agreement and the Company Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.2.
<U>Nontransferable</U>. The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.3. <U>No Certificate; Registration; Registration of Transfer; Change of Address</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) The CVRs will not be evidenced by a certificate or other instrument. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent, acting solely for this purpose as a <FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of Parent, will keep a
register (the &#8220;<U>CVR Register</U>&#8221;) for the purpose of recording the names and addresses of the applicable Holders, as well as transfers of CVRs as herein provided. The entries in the CVR Register shall be conclusive absent manifest
error, and Parent and the Rights Agent shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Holder hereunder for all purposes of this Agreement.&nbsp;The Register shall be available for inspection by the
Parent at any reasonable time and from time to time upon reasonable prior notice. The parties intend that any imputed interest in or with respect to the CVRs under this Agreement be treated as being issued and maintained in &#8220;registered
form&#8221; within the meaning of Sections 163(f), 871(h)(2), and 881(c)(2) of the Code and any regulations thereunder, including under United States Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;5f.103-1(c)</FONT> and Proposed
Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.163-5</FONT> (and any successor provisions), and the provisions of this Agreement shall be construed in a manner that gives effect to such intent. The CVR Register shall set forth
(x)&nbsp;with respect to holders of Company Common Stock that hold such shares in book-entry form through DTC immediately prior to the Effective Time, one (1)&nbsp;position for Cede&nbsp;&amp; Co. (as nominee of DTC) representing all such shares of
Company Common Stock that were converted into the right to receive the Merger Consideration as a consequence of the Merger in accordance with the terms of the Merger Agreement, and (y)&nbsp;with respect to (A)&nbsp;holders of shares of Company
Common Stock that hold such shares in certificated form immediately prior to the Effective Time that were converted into the right to receive the Merger Consideration as a consequence of the Merger in accordance with the terms of the Merger
Agreement, upon delivery to the Paying Agent by each such holder of the applicable stock certificates, together with a validly executed letter of transmittal and such other customary documents as may be reasonably requested by the Paying Agent, in
accordance with the Merger Agreement, (B)&nbsp;holders of shares of Company Common Stock that hold such shares in book-entry form through the Company&#8217;s transfer agent immediately prior to the Effective Time that were converted into the right
to receive the Merger Consideration as a consequence of the Merger in accordance with the terms of the Merger Agreement, upon delivery to the Paying Agent by each such holder of a customary agent&#8217;s message and such other customary documents as
may be reasonably requested by the Paying Agent, in accordance with the Merger Agreement, (C)&nbsp;holders of In the Money Options, and (D)&nbsp;holders of Company RSUs, in each case of <U>clauses (A)</U>&nbsp;through <U>(D)</U>, the applicable
number of CVRs to which each such holder is entitled pursuant to the Merger Agreement (other than, in the case of the foregoing clauses (x), (y)(A) and (y)(B), those who have perfected their appraisal rights in accordance with Section&nbsp;262 of
the General Corporation Law of the State of Delaware), and (z)&nbsp;with respect to holders of Company Warrants, the applicable number of CVRs to which such holder is entitled pursuant to the Merger Agreement and the Company Warrants upon exercise
of such Company Warrants. The CVR Register will be updated as necessary by the Rights Agent to reflect the addition or removal of Holders (pursuant to any Permitted Transfers), upon the written receipt of such information by the Rights Agent. The
Rights Agent will have no responsibility whatsoever directly to the street name holders with respect to transfers of CVRs. With respect to any payments to be made under <U>Section</U><U></U><U>&nbsp;2.4</U>, the Rights Agent will accomplish the
payment to any former street name holders of shares of Company Common Stock by sending one lump payment to DTC. The Rights Agent will have no responsibilities whatsoever with regard to the distribution of payments by DTC to such street name holders.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) Subject to the restrictions on transferability set forth in
<U>Section</U><U></U><U>&nbsp;2.2</U>, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer in form reasonably satisfactory to the Rights Agent pursuant to its guidelines, duly executed by the
Holder thereof, the Holder&#8217;s attorney duly authorized in writing, the Holder&#8217;s personal representative or the Holder&#8217;s survivor, and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of
such written notice, the Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form and the transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of
<U>Section</U><U></U><U>&nbsp;2.2</U>), register the transfer of the CVRs in the CVR Register. No service charge shall be made for any registration of transfer of a CVR, but Parent and the Rights Agent may require the Holder to pay a sum sufficient
to cover any Tax or governmental charge that is imposed in connection with any such registration of transfer. The Rights Agent shall have no duty or obligation to take any action under any section of this Agreement that requires the payment by a
Holder of a CVR of applicable Taxes or charges unless and until the Rights Agent is satisfied that all such Taxes or charges have been paid by the Holder or that no payment of any such Taxes or charges is required. All duly transferred CVRs
registered in the CVR Register will be the valid obligations of Parent and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a CVR will
be valid until registered in the CVR Register. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) A Holder may make a written request to the Rights Agent to change such Holder&#8217;s
address of record in the CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form,
promptly record the change of address in the CVR Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.4. <U>Payment Procedures</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) On the Approval Milestone Payment Date, if any, Parent shall deposit or cause to be deposited with the Rights Agent by wire transfer to the
account designated by the Rights Agent an amount equal to the product of (i)&nbsp;the Approval Milestone Payment multiplied by (ii)&nbsp;the number of CVRs held by the Holders (other than Equity Award CVRs), and the Rights Agent shall promptly (but
in any event within five (5)&nbsp;Business Days) pay to each Holder of record of the CVRs (other than Equity Award CVRs) as of 5:00 PM EST on the Approval Milestone Payment Date, an amount equal to the product of (i)&nbsp;the Approval Milestone
Payment multiplied by (ii)&nbsp;the number of CVRs held by such Holder as of the Approval Milestone Payment Date by check mailed to the address of each Holder as reflected in the CVR Register or, in the case of any former street name holders of
shares of Company Common Stock, by sending one lump payment to DTC pursuant to <U>Section</U><U></U><U>&nbsp;2.3(b)</U>. Parent will pay through the Surviving Corporation&#8217;s or another of its Affiliates&#8217; payroll system, payroll provider
or standard accounts payable procedure, as applicable, to each Holder of an Equity Award CVR an amount equal to the product of (i)&nbsp;the Approval Milestone Payment multiplied by (ii)&nbsp;the number of Equity Award CVRs held by such Holder as of
the Approval Milestone Payment Date (less applicable Tax withholdings and other authorized deductions) within five (5)&nbsp;business days of the Approval Milestone Payment Date, subject to <U>Section</U><U></U><U>&nbsp;2.4(b)</U>. Notwithstanding
the foregoing, in no event shall Parent be required to pay any Approval Milestone Payment more than once. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Parent and any of its Affiliates and the Rights Agent shall be entitled to deduct and
withhold, or cause to be deducted and withheld, from any amounts payable or otherwise deliverable pursuant to this Agreement to any Holder such amounts as are required to be deducted and withheld therefrom under the Code or the Treasury Regulations
thereunder or any other Legal Requirement. With respect to Holders who received Equity Award CVRs, any such withholding may be made, or caused to be made, by Parent through the Surviving Corporation&#8217;s or its Affiliates&#8217; (including
Parent&#8217;s) payroll system, payroll provider or standard accounts payable procedure, as applicable, or any successor of the foregoing. To the extent such amounts are so deducted or withheld, such amounts shall be treated for all purposes under
this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) Any portion of any Approval
Milestone Payment that remains undistributed to the Holders six (6)&nbsp;months after the Approval Milestone Payment Date will be delivered by the Rights Agent to Parent, upon demand, and any Holder will thereafter look only to Parent for payment of
such Approval Milestone Payment, without interest, but such Holder will have no greater rights against Parent than those accorded to general unsecured creditors of Parent under applicable Legal Requirement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) Neither Parent nor the Rights Agent will be liable to any Person in respect of any Approval Milestone Payment delivered to a public
official pursuant to any applicable abandoned property, escheat or similar Legal Requirement. If any Approval Milestone Payment has not been paid immediately prior to the date on which such Approval Milestone Payment would otherwise escheat to or
become the property of any Governmental Body, any such Approval Milestone Payment will, to the extent permitted by applicable Legal Requirement, become the property of Parent, free and clear of all claims or interest of any Person previously
entitled thereto. In addition to and not in limitation of any other indemnity obligation herein, Parent agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be
subject to in connection with transferring such property to Parent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e) Except to the extent otherwise required pursuant to a
&#8220;determination&#8221; within the meaning of Section&nbsp;1313(a) of the Code, Parent, the Rights Agent and/or Holders, as applicable, shall determine the portion of the Approval Milestone Payment required to be treated as interest for U.S.
federal income tax purposes pursuant to Section&nbsp;483 of the Code and the Treasury Regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f) The Rights
Agent shall be responsible for information reporting required under applicable Legal Requirements with respect to the CVRs (other than Equity Award CVRs), including reporting the fair market value of the CVRs (other than Equity Award CVRs) upon the
Holders&#8217; receipt of such CVRs on Internal Revenue Service Form <FONT STYLE="white-space:nowrap">1099-B</FONT> and reporting the Approval Milestone Payments hereunder on Internal Revenue Service Form
<FONT STYLE="white-space:nowrap">1099-B</FONT> or other applicable form to the extent required under applicable Legal Requirement. Parent shall provide the Rights Agent with properly completed &#8220;Standard Tax Reporting Instructions&#8221;
contained in Annex I hereto, which shall contain the fair market value of the CVRs and the Parent shall use commercially reasonable efforts to cooperate with the Rights Agent to provide any other information reasonably necessary for the Rights Agent
to carry out its obligations in this <U>Section</U><U></U><U>&nbsp;2.4(f)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.5. <U>No Voting, Dividends or Interest; No Equity or Ownership Interest in Parent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) The CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable on the CVRs to any Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) The CVRs will not represent any equity or ownership interest in Parent or in any constituent company to the Merger. It is hereby
acknowledged and agreed that a CVR shall not constitute a security of Parent or any of its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.6. <U>Diligence Obligation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) From the Closing Date until the Termination Date, Parent shall, and shall cause the Surviving Corporation to, use Commercially Reasonable
Efforts to (i)&nbsp;conduct the SYNCHRONY Histology clinical trial and the SYNCHRONY Outcomes clinical trial and (ii)&nbsp;upon achievement of the primary end point in both such clinical trials, file for and seek FDA Approval for the Product for the
treatment of patients with compensated cirrhosis (consistent with stage F4c fibrosis) due to metabolic dysfunction-associated steatohepatitis. Parent&#8217;s obligation to use Commercially Reasonable Efforts under this
<U>Section</U><U></U><U>&nbsp;2.6(a)</U> shall be fully satisfied and shall cease, and thereafter Parent shall have the right, in its sole and absolute discretion, to direct and control the development of the Product in all respects without any
further obligations pursuant to this Agreement upon the earlier of (i)&nbsp;the first filing for FDA Approval for the Product for the treatment of patients with compensated cirrhosis (consistent with stage F4c fibrosis) due to metabolic
dysfunction-associated steatohepatitis and (ii)&nbsp;the date on which the SYNCHRONY Histology clinical trial or the SYNCHRONY Outcomes clinical trial does not meet its primary endpoint. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Parent owes no obligation or duty, as a fiduciary or otherwise, to the Rights Agent, any Holder or any other Person in connection with its
operation of the Surviving Corporation&#8217;s business following the Closing except as set forth in <U>Section</U><U></U><U>&nbsp;2.6(a)</U> above. The Rights Agent (on behalf of itself and on behalf of the Holders) acknowledges that
(i)&nbsp;Parent makes (x)&nbsp;no guarantees or promises that the Approval Milestone will be achieved at all or by a specific date or is achievable or that any clinical trial for the Product will meet its primary endpoint or otherwise be successful,
and (y)&nbsp;no assessments or predictions regarding the likelihood of the Approval Milestone being achieved has been or is provided hereby, and no reliance thereon should be made, (ii)&nbsp;there is no assurance that the Holders will receive any
payment as described under <U>Section</U><U></U><U>&nbsp;2.4</U> unless the Approval Milestone is achieved, (iii)&nbsp;Parent has not, prior to or after the date hereof, promised or projected any amounts to be received by the Holders in respect of
any payments described in <U>Section</U><U></U><U>&nbsp;2.4</U>, (iv) subject to the obligations in <U>Section</U><U></U><U>&nbsp;2.6(a)</U>, none of the Rights Agent and any Holder is relying on or has relied on any promises, projections,
representation or warranty of any kind or other information, documents or materials (or absence thereof) in respect of any payments described in <U>Section</U><U></U><U>&nbsp;2.4</U> including with respect to the operation of the Surviving
Corporation&#8217;s business following the Closing, (v)&nbsp;except for Parent&#8217;s obligations set forth in <U>Section</U><U></U><U>&nbsp;2.6(a)</U>, Parent shall have the right to own, operate, use, license, develop and otherwise commercialize
the assets of the Surviving Corporation&#8217;s business (or not) in any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
way that Parent deems appropriate in its sole business judgment and (vi)&nbsp;except for Parent&#8217;s obligations set forth in <U>Section</U><U></U><U>&nbsp;2.6(a)</U>, Parent does not have any
obligation, express or implied, to develop, manufacture, commercialize, or otherwise exploit the assets of the Surviving Corporation&#8217;s business in order to maximize or expedite the payments described in <U>Section</U><U></U><U>&nbsp;2.4</U>.
Except for Parent&#8217;s obligations set forth in <U>Section</U><U></U><U>&nbsp;2.6(a)</U>, the Rights Agent (on behalf of itself and on behalf of the Holders) hereby (a)&nbsp;disclaims reliance on any such promises, projections, representations,
warranties or other information, documents or materials (or absence thereof), and (b)&nbsp;understands and agrees that any such promises, representations, warranties, projections and other information, documents and materials (or absence thereof)
are specifically disclaimed by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. THE RIGHTS AGENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1. <U>Certain Duties and Responsibilities</U>. The Rights Agent will not have any liability for any actions taken or not taken in connection with this
Agreement, except to the extent of its willful misconduct, bad faith or gross negligence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2. <U>Certain Rights of the Rights Agent</U>. The Rights
Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent. In addition: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) the Rights Agent may rely and will be protected in acting or refraining from acting upon any resolution, certificate, statement,
instrument, opinion, report, notice, request, direction, consent, order or other paper or document reasonably believed by it to be genuine and to have been signed or presented by the proper party or parties; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking, suffering or omitting any action
hereunder, the Rights Agent may rely upon an Officer&#8217;s Certificate, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of bad faith, gross negligence or willful
misconduct on its part, incur no liability for or in respect of any action taken, suffered or omitted to be taken by it under the provisions of this Agreement in reliance upon such certificate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) the Rights Agent may engage and consult with counsel of its selection and the written advice of such counsel or any opinion of counsel will
be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) the permissive rights of the Rights Agent to do things enumerated in this Agreement will not be construed as a duty; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e) the Rights Agent will not be required to give any note or surety in respect of the execution of such powers or otherwise in respect of the
premises; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f) the Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this
Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by Parent only; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g) the Rights Agent will have no liability in respect of the validity of this Agreement or
the execution and delivery hereof (except the due execution and delivery hereof by the Rights Agent); nor shall it be responsible for any breach by Parent of any covenant or condition contained in this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(h) Parent agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless against, any loss, liability, claim, demands, suits or
expense arising out of or in connection with the Rights Agent&#8217;s duties under this Agreement, including the reasonable costs and expenses of defending the Rights Agent against any claims, charges, demands, suits or loss, incurred in the absence
of bad faith, gross negligence or willful misconduct on its part; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) the Rights Agent shall not be liable for consequential damages under
any provision of this Agreement or for any consequential damages arising out of any act or failure to act hereunder in the absence of bad faith, gross negligence or willful misconduct on its part; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(j) No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in
the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to
it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.3. <U>Resignation and Removal; Appointment of Successor</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent may resign at any time by giving written notice thereof to Parent specifying a date when such resignation will take
effect, which notice will be sent at least sixty (60)&nbsp;days prior to the date so specified but in no event will such resignation become effective until a successor Rights Agent has been appointed. Parent has the right to remove the Rights Agent
at any time but no such removal will become effective until a successor Rights Agent has been appointed. Notice of such removal will be given by Parent to the Rights Agent, which notice will be sent at least sixty (60)&nbsp;days prior to the date so
specified. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) If the Rights Agent provides notice of its intent to resign, is removed or becomes incapable of acting, Parent will as soon
as is reasonably possible appoint a qualified successor Rights Agent who may be a Holder but may not be an officer of Parent. The successor Rights Agent so appointed will, forthwith upon its acceptance of such appointment in accordance with
<U>Section</U><U></U><U>&nbsp;3.4</U>, become the successor Rights Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) Parent will give notice of each resignation and each removal
of a Rights Agent and each appointment of a successor Rights Agent by mailing written notice of such event by first-class mail to the Holders as their names and addresses appear in the CVR Register. Each notice will include the name and address of
the successor Rights Agent. If Parent fails to send such notice within twenty (20)&nbsp;days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.4. <U>Acceptance of Appointment by Successor</U>. Every successor Rights Agent appointed hereunder will
execute, acknowledge and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and thereupon such successor Rights Agent, without any further act, deed or conveyance, will
become vested with all the rights, powers, trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring Rights Agent will execute and deliver an instrument transferring to the successor Rights
Agent all the rights, powers and trusts of the retiring Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. COVENANTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1. <U>List of Holders</U>. Parent will furnish or cause to be furnished to the Rights Agent in such form as Parent receives from the Company&#8217;s
transfer agent (or other agent performing similar services for the Company with respect to other shares of Company Common Stock, In the Money Options, Company RSUs or Company Warrants), the names and addresses of the Holders within twenty
(20)&nbsp;Business Days of the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. AMENDMENTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1. <U>Amendments without Consent of </U><U>Holders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Without the consent of any Holders or the Rights Agent, Parent at any time and from time to time, may enter into one or more amendments
hereto, to evidence the succession of another Person to Parent and the assumption by any such successor of the covenants of Parent herein as provided in, and to the extent consistent with, <U>Section</U><U></U><U>&nbsp;6.3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Without the consent of any Holders or the Rights Agent, Parent and the Surviving Corporation, at any time and from time to time, may enter
into one or more amendments hereto, for any of the following purposes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) to evidence the succession of another Person as a successor
Rights Agent and the assumption by any such successor of the covenants and obligations of the Rights Agent herein; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) to add to the
covenants of Parent such further covenants, restrictions, conditions or provisions as Parent and the Rights Agent will consider to be for the protection of the Holders; <U>provided</U> that, in each case, such provisions do not adversely affect the
interests of the Holders (as a group and in their capacity as such); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii) to cure any ambiguity, to correct or supplement any provision
herein that may be defective or inconsistent with any other provision herein, or to make any other provisions with respect to matters or questions arising under this Agreement; <I>provided</I> that, in each case, such provisions do not adversely
affect the interests of the Holders (as a group and in their capacity as such); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iv) as may be necessary or appropriate to ensure that the
CVRs are not subject to registration under the Securities Act (and the rules and regulations promulgated thereunder) or the Exchange Act, and to ensure that the CVRs are not subject to any similar registration or prospectus requirement under
applicable securities Legal Requirements outside of the United States; <U>provided</U> that, in each case, such amendments do not change the Approval Milestone, the Termination Date or the amount of the Approval Milestone Payment; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(v) to reduce the number of CVRs, in the event and to the extent any Holder agrees to
renounce such Holder&#8217;s rights under this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;6.4</U>; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(vi) any other
amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition, elimination or change is adverse to the interests of the Holders (as a group and in their capacity as such). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this
<U>Section</U><U></U><U>&nbsp;5.1</U>, Parent will mail (or cause the Rights Agent to mail) a notice thereof by first class mail to the Holders at their addresses as they appear on the CVR Register, setting forth such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.2. <U>Amendments with Consent of Holders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Without limiting the right to amend pursuant to <U>Section</U><U></U><U>&nbsp;5.1</U>, with the consent of the Holders of not less than
twenty percent (20%) of the outstanding CVRs, whether evidenced in writing or taken at a meeting of the Holders, Parent and the Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any
provisions of this Agreement, even if such addition, elimination or change is materially adverse to the interests of the Holders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)
Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this <U>Section</U><U></U><U>&nbsp;5.2</U>, Parent will mail (or cause the Rights Agent to mail) a notice thereof by first class mail to the
Holders at their addresses as they appear on the CVR Register, setting forth such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.3. <U>Execution of Amendments</U>. In executing any
amendment permitted by this <U>Section</U><U></U><U>&nbsp;5</U>, the Rights Agent will be entitled to receive, and will be fully protected in relying upon, an opinion of counsel selected by Parent (including
<FONT STYLE="white-space:nowrap">in-house</FONT> counsel) stating that the execution of such amendment is authorized or permitted by this Agreement. The Rights Agent may, but is not obligated to, enter into any such amendment that affects the Rights
Agent&#8217;s own rights, privileges, covenants or duties under this Agreement or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.4. <U>Effect of Amendments</U>. Upon the execution of any
amendment under this <U>Section</U><U></U><U>&nbsp;5</U>, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. OTHER PROVISIONS OF GENERAL APPLICATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1. <U>Notices to
the Rights Agent and </U><U>Parent</U>. All notices and other communications required or permitted to be given to any party hereunder shall be in writing and shall be deemed properly delivered on (a)&nbsp;the date and time of delivery if delivered
personally, (b)&nbsp;the date and time of transmittal if delivered by email (<I>provided</I>, no &#8220;bounce back&#8221; or similar message of <FONT STYLE="white-space:nowrap">non-delivery</FONT> is received with respect thereto), (c) the first
(1st) business day following the date of dispatch if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivered utilizing a <FONT STYLE="white-space:nowrap">next-day</FONT> service by a recognized <FONT STYLE="white-space:nowrap">next-day</FONT> courier or (d)&nbsp;upon confirmed receipt if
delivered by registered or certified mail, return receipt requested, postage prepaid. All notices or other communications hereunder shall be delivered to the addresses or email addresses set forth below, or pursuant to such other instructions as the
party to receive such notice or communication shall have specified in a written notice given to the other parties: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to the Rights Agent:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&#8201;<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to Parent or Ultimate Parent: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&#8201;<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Ropes&nbsp;&amp; Gray LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">800
Boylston Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston, MA 02199 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:&#8195;&#8195;Emily J. Oldshue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;Christopher D. Comeau </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&#8195;&#8195;&#8195;&#8201;emily.oldshue@ropesgray.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;christopher.comeau@ropesgray.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2. <U>Notice to Holders</U>. Where this Agreement provides for notice to Holders, such notice will be sufficiently given (unless otherwise herein expressly
provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at the Holder&#8217;s address as it appears in the CVR Register, not later than the latest date, and not earlier than the earliest date, if any,
prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder will affect the sufficiency of such notice with
respect to other Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.3. <U>Parent Successors and Assigns</U>. Parent shall not assign any of its rights, interests or obligations hereunder, other
than in accordance with this<U> Section</U><U></U><U>&nbsp;6.3</U>. Parent may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more Affiliate(s) of
Parent or to any purchaser or exclusive licensee of all or substantially all rights to the Product (each, an &#8220;<U>Assignee</U>&#8221;); <I>provided</I> that the Assignee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agrees to assume and be bound by all of the terms of this Agreement. Any such Assignee may thereafter assign, in its sole discretion and without the consent of any other party, any or all of its
rights, interests and obligations hereunder to one or more additional Assignees in compliance with this <U>Section</U><U></U><U>&nbsp;6.3</U>. In connection with any assignment to an Assignee, Parent (and such assignor, if applicable) will remain
liable for performance by Parent (and such assignor, if applicable) of its obligations hereunder. This Agreement will be binding upon, inure to the benefit of and be enforceable by each Assignee, and this Agreement shall not restrict Parent&#8217;s
or any of its Affiliates&#8217; or Assignee&#8217;s ability to merge or consolidate, subject to compliance with this <U>Section</U><U></U><U>&nbsp;6.3</U> to the extent there is an applicable assignment in connection with such merger or
consolidation. Each of Parent&#8217;s <FONT STYLE="white-space:nowrap">non-Affiliate</FONT> Assignees shall expressly assume by an instrument supplemental hereto, executed and delivered to the Rights Agent, the due and punctual payment of the CVRs
and the due and punctual performance and observance of all of the covenants and obligations of this Agreement to be performed or observed by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.4.
<U>Benefits of </U><U>Agreement</U>. Nothing in this Agreement, express or implied, will give to any Person (other than the Rights Agent, Parent, Parent&#8217;s successors and assignees, the Holders, and the Holders&#8217; successors and assigns
pursuant to a Permitted Transfer) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the, Rights
Agent, Parent, Parent&#8217;s successors and assignees, the Holders, and the Holders&#8217; successor and assigns pursuant to a Permitted Transfer. The rights of Holders are limited to the right to receive payment from the Rights Agent in respect of
the CVRs when due and payable in accordance with <U>Section</U><U></U><U>&nbsp;2.4</U>. All other obligations of Parent or its successor or assigns hereunder may only be enforced by the Rights Agent. Neither the Holders nor the Rights Agent shall be
entitled to specific enforcement of <U>Section</U><U></U><U>&nbsp;2.6</U>. Notwithstanding anything to the contrary contained herein, any Holder may agree to renounce, in whole or in part, such Holder&#8217;s rights under this Agreement by written
notice to the Rights Agent and Parent, which notice, if given, shall be irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.5. <U>Governing Law</U>. This Agreement, the CVRs and any other
matters or disputes relating thereto shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. In any
action or proceeding arising out of or relating to this Agreement or the CVRs: (i)&nbsp;each of the parties irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of: (A)&nbsp;the Chancery Court of the State of
Delaware and any state appellate court therefrom, (B)&nbsp;if (but only if) the court in <U>clause (A)</U>&nbsp;lacks subject matter jurisdiction, the Superior Court of the State of Delaware sitting in New Castle County and any state appellate court
therefrom or (C)&nbsp;if (but only if) the courts in <U>clauses (A)</U>&nbsp;and <U>(B)</U> lack subject matter jurisdiction, the United States District Court in the State of Delaware and any appellate court therefrom (collectively, the courts
described in <U>clauses (A)</U>&nbsp;through <U>(C)</U>, the &#8220;<U>Delaware Courts</U>&#8221;); and (ii)&nbsp;each of the parties irrevocably consents to service of process by first class certified mail, return receipt requested, postage
prepaid, to the address at which such party is to receive notice in accordance with <U>Section</U><U></U><U>&nbsp;6.1</U>. Each of the parties irrevocably and unconditionally (1)&nbsp;agrees not to commence any such action or proceeding except in
the Delaware Courts, (2)&nbsp;agrees that any claim in respect of any such action or proceeding may be heard and determined in the Delaware Courts, (3)&nbsp;waives, to the fullest extent it may legally and effectively do so, any objection that it
may now or hereafter have to the jurisdiction or laying of venue of any such action or proceeding in the Delaware Courts and (4)&nbsp;waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such
action or proceeding in the Delaware Courts. The parties agree that a final </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable Legal Requirements;
<I>provided</I>,<I> however</I>, that nothing in the foregoing shall restrict any party&#8217;s rights to seek any post-judgment relief regarding, or any appeal from, such final trial court judgment. In the event of any litigation or other
proceeding between the parties to this Agreement arising out of or in any way related to the Approval Milestone or payment thereof, the prevailing party in such litigation or other proceeding shall be entitled to recover its reasonable
attorneys&#8217; fees, costs and expenses incurred in connection with such litigation or other proceeding, in addition to any other relief to which such party may be entitled; <I>provided</I>, <I>however</I>, that in no event will any party to this
Agreement be required to pay any contingency based attorneys&#8217; fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.6. <U>Severability</U>. Any term or provision of this Agreement that is
invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other
situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties agree that the court making such determination shall have
the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or
unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties agree to replace such invalid or unenforceable
term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.7. <U>Counterparts and Signature</U>. This Agreement may be executed in two or more counterparts, including by
<FONT STYLE="white-space:nowrap">e-signature</FONT> or by email with .pdf attachments, all of which shall be considered one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the parties and
delivered to the other parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.8. <U>Termination</U>. This Agreement will be terminated and of no force or effect, the parties hereto will have no
liability hereunder (other than with respect to monies due and owing by Parent to the Rights Agent prior to the effectiveness of such termination), and no payments will be required to be made, upon the earlier to occur of (a)&nbsp;the payment by the
Rights Agent or Parent or one (1)&nbsp;or more of its Affiliates, as applicable, to each Holder as reflected in the CVR Register of the full amount of the Approval Milestone Payment required to be paid under the terms of this Agreement and
(b)&nbsp;the failure to achieve the Approval Milestone prior to the Termination Date. No termination shall affect the Holders&#8217; rights to any payment accrued prior to the effective date of such termination and the provisions of this
<U>Section</U><U></U><U>&nbsp;6</U> shall survive any such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.9. <U>Entire Agreement</U>. This Agreement, the Merger Agreement (including its
Exhibits, Annexes and the Company Disclosure Schedule) and the Confidentiality Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties and their
respective Affiliates, with respect to the subject matter hereof and thereof. If and to the extent that any provision of this Agreement is inconsistent or conflicts with the Merger Agreement, this Agreement will govern and be controlling with
respect to CVRs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.10. <U>Confidentiality</U>. The Rights Agent and Parent agree that all books, records, information and
data pertaining to the business of the other party that are exchanged or received pursuant to the negotiation or the carrying out of this Agreement, including the amount and terms of fees for services, shall remain confidential, and shall not be
voluntarily disclosed to any other person, except as may be required by applicable Legal Requirements. However, each party may disclose relevant aspects of the other party&#8217;s confidential information to its officers, Affiliates, agents,
subcontractors and employees to the extent reasonably necessary to perform its duties and obligations under this Agreement if such disclosure is not prohibited by applicable Legal Requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.11. <U>Parent Guarantee</U>. Ultimate Parent hereby guarantees the due and punctual performance by Parent of its obligations in accordance with this
Agreement, and agrees that in the event Parent fails to timely perform any obligation under this Agreement in accordance with the terms of this Agreement, Ultimate Parent will perform such obligation in accordance with the terms of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its
behalf by its duly authorized officers as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[PARENT]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Solely with respect to <U>Section</U><U></U><U>&nbsp;6.11</U>,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">NOVO NORDISK A/S</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its
behalf by its duly authorized officers as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[RIGHTS AGENT]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ANNEX I </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Standard Tax Reporting Instructions </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#9679;] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF CERTIFICATE OF INCORPORATION OF THE SURVIVING CORPORATION </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FIFTH AMENDED AND RESTATED </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CERTIFICATE OF INCORPORATION </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>OF </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AKERO THERAPEUTICS,
INC. </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The name of this corporation is Akero Therapeutics, Inc. (the &#8220;<U>Corporation</U>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The registered office of this Corporation in the State of Delaware is located at: c/o The Corporation Trust Company, 1209 Orange Street in
the City of Wilmington, County of New Castle, 19801. The name of the registered agent at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General
Corporation Law of the State of Delaware (the &#8220;<U>DGCL</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. The total number of shares of stock that the Corporation
shall have authority to issue is 100 shares of common stock, $0.001 par value per share (&#8220;<U>Common Stock</U>&#8221;). Each share of Common Stock shall be entitled to one vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Shares of Common Stock may be issued in fractions of a share. Each fractional share of Common Stock shall be entitled to a vote in
proportion to such fractional share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Except as otherwise provided in the provisions establishing a class of stock, the number of
authorized shares of any class or series of stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the Corporation entitled to
vote irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. The business and affairs of the Corporation shall be
managed by or under the direction of the Board of Directors. The size of the Board of Directors shall be determined as set forth in the bylaws of the Corporation, as in effect from time to time (the &#8220;<U>Bylaws</U>&#8221;). The election of
directors need not be by written ballot unless the Bylaws shall so require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. In furtherance and not in limitation of the power
conferred upon the Board of Directors by law, the Board of Directors shall have power to make, adopt, alter, amend and repeal from time to time the Bylaws, subject to the right of the stockholders entitled to vote with respect thereto to alter and
repeal Bylaws made by the Board of Directors. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. (a) A director of the Corporation shall not be personally liable to the Corporation or
its stockholders for monetary damages for breach of his or her fiduciary duty as a director, except for liability (a)&nbsp;for any breach of the director&#8217;s duty of loyalty to the Corporation or its stockholders, (b)&nbsp;for acts or omissions
not in good faith or which involve intentional misconduct or a knowing violation of law, (c)&nbsp;under Section&nbsp;174 of the DGCL or (d)&nbsp;for any transaction from which the director derived an improper personal benefit. If the DGCL is amended
after the effective date of this Fifth Amended and Restated Certificate of Incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be
eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any amendment, repeal or modification of this
Section&nbsp;9 either of (i)&nbsp;the stockholders of the Corporation or (ii)&nbsp;an amendment to the DGCL, shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts
or omissions occurring before such amendment, repeal or modification of a person serving as a director at the time of such amendment, repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Corporation shall have the power to purchase and maintain, at its expense, insurance on behalf of any person who is or was a director,
officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, limited liability company, joint venture, trust or other enterprise,
against any expense, liability or loss asserted against such person and incurred by such person in any such capacity, or arising out of such person&#8217;s status as such, whether or not the Corporation would have the power to indemnify such person
against such expense, liability or loss under the DGCL or the terms of this Fifth Amended and Restated Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
Notwithstanding anything herein to the contrary, the affirmative vote of not less than two thirds (2/3) of the outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of not less than two thirds (2/3) of the
outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of this Section&nbsp;9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. An Officer (as defined below) of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary
damages for breach of his or her fiduciary duty as an officer of the Corporation, except for liability (a)&nbsp;for any breach of the Officer&#8217;s duty of loyalty to the Corporation or its stockholders, (b)&nbsp;for acts or omissions not in good
faith or which involve intentional misconduct or a knowing violation of law, (c)&nbsp;for any transaction from which the Officer derived an improper personal benefit, or (d)&nbsp;arising from any claim brought by or in the right of the Corporation.
If the DGCL is amended after the effective date of this Fifth Amended and Restated Certificate of Incorporation to authorize corporate action further eliminating or limiting the personal liability of Officers, then the liability of an Officer of the
Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. For purposes of this Section&nbsp;10, &#8220;Officer&#8221; shall mean an individual who has been duly appointed as an officer of the Corporation
and who, at the time of an act or omission as to which liability is asserted, is deemed to have consented to service of process to the registered agent of the Corporation as contemplated by 10 Del. C. &#167; 3114(b). Any amendment, repeal or
modification of this Section&nbsp;10 by either of (i)&nbsp;the stockholders of the Corporation or (ii)&nbsp;an amendment to the DGCL, shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification
with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a Director or Officer, as applicable, at the time of such amendment, repeal or modification </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. The books of the Corporation may (subject to any statutory requirements) be kept outside
the State of Delaware as may be designated by the Board of Directors or in the Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. The Corporation shall not be governed by
Section&nbsp;203 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. (a) Unless the Corporation consents in writing to the selection of an alternative forum, the Court of
Chancery of the State of Delaware (the &#8220;<U>Chancery Court</U>&#8221;) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation,
(ii)&nbsp;any action asserting a claim for breach of a fiduciary duty owed by any director, officer, employee or agent of the Corporation to the Corporation or its stockholders, (iii)&nbsp;any action asserting a claim against the Corporation arising
pursuant to any provision of the DGCL, this Fifth Amended and Restated Certificate of Incorporation or the Bylaws, or (iv)&nbsp;any action asserting a claim against the Corporation governed by the internal affairs doctrine, in all cases, subject to
the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. Any person or entity purchasing or otherwise acquiring any interest in the shares of capital stock of the Corporation will be deemed to have notice of
and consented to the provisions of this Section&nbsp;13. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any person or entity that purchases or otherwise acquires any interest in
the shares of capital stock of the Corporation will be deemed to have (i)&nbsp;consented and submitted to the personal jurisdiction of the Chancery Court in connection with any action described in Section&nbsp;13(a) above (an
&#8220;<U>Action</U>&#8221;), (ii) waived any objection to the exercise of personal jurisdiction over such stockholder in the Chancery Court, (iii)&nbsp;waived any argument relating to the inconvenience of the forums referenced above in connection
with any Action, (iv)&nbsp;agreed not to commence any such Action other than before the Chancery Court nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such Action to any court other than
the Chancery Court whether on the grounds of inconvenient forum or otherwise, and (v)&nbsp;consented to having service of process made upon such person or entity by service upon such person&#8217;s or entity&#8217;s counsel as agent for such person
or entity in the event that such person or entity brings an Action in a court other than the Chancery Court. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Fifth Amended and Restated Certificate of Incorporation is executed as of this __ day
of __, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AKERO THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Fifth Amended and Restated Certificate of Incorporation</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d42650dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENT TO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BYLAWS </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AKERO THERAPEUTICS, INC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE VI </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>MISCELLANEOUS
PROVISIONS </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>SECTION 8.</U></B><B> </B><B><U>Exclusive Jurisdiction of Delaware Courts or the United States Federal District Courts.</U></B>
Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if such court does not have jurisdiction thereof, another state court or a federal district court located within
the State of Delaware) shall be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by
any current or former director, officer or other employee of the Corporation to the Corporation or the Corporation&#8217;s stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation
Law or the Certificate or Bylaws (including the interpretation, validity or enforceability thereof), or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Unless the Corporation consents in writing to the selection of
an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or
entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section&nbsp;8. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d42650dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Advances Akero&#8217;s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 </B>&#8211; Akero Therapeutics, Inc. (&#8220;Akero&#8221;) (Nasdaq: AKRO), a clinical-stage company developing
transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has entered into a definitive agreement to be acquired by Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;) for up to
$5.2&nbsp;billion in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Akero shareholders will receive $54.00 per share in cash at closing and a <FONT
STYLE="white-space:nowrap">non-transferable</FONT> Contingent Value Right (&#8220;CVR&#8221;). Each CVR will entitle its holder to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin (&#8220;EFX&#8221;) for
treatment of compensated cirrhosis due to MASH by June&nbsp;30, 2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The upfront cash portion of the consideration represents an equity value of
approximately $4.7&nbsp;billion, a 19% premium to Akero&#8217;s <FONT STYLE="white-space:nowrap">30-day</FONT> Volume Weighted Average Price (VWAP), and a 42% premium to Akero&#8217;s closing price on May&nbsp;19, 2025 prior to market speculation.
Combined, the upfront and potential contingent value payment represent, if achieved, an equity value of approximately $5.2&nbsp;billion, a 32% premium to Akero&#8217;s <FONT STYLE="white-space:nowrap">30-day</FONT> VWAP, and a 57% premium to
Akero&#8217;s closing price on May&nbsp;19, 2025 prior to market speculation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akero&#8217;s innovative EFX program &#8211; focused on developing a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for metabolic dysfunction-associated steatohepatitis (&#8220;MASH&#8221;) &#8211; will complement Novo Nordisk&#8217;s leadership in <FONT
STYLE="white-space:nowrap">GLP-1</FONT> based metabolic treatments. Novo Nordisk&#8217;s world leading capabilities in cardio-metabolic disease will enhance and accelerate evaluation of EFX in the Phase 3 SYNCHRONY program, preparation for a
successful commercial launch, and delivery of EFX to patients in need around the globe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;We are excited to enter into this transaction with Novo
Nordisk, which follows a comprehensive review undertaken by our Board of Directors, delivers meaningful value to Akero shareholders, and positions us to expand treatment options for people around the globe through Novo Nordisk&#8217;s
industry-leading development capabilities and commercial infrastructure,&#8221; said Andrew Cheng, M.D., Ph.D, President and CEO of Akero Therapeutics. &#8220;I want to thank Akero&#8217;s talented employees for their tireless commitment to
advancing EFX and meeting a critical global unmet need. We look forward to joining the Novo Nordisk family and accelerating the momentum of EFX to deliver a transformational impact on patients&#8217; lives.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction has been unanimously approved by Akero&#8217;s Board of Directors and is expected to close around
<FONT STYLE="white-space:nowrap">year-end,</FONT> subject to approval by Akero shareholders and upon satisfaction of customary closing conditions including approvals by regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC and J.P. Morgan Securities LLC are serving as financial advisors to Akero Therapeutics, and Kirkland&nbsp;&amp; Ellis LLP as
its legal advisor. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Akero Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical
need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero&#8217;s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY<I>&nbsp;Histology</I>&nbsp;in
patients with <FONT STYLE="white-space:nowrap">pre-cirrhotic</FONT> <FONT STYLE="white-space:nowrap">(F2-F3</FONT> fibrosis) MASH, SYNCHRONY<I>&nbsp;Outcomes</I>&nbsp;in patients with compensated cirrhosis (F4) due to MASH, and
SYNCHRONY<I>&nbsp;Real-World</I>&nbsp;in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with <FONT
STYLE="white-space:nowrap">pre-cirrhotic</FONT> MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at&nbsp;<U>Akerotx.com</U>&nbsp;and follow us
on&nbsp;<U>LinkedIn</U>&nbsp;and&nbsp;<U>X</U>&nbsp;for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novo Nordisk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic
diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. As of August 2025, Novo Nordisk employed about 78,400 people in 80
countries and markets its products in around 170 countries. Novo Nordisk&#8217;s B shares are listed on Nasdaq Copenhagen <FONT STYLE="white-space:nowrap">(NOVO-B).</FONT> Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit&nbsp;<U>novonordisk.com</U>,&nbsp;<U>Facebook</U>,&nbsp;<U>Instagram</U>,&nbsp;<U>X</U>,&nbsp;<U>LinkedIn</U>&nbsp;and&nbsp;<U>YouTube</U>.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About EFX and the SYNCHRONY program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EFX, Akero&#8217;s
lead product candidate, is currently being evaluated in three ongoing phase 3 trials. In multiple phase 2 trials, EFX has been observed to reverse fibrosis (including compensated cirrhosis), resolve MASH, reduce
<FONT STYLE="white-space:nowrap">non-invasive</FONT> markers of fibrosis and liver injury, and improve insulin sensitivity and lipoprotein profile. This holistic profile offers the potential to address the complex, multi-system disease state of all
stages of MASH, including improvements in risk factors linked to cardiovascular disease &#8211; the leading cause of death among MASH patients. Engineered to mimic the biological activity profile of native FGF21, EFX is designed to offer once-weekly
subcutaneous dosing and has been generally well-tolerated in clinical trials to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ongoing global phase 3 SYNCHRONY program (total ~3,500
participants) is comprised of three, randomized, placebo-controlled trials evaluating the efficacy and safety of EFX in both compensated cirrhosis (F4) due to MASH and <FONT STYLE="white-space:nowrap">pre-cirrhotic</FONT> <FONT
STYLE="white-space:nowrap">(F2-F3)</FONT> MASH. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SYNCHRONY<I>&nbsp;Real-World</I>, assessing the safety and tolerability of EFX (50 mg) in patients with
noninvasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (MASLD) <FONT STYLE="white-space:nowrap">(F1-F4).</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SYNCHRONY<I>&nbsp;Histology</I>, evaluating the efficacy and safety of EFX (28 mg and 50 mg) in patients with
biopsy-confirmed <FONT STYLE="white-space:nowrap">pre-cirrhotic</FONT> <FONT STYLE="white-space:nowrap">(F2-F3)</FONT> MASH. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SYNCHRONY<I> Outcomes</I>, evaluating the efficacy and safety of EFX (50 mg) for the treatment of compensated
cirrhosis (F4) due to MASH. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Important Information and Where to Find It </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed transaction between Akero Therapeutics, Inc. (&#8220;<U>Akero</U>&#8221;) and Novo Nordisk A/S (&#8220;<U>Parent</U>&#8221;),
Akero intends to file with the Securities and Exchange Commission (&#8220;<U>SEC</U>&#8221;) a proxy statement (the &#8220;<U>Proxy Statement</U>&#8221;), the definitive version of which will be sent or provided to Akero stockholders. Akero may also
file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other document which Akero may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY
STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy
Statement (when it is available) and other documents that are filed or will be filed with the SEC by Akero through the website maintained by the SEC at <U>www.sec.gov</U>, Akero&#8217;s website at
<U><FONT STYLE="white-space:nowrap">https://ir.akerotx.com/financial-information/sec-filings</FONT></U> or by contacting the Akero investor relations department at the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christina Tartaglia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(212)
<FONT STYLE="white-space:nowrap">362-1200</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>IR@akerotx.com </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Participants in the Solicitation </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
communication does not constitute a solicitation of a proxy, an offer to purchase or a solicitation of an offer to sell any securities. Akero and certain of its directors and executive officers may be deemed to be participants in the solicitation of
proxies in respect of the proposed transaction. Information regarding Akero&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i)&nbsp;the
&#8220;Directors, Executive Officers and Corporate Governance,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; sections of the Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;
31, 2024 of Akero, which was filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001744659/000095017025029514/akro-20241231.htm">February<U></U>&nbsp;28, 2025</A> and (ii)&nbsp;the
&#8220;Proposal 1 &#8211; Election of Class&nbsp;III Directors,&#8221; &#8220;Executive Compensation,&#8221; and &#8220;Principal Stockholders&#8221; sections of Akero&#8217;s proxy statement for its 2025 annual meeting of stockholders, which was
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001744659/000095017025058964/akro-20250426.htm">April<U></U>&nbsp;28, 2025</A>, and will be contained in the proxy statement to be filed by
Akero in connection with the proposed transaction. Any change of the holdings of Akero&#8217;s securities by its directors or executive officers from the amounts set forth in the proxy statement for its 2025 annual meeting of stockholders have been
reflected in the following Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC: by Jonathan Young, filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000119312525230294/xslF345X05/ownership.xml">October<U></U>&nbsp;3,
 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114666/xslF345X05/ownership.xml">September<U></U>&nbsp;
12, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000177980525000007/xslF345X05/ownership.xml">September<U></U>&nbsp;
4, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025108234/xslF345X05/ownership.xml">August<U></U>&nbsp;
13, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093321/xslF345X05/ownership.xml">July<U></U>&nbsp;
2, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088635/xslF345X05/ownership.xml">June<U></U>&nbsp;
20, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085667/xslF345X05/ownership.xml">June<U></U>&nbsp;
12, 2025</A>; by Catriona Yale, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114665/xslF345X05/ownership.xml">September<U></U>&nbsp;
12, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025097013/xslF345X05/ownership.xml">July<U></U>&nbsp;
18, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093322/xslF345X05/ownership.xml">July<U></U>&nbsp;
2, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088636/xslF345X05/ownership.xml">June<U></U>&nbsp;
20, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088207/xslF345X05/ownership.xml">June<U></U>&nbsp;
20, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085671/xslF345X05/ownership.xml">June<U></U>&nbsp;
12, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025074708/xslF345X05/ownership.xml">May<U></U>&nbsp;
19, 2025</A>; by Richard William White, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114664/xslF345X05/ownership.xml">September<U></U>&nbsp;
12, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093319/xslF345X05/ownership.xml">July<U></U>&nbsp;
2, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088637/xslF345X05/ownership.xml">June<U></U>&nbsp;
20, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085672/xslF345X05/ownership.xml">June<U></U>&nbsp;
12, 2025</A>; by Timothy Rolph, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114662/xslF345X05/ownership.xml">September<U></U>&nbsp;
12, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000177947925000007/xslF345X05/ownership.xml">September<U></U>&nbsp;
10, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025104623/xslF345X05/ownership.xml">August<U></U>&nbsp;
7, 2025</A>,<A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025094882/xslF345X05/ownership.xml"> July<U></U>&nbsp;
9, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093318/xslF345X05/ownership.xml">July<U></U>&nbsp;
2, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088638/xslF345X05/ownership.xml">June<U></U>&nbsp;
20, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085673/xslF345X05/ownership.xml">June<U></U>&nbsp;
12, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025083878/xslF345X05/ownership.xml">June<U></U>&nbsp;
9, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025067381/xslF345X05/ownership.xml">May<U></U>&nbsp;
8, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025059449/xslF345X05/ownership.xml">April<U></U>&nbsp;
28, 2025</A>; by Andrew Cheng, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025114661/xslF345X05/ownership.xml">September<U></U>&nbsp;
12, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025108232/xslF345X05/ownership.xml">August<U></U>&nbsp;
13, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025095409/xslF345X05/ownership.xml">July<U></U>&nbsp;
11, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093316/xslF345X05/ownership.xml">July<U></U>&nbsp;
2, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088641/xslF345X05/ownership.xml">June<U></U>&nbsp;
20, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085674/xslF345X05/ownership.xml">June<U></U>&nbsp;
12, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025070811/xslF345X05/ownership.xml">May<U></U>&nbsp;
13, 2025</A>; by Scott Gangloff, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025110352/xslF345X05/ownership.xml">August<U></U>&nbsp;
19, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093317/xslF345X05/ownership.xml">July<U></U>&nbsp;
2, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088640/xslF345X05/ownership.xml">June<U></U>&nbsp;
20, 2025</A>; by Jane Henderson, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025107545/xslF345X05/ownership.xml">August<U></U>&nbsp;
12, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082311/xslF345X05/ownership.xml">June<U></U>&nbsp;
5, 2025</A>; by Patrick Lamy, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025094011/xslF345X05/ownership.xml">July<U></U>&nbsp;
3, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025093320/xslF345X05/ownership.xml">July<U></U>&nbsp;
2, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088639/xslF345X05/ownership.xml">June<U></U>&nbsp;
20, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025088206/xslF345X05/ownership.xml">June<U></U>&nbsp;
20, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025085670/xslF345X05/ownership.xml">June<U></U>&nbsp;
12, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025081774/xslF345X05/ownership.xml">June<U></U>&nbsp;
4, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025077131/xslF345X05/ownership.xml">May<U></U>&nbsp;
23, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025068392/xslF345X05/ownership.xml">May<U></U>&nbsp;
9, 2025</A>; by Mark T. Iwicki, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082309/xslF345X05/ownership.xml">June<U></U>&nbsp;
5, 2025</A>; by Seth Loring Harrison, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082310/xslF345X05/ownership.xml">June<U></U>&nbsp;
5, 2025</A>; by Yuan Xu, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082308/xslF345X05/ownership.xml">June<U></U>&nbsp;
5, 2025</A>; by Tomas J. Heyman, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082307/xslF345X05/ownership.xml">June<U></U>&nbsp;
5, 2025</A>; by Judy Chou, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082303/xslF345X05/ownership.xml">June<U></U>&nbsp;
5, 2025</A>; and by Graham G. Walmsley, dated <A HREF="http://www.sec.gov/Archives/edgar/data/1744659/000095017025082306/xslF345X05/ownership.xml">June<U></U>&nbsp;5, 2025</A>. Akero stockholders may obtain additional information regarding the direct
and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Akero directors and executive officers in the transaction, which may be different than those of Akero
stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the transaction. These documents (when available) may be obtained free of charge from the website
maintained by the SEC at <U>www.sec.gov</U> and Akero&#8217;s website at <U><FONT STYLE="white-space:nowrap">https://ir.akerotx.com/financial-information/sec-filings</FONT></U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements Disclaimer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication contains forward-looking statements related to Akero, Parent and the proposed acquisition of Akero by Parent (the
&#8220;<U>Transaction</U>&#8221;) that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend&#8221;, &#8220;goal,&#8221; &#8220;may&#8221;, &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221;
&#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions. In this communication, Akero&#8217;s forward-looking statements include statements about the parties&#8217; ability to satisfy the
conditions to the consummation of the Transaction; statements about the expected timetable for completing the transaction; Akero&#8217;s plans, objectives, expectations and intentions, the financial condition, results of operations and business of
Akero, the U.S. Food and Drug Administration&#8217;s approval of Akero&#8217;s new drug application for efruxifermin for the treatment of metabolic dysfunction-associated steatohepatitis, Akero&#8217;s ability to commercialize current and future
product candidates, and the anticipated timing of closing of the Transaction. Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ
materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include,
among other things: uncertainties as to the ability to obtain shareholder approval; risks related to <FONT STYLE="white-space:nowrap">non-achievement</FONT> of the CVR milestones and that holders of the CVRs will not receive any payments in respect
of those CVRs; the possibility that competing offers will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant
approval for the consummation of the Transaction; the effects of the Transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of FDA approvals or actions, if
any; the impact of competitive products and pricing; that Parent may not realize the potential benefits of the Transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217;
control; transaction costs; actual or contingent liabilities; and other risks listed under the heading &#8220;Risk Factors&#8221; in Akero&#8217;s periodic reports filed with the U.S. Securities and Exchange Commission, including quarterly reports
on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and annual reports on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the Proxy
Statement to be filed with the U.S. Securities and Exchange Commission in connection with the proposed transaction. While the list of factors presented here is, and the list of factors presented in the Proxy Statement will be, considered
representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. You should not place undue reliance on these statements. All forward-looking statements are based on information currently
available to Akero and Parent, and Akero and Parent disclaim any obligation to update the information contained in this communication as new information becomes available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christina Tartaglia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precision AQ </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(212)
<FONT STYLE="white-space:nowrap">362-1200</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>IR@akerotx.com </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jamie Moser / Andrew Siegel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joele Frank, Wilkinson Brimmer Katcher </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(212) <FONT
STYLE="white-space:nowrap">355-4449</FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>akro-20251008.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/10/2025 12:28:06 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:akro="http://www.akerotx.com/20251008"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.akerotx.com/20251008"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akro-20251008_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akro-20251008_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>akro-20251008_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/10/2025 12:28:06 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>akro-20251008_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 10/10/2025 12:28:06 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="akro-20251008.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001744659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AKERO THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5266573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601 Gateway Boulevard<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">487-6488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AKRO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d42650d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>akro-20251008.xsd</File>
    <File>akro-20251008_lab.xml</File>
    <File>akro-20251008_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d42650d8k.htm">d42650d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d42650d8k.htm": {
   "nsprefix": "akro",
   "nsuri": "http://www.akerotx.com/20251008",
   "dts": {
    "schema": {
     "local": [
      "akro-20251008.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "akro-20251008_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "akro-20251008_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d42650d8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-10-08_to_2025-10-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d42650d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-10-08_to_2025-10-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d42650d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.akerotx.com//20251008/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-235919-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-235919-xbrl.zip
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MS>]QFA6>0BN839D:82L2K0T,JBTU098)5"K,^Y;MV:AK &LOCN]]T08%"9H
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MJ-.W^M&Y)\T$K4:C7<>OASP6^G'^.0ISC_//(@J3NYH33@CT9J.Q;\"(O45
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M6@9*LF^@D%Y[=LNBFV7Q]*R=?V9SXBK' /*BW/+K.SKH,7\K0+)_V5T6BLC
M%KJAD&<QY-%&)'PQDH.U6H1*V<G=B9-,G'F5JI,G^E^1 )TX5(;P*(6=1F0L
ML5)AFBFI22D3,+-<7SU \% /8'4B.J1GK5HSN]9$31<DM<Q;]/8XZUQA,-C2
M]I4<!DVFK/=8=HUZB&G/(+G1 GI^QNT9.SX>FV2&"(,OH3[S7SOH(\T4B\QB
M$ZGCLCDKT ZX/?_AN21&I>9CU2"./ AU.J[.YXKQI,P@HEM ]KT#_,IHU1I[
M#]2/1F\E)X!A8,<RA#4URBA&U@UCZ54+=.E4%&+=VU&2#A!<L!G)F;-@PO'P
MX!E^*+L629YH0Y5'\G+9S29T(L_4+6<X+KDH9FTP6<W<E59 A6$:C/H6[6S\
M1C\A_>@_E#;.#&QME:]R\O0A(&;QZ;"NY4I7I EB<87-#N3'2/X'KD,BD>VY
M*1Z_7J.49J/Z2T4KY/]-J3\P8/4AX_RO'H9NSM/Z7=7J.[;4G%HXWG:+<P[)
M''-;C/K@YKO?BP@M*"*T4VNTO^$B0EW,P5-D%;(N@NO+Z'.NRRZRSL\SS$,X
M8B?J0@*0,\@!8)1/@D>;*3&TT:H^^[JJ3Y8CI*UF&5? W#'Z75[#?O"M/N#J
M=*+*/R*N#$Z+AX(E>8WB#KP6%&82P^K4#P>1F@"T@\\=RJ 1V<-JK]BOO4J^
MDMP^VF$ 4&P ,FV4OLQ93BE^F PG2EM'&TOM6M.84'1SN$Q@2YOFNZ1[+DFW
M_VV72[L@+7J&.6+QUU 0[9*Z)?8%EB007TT%--NLT,5[*+A >6L$*@^"$&PT
ME$$B*T%W?S_)XOF# V!Z+1VQF ?(!FDVK6\U66WJE.>WG@?T_<SM>\'(-27@
M 4C VC<L E^;(K4#709#'W(3'ZXC%S?7O^=;IJTU^_=LNR^_/CJ9+R3ZD-U_
M\@XMFR&/>[1H>?%"-FFA'VY=_2S9M5Q;E?D6+O+S@_:SM55Y3,^4%0)0D0<U
M[3@/UY9_^6K_:];\WR3<IUEPT(:9MD/M]0*RGL.L[B4,7]1+OP$S!VDZ^&FK
M]30[OEY3C$5VD2H?WJHUGV;+8%[8"L[&$56<[[1V=QJNN&LU:^-DLKSN;X6"
MF#K=5!FDS-BB0W7^/PG1W2TIS5N9*T);4OJU]D\0;[RL:\E?@ +:STP!;4T!
MQMW'"%/)-II@B(R!:,I8%-"I_57W$;VD9]W!@P.UA7E?5?F%P)ZE];+#H,C.
M?]E=:S8Z3[AI)W3/YQ+3"'JH%;G,U3GE"6>O/4QR,2KOB<RY_P)KOK6>-?_/
M;\"6'V!H)<40OE7>0A43LFO>HE?+=AO-;?YR>X?ZCO3%=>JKU(%5L99!]1=M
M!^8*K*F3>8J-)_RSH$.%41IA17@6I].I3Z8 )5I-/7G.D*6;&4!CLPB5VO1G
MBII<71P;G)T<F88JE?G3,#S6U*_D,JRSC*+[]^]L=>[=A\@N\%I1)5=FUMIB
M@QI]B_,YFT0M,JC_29;"SI'Y^?S)+&O?Q9Q@=!"WT,YY0<OOHRSD$8+X@[]Z
MF%>KC/_[1ECO>=#AQ66QR_WJ+SHMVT5CV-75!/5QO$K0]@)3ZM@4TL&+\[HO
MD;I3OI9=_-6UK%A@J&^DU4.9N<]6[8C)'\K*I&#E<'MGE'BB:A-6=62ZW[(H
MY7_Q=JE;-7*GLNI;NMT()I+B41^*2BQ;FYWC/\=-%%F=(5<9]R&4<TECF+#B
MW-Y3QDK6F@;O]2L$RX,!G; 1J\S5K"*&]AGRU5_D9\A45.Z%$%?,D\AE:.=3
M1A9ME*(8_;Z^Z<\IBT;1ATY.+2S79 GE(%!+RT M;"^F:?3.?ST;7%WT!ZQ[
M?HH??>CWKCZQMQ?OP)J"#_MG[$/_S=DIN[I@_;,N_'Q[QB[[%[]]8H.K[M79
M^[/S*WJU>_Z)7<"7?7CLW=FO7?CX].+D WX_@)>Z5S36Z]X[&.NBSS[VWKUC
M/^L//O:NWM+(  "0Y8!]/(.ONP,:M0MCG,IQX,7!A\O+=V=JV M\:7"6S51A
M)S#-ZP_OWGTBJ'KG^$2OS^#+7O\,5O;SV4GW [P"'W]B)Q?G5UUX1@.D_^Z]
MO[SH7^$:>N>O+_KONU>]BW/6_?GBPY5&P.7% +'2[YX/NB?R:Y@/U@Y(.67P
MQA7@K\:RG#-*TU8M(DW6)F5"R:(SHT@(RRQ9M,N8T8PY@W2,=<,]'W7TR_(<
M'4S#D^?;5DJ2_"!'F\:32L91F%[++V[%D,K?X&5=E<.4&4!8<^WV]K8&"ZI=
MAS=*E!@G6K\+3ZVT;,9),HT/ZW4OJG$<)+FK.>&D;AK:5:W$JSK,5U7WYXPQ
M%%'C/4RT<DS](2W9)/)5#3?,;'.Q1K<TPI399HJ='CXD.>%^S1/&$25/<'8%
M0/!KW^-+YMS(3;/M5K/U<O4FM'=;U6:KT=!(?6*H>OW_L?;ZZ[7R+O4==U6V
MB*C?5M#/:-MEE8=PXC6-!ZE;J<Y 2/?T\%I;&H$BCZ5%L<#>R)Z,!98S0Z?!
M6 (URXRP[KEB;JIKJA_)6H_P#NE:&,YSM+#+3-!$%4F;QW 1)%R#JOB]AGE:
MRUGDF=K-2ZA5P-H%>/B"='(ORNKDR'LX,06,<Q*>[MS8C4DJNN^'N5ZY;1=\
M4C:/*2-5 9M+ W:AL8CPGNB\ O:&KKGA[8.*-I?5*-FK)_JZ"J5HR8=P%/6@
M[EO,+LR=+DP/5YO[,]U'IT-;^;V\H,H#?IV%U?NJI-# *I'V7MZ3UA.J2R:D
MV_);D4MWO5^VJQ97VBP:R81 W44"(#H5CIB8""[>LF@U6AV=GWS+XT7Z$!E;
M!R-1/8%VLI1=O0O\@Y6[Z\(%XJJ[/.'U6DW]W[O[%VCAGQ8^A VP]CJ=W9T#
M_+5QL -_-EH[C=;!3K-3YY^CL(K0-5LZ=/U:#*.41S,)?4L%H#&06;B';U'/
MI:YUUJ1/FH#[,S^[X7/B\SB6+_5ZO:QDV7KD4UE /Y<1L IPL&]O_QK[7C3[
M1^J2+"X1DWR0**PF&+;]_97MW\[^P6ZV?SN-3FM7'3UDI8+MS:MD=RP+.>):
MJN40(R6E7*<QU4HN?2^6B-U@EA7/--5%I'@J;DLFZ^G"=DZP4W&;.;G^/8OI
M&2L'F X LAG<@D:$C^ K*V@[=Q<C:PI@)>^@0%&]2Q;I"M(E2J!W%G#J(5V%
M"P-.)3T^P8*N*]ICN3\/6[S9;!ZTFZT=^%\;I&NG?A?[K]N=G=\:.W5S<[EV
M-_&WCG,G?&V;1Q\QO1$-S69G=W=WR?0#,4TL!=5L;0B"YM[>P7X#$$#MJ??6
MAZ"S<10T]EOM93O03:_3.-%=R#<]?>.@W6XUETS_[]37^G7C<^_O[[9WELZM
M;X&V&@7=OIGY=W9WE^U]-K]->$?(E2<\B?!2)_O$?:&/PS?&$LN0\E0L89'$
M7J/97HLDFOM/0H^M+TB/RZ318GK<V.2MI8+H:2??V=U;+@46<<+F.'&OL]?8
M7S+_>ZXI[J# B'T/;Y.Z[".8BQZ?L(_H"VV<(9<)Z&=@R':[>? %>>+^9+E1
M&;VW7!Z4RFBP#L'"!1()_>EXXR2Q#*BG-%LZ>P?W-UN:&Q<9S49GM[5,2]AV
MRYXU^V8XH@/B<LGD+&.)@R=AQV7"ZJG9<?G<3ZPEEAL&BWAQ4Y.W]_?66_GF
M=QR6O;],/1KU5 Q!;63VG8-.9YGX+PFCD SL!FX$[O')6*#ON&$1N PE3ZX5
MR7%:)@.>VG':Z3364\K-YI.(H.66ZI.*H,YZMN(3B:!EQMB3&ZJ-_>9:DL"F
M..)$ZC_.WO#@V@]'H\WR8J.]LS8G/(T^7&XB+B#&#5J(0(^->],C[<F_>2#8
M6SP*B6(LA;O!/6GL[726N?&Y/7D:O+3:2TDUP\M. 2V7&-QP/K-W?#+;)%+
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MM,#GST*MK<Z8?*(<QM=A= M<47T7AI\+I_*G6!^1PPC1 ^KZ/#8ST;0$'RD
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M/H_CM:[QPW>P=^_B_]DU/DFC-2F)A^^8[-[% SS,KI(B-TIYG:+\"+R4N[B
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MD1(I"B2<=!N0)GRZ[0Z]U[U P/JBS1!?59;%P%F5I\U_&,7EL$@&SO&U4+/
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M6 \RB8V8MF=+?+.?RB=IR9MS22HFP@I5O")D56$FT+KC*0S=K$6'%M9,5-$
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ML>4923F:,2JB:XX3HJ8S,^"U,6K;#9RF*Y8]KYP=1!WKU<B]^8TT/+SOS4K
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MN05*_55_Y)HP.JDV?7@__/V46E<&BAZJMC3+ZX5_W,JLB9G^ :M+.N5T67+
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MP GP^DDJG\'W/VM6-UL+P<N]O?#EWJLE#^W<_8X*[E(T?; 7/GOQ/-Q[N>,
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MT>423*81\3'B!F G+T*L(Q/'B6E%=TI _TT_*88QVDE><MHVJ[I ,\I%H%!
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MG"L-@S2:RFH0I781@*Q>RH7L\%A!I,B7[/B[A]\^>F&+;-GKLEF\W)V868W
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MG"'/,09<9 '?6A: -12.+F3VI,X$N&+J*CJ1VG&;T)))J!KQS@IQ(M:,A"<
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MXF6'/=]M2V\T'J7%"&(W2W0L)%UG!^$S^8A969^&&)5=U*2+0G()5K9%ILX
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MO]F'4;31]*.E@JY0@?$SK*O.3#S.47N1*80ACB%W7UHIJ[YIBK@D56W"SO8
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M.32I[F:CA0.MA&^JWU_L[.YN[2/S]MZFU;4_7/U<+#!E\/ )OMJ9%P2%%/.
MKVFYD=E%*SNM_,UF V/'%NA?PPE2A6.VBDV8A!/ZIJE"ZT=!Q\R&UID(C>T
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M/9-$;-B!7[@/(;10SJYIFBT=BX:W@EX4)ML:#0E KQD5C=VND^%_RY>LZ29
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MH].8T=EF:(ID<T5T6*\)9@XG%FW8&-*!O.NC<@Z\-E92PJ3I/U_,"G!58+G
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M\]O7NVB5C:,LYS-J;.'W\Q:%00[,8$,U[E[$::RD$1KA2\Y+((+-\ 03A9\
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MN"$2E'=9B<[L05#T T_V/2GMF;4AQ0J;^!ALP#"F=B.R*0P2 W,N5!SFBQJ
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M2]B)I0<A!;'];DSL0.$A2MCE(@+U$>_!5PQ^-R?9@]0."^YI:C?-\S>-LU6
MC-))&^ZQ0ZF!D;3<B5!QU_EX6<G^VD"3^('F^W-S(660-UD!$(K4!JQ2=23@
M<(T)J9!R 7O&O[,GQ?E.L^R*!N!'TVN5"@H.A]^D&&.&D'N!8FG0!OEB,?,<
M<9;ARF'&S%R[EYS8HEO6LZ1#<Y"1XSPRI#Y!Z[YVG>0^F@:$D,!X!>=XO5VN
MLEE_CG*B8!!(K%?,"L8OT#P.!B-R'L^_%1!9+8)%HPV_X_C@F^?XX(,C8'8%
M 7-HS(7R-L^3M_D\GQ:+I\2\O _XC<&:&FZS:+DU$LT\ K@V1!Y+)I-X_4MD
MRZ^-B$!"<_B"BI;S4RUJTXB,^1)!4K( 1F0;I5H/-G+ZB^XHM:RN"8^I6]RC
M-G59&?@F)$HV?0M [$,4^YS9D?95***PM Y]@%R&$DB?DE"N9T;O%1,$N]U<
ME%!O9$>*/A5A\D%1Z%$2H6EQB?IHD6-:1'$[Z#4<;%!$#JN\8'UR:<VH7]2^
M($.V+QI+HA2I4W>8,!<U/BF7HX5=.!@&_:>%Z;GDUZ:'=N4S\@*/!V_R$%8S
M#9@\&ANN:SXI2ZJZ/0*)&O \SSC5#IWH0=P:V9%4U$:B5L=KDS2HN1,YC'Z^
M)%0''L878-M!B!=J;D"H@<7O@I3@5PR-+ZWZD*\,EYA)OP":#@F7C,HY1'*]
M9\(J.ULF%?Y/<K[0O@3L1Y5+E3 ^ U87KD@8FL;DEZ#]C3GBX.W?WSH9PV3M
MA4HBZZ3]/BYH: J57O=N+["@>'T *DZ+XM8#/<AYS?>-+7,,L9M+A&L', 4C
M!A9"RC'\NDD4P^9V7Y9+11KH;Z3F[PM>3\^+[LKM RX#V9(R;A*^D;2ZMLK1
MC0!M -]+&>'GAD/X# @#&D=[B7%:D;':UV/YJF!I.NC;*N\V]\3ZE<VC7QG;
M-IN\@(OA7F>$**G7\ P#)2-% HVZ776>5WZ!SJY1PB_X[/+)M^TSO+/.8[S*
M;B_);8B<.$R/S^&@4,W(1-B2]$E,W?U(Y;38<\AO\;^/S-W8(8O6Q4B8"H;N
MHA1 S_["/%8 9W0)"P +P5D:D^2XR6=3$$YN>6&[G-P__,H]A9UYXZ3^ILOL
MLT\I[8 8V--HJB%"#W8XZ;G#C2%L8O4\G5(;)&HVL@M4_OVO5ZG:=KC2$6F(
M&#_]:=SD2CNL 'F@&_LF)IOL;4PZ+V-S/+8M >09X P0KM;S:QX9_?.>;9B8
M]>$MF(/;/:B1FCRLC9J2$G;8(X1&*JB)_?W0,^3:3L9@8YVCD=H.D&AQQ*9-
M;JZ(2G?5[/V%HCB(52*3-<-)679'?A95$MW'<J6.:)GS4S#"C3>[=[?SN#3$
M3IK(B4!@134NN.^81"F,Q^0B%)A*:=W'Z1(&40&P%_V -HGFJG-R,TQ=S&XI
M91M'B1!TGO]1,_AU@F%M+ (BT. FOIT#;KC-N?''BU$QBZ(&\&UB:]A0F%->
M5YC@A9O)2!JO%6H4&!MVBN]_80K=\"&VR&KL#NR17>I2U#N<?C>+P48O2^F[
MC3?]\!QONE_%H6\CJV@LE$2HBA65X!!F%;GO'HN&:G'H)_K=[_@KJMB6>061
MZW:R1%4FEH/5 S'$%=P48Z#9()2,J*P:,B-JW041\<@%K2D&31)G1LTUL$1
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MP73P;6:;CWY?I_20)MI&MV 7*(145,F<X@I9)86<:DCS6&B2:QAL -9\Q=S
M[(I*.:?"6"E/(311L%.6Q:($%.T8[?01SXRKND_&BW*45YW'\(AYY [E=X>
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MC0"^Q082LLD$O%#'>HHN(4>+A/0>&2^(\2K*9;**:P;9:;:2PSO<_^&V(/5
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MHF@S7A]@!.9D_EN> ;9X+]GN6(1O,X2='W]\.=AXFYW7UUE>31[]_>_RN7G
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MF0Y@8,#&<8$O8: BN&GI,5C,F> -\)0:HRXUP[8% ?]!5_X*WA-KA(CY%>Q
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MZRVEQD#B4$A'E+LVEN[T>_*#HB][N?[RBZ Q6\DM3%#U2A_&?UA:W'8L$OT
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M6M2,U[=E_?XN'5[/?*O_D<_O>0;GOT7;26O)C7?U^_^(?'Y7:4KC(2R8ZPZ
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MB@Q"*1 >-D@3#F2]ILS1V:=/G;-!O]UT%B*:A*/)+,L7QLB ?JJ*X26F4_!
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MAK#;,*C1.U?JACT_E1M@0I3"EV#;D1X8@Y=PR]EB"@_CQT\J.)J1#Q&VDU]
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M3.6%9$"J%C-?L)[,E UV(9$!"8[D!6@&=%9BS*<DC6))DNMI [.DG-O*L_7
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M.>J#/$&!I8NC,.!,N8+L-D8#G7[\XIT195__JG/LP/A'V9N?8TLXHF>+VH9
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M/$EHD?5?2A12W9/K/R8*\>/G<)7V+F>Z>RFH+K]-H( YK*$)E-ZS808LE2)
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MOE]N[^XR+O%)?I7W>R?H3"D_1_M_/D-HX,-DFI:7(,1BSWS&V*')RL\)BO+
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M#++E0*UN<-D^F)6;$=VI $!0$X<BZU0+QO=J[-2B'M3$M[ZJ!9NY0Y3#*.S
M: 0.M&G,#+RV:AHZFB"\1BF\H=A39.5D-<65.SJS 6EQUQ@PMH(=@4N"6S!3
MZ:U"<(A%%XLS%S/YB6*2=3GRRUR28]S&0@-=41BFG<&F5X4\)],2 $5IU2OI
M88T+$2D1 EX.K+_A1M59FBC=T7$[EXC)Y!'@BH!)!"%VP0)<FC:21A*A-1DB
M;",1O-^5X]>=$!0@UM&"^7T/(BZ,BV:KK%S7;[ 8I2H-B7C]I!G\5LT/<--E
M'<,@3*TKI.ZD]347Y7YG"\X4PY&XI)0U2EV2\Y(NREA'B>IM,1W<U9_PL]=<
M#VF#)Y_3Z<B'\K&^D=BK'\Z)U]J000=JIV (&"NDX\V6T-97C',-M[7NRNS6
MS@AB<%OU#).JY,JBJ%'%=%I[=U3B\3*#C-8 DA^+-XO.!,@-041ML=I;+C-,
M2V4<^2TG8:$"FY>WW+0V&'YF4\^BC]4S]<.39^I;VF3]WC4ECR8VJ(](K253
MD('J1C7MGR.L//U>C2YLR?;&57J/B\O:MNJ' E/.OCQ6?FLE>B-<S[E'.0W]
MKK#&D#)X@N45AX:$D*]'=UYSA-PD%5N3Y$LZ0?YJB9&.TKD$WNZN0;?[O:/O
M.=Z-+>L.MB@;/A['(IP].3QN;2#9W33(V[+%1>$.AWN>['!"Y_YU^YH@(BCS
MT#):]):&UML6N:8%O?!2?CL:RM!<RUH*QDUAT<B'Y(/0 66S:'5@_-NX])[!
M2>6]17'=)V#7[X[E^DRQ7$U!8:?#BAD$8-A.:T7Y#F2TF;@3N+ =)9,6;B8R
M75BJ2,84WL]_M$)0IV6 ,61:\P/8Z8J?AT-)!)(C[KTX&B0CC)TA.581711Y
MB?@4%^(HO8^)W O&]-1BWM97?WU(-<9-RV5.YTF,Q)F"XIVT2$9N@BAQ+;@H
M&8^^+-?XSYI,/G &$IU.E:[31-:WK^ST5 J;NH4&"M,@/7J)$&/#R[SY:2T^
MZ=:L&3P6N%K- 64BS6TABZ!@$CK)N$A22A_A?&7^A3V\5)'L",P\[*J8,*=Y
MD+%X22ORT%"%M^'='%J/;1V@5!;&XCKD-R*6$CU5B"-&^/R2&?^I>LX/QR+K
MK9$373J78QYTO%+*DWGNI9L*^R ?VO%C[B@H=8-,$I(7BJ[X>BU.KH##)IA.
M-JY2KHKC1'&)Y8#>Q[,QS^X5]Q(Y\08(@T(Y?IISEWRF\PP6?IM"IC['?#8&
M8E %UN]YN(K=<B72$2UAC=28?T $Z7NL;0F+H\X5$?7X7^HNNZZT?5N%I7L?
MJ"*K(^.&AN0T:5*K_9[3JVA4D*N(\)TY[PR41ZCM\SJIN%>83@I?1YFG(Y>D
M0<E[HAV!Y=8EX"]%<Z2/B=%#X\ZA%!]1^-[%==BA=,ST0F''<&57V5R=YYC6
MF^F.!O^4:=89U9KA9$19-)KV8Y\3!RVKEHC(@O@76^#-(D4?YB26Y?)UERGD
M:7-Y0/"."_3S\4;,L>N&DVX-LS/BV:&$U9)@>8O._9D..;3987T9Z-")T$DW
M&3Q\[&>'+$J.=_3!KZ&CID4,_5;Z28<7XN+$WVC]EW"4FR]J@L#6%U'3LIRQ
MV9Y?4^EF$?#$U)[#PG-#UOU:N&S:]:*.A.2<B_X::-*430CFGMLMG41EG#"S
M3Z&,Q0UZ%\^$Y?S<8,1A+\-T87IQ@NBL6#3@(%7=MS@/3SZ"YIT+8 8D,&Y/
M)\P45_F#9N+K1^N<^O').?6MZ8G:M8+6I[C]O+GX"2=$4F!J^B\OV)/J] /*
MJ07N%+3Q#3W*8;RB6G5W2Z7/YFLJ'Q%:OWE;'C N69QA6$;>(E *83[A1,RU
M)!4!2YB9UJ"W+S>7U1<T)F^L^%=4==#XV98AR!&-0[L96'RQ7W1 _HY8ZJ9*
MW.$I4Q,F5:L/DB*EH"PF)<!HLJ'7QAY5)X(EVU=.J&WP-G[V-'GV708(5D"P
M!I16D.H=F;'4_S<#0'(.Y?@G^L1B10)JZ9P, YFR'MZ-6,D$B7DS,SEJMY+O
M?ZM+;['56:1>8L<9)9/DPI4Y2FR,#>_6Y6[76OM[:N(B-B0]EZ19Q0R5>"6P
M&.]T2.D<?12<>U^^OV]B!NJRL>,)\5'(ZC8G23M9US"*GSEI^GH*5KPDN_J&
M%A[#"%4C!<5&!6Z^!F>E+!ZD1(;5RUF4=1E4,,L\*#2LWJI NF,VWOU"#+M@
M89:HC6,R>- 1P<N4:D4]O"XR<FQWP%[YWXK#(JSF\.1&FX(L9X9-PZ' 1>NZ
M5TH*J75^4#2?[*%^+[T7GRVSV)P*(H_N9*>,:OL:H_R83J']/M,ZYO7F'K?X
M+;#]RL=!=!NP=UYP0":$K%+'N5<RRPY'BK,GG(: [AH%NW,CP^6W<(2$784@
MR-4-(F]69QRG \^C#"86B3&_P%QOO-S1< ?B=#3K)<O<HV<=4#VN0].@-S?:
M(Y6(QL*AK^!1MYDH"<\J0LIYN1E!6)IPC9NK&S2K/\85 =E)PQ@(60;AZUMV
MPH.JJZWV?CKR37V @#:?TK><GGZO1OEZGQOC8!-+=!NZ5I*)2NVBJ#JF^N!I
M1'&).95DHEY$GAZ\;YC,./%J++YA&U)EV&6,\:+C,!$D0JNI9K"=D<DJ,P9S
MB[@\++X=LXPH$0+Z8#E[4(0\OC<$?&&WHTM3YPA#QSMAV5B9D<I>"A>0.4<>
M-4(H'*+9KON'4D%:S=8$5U^5J?M,$X.\:N#V%JX%#,&?0_*-./F@@T51T_=R
M<<)H"02PV$A,HGN2<#_H7-"#!6%PM:A?'7]6;(,%)_-N@;5;EO1,'7^!-5-:
MM%)B07NPRKH5[^\HJ:U]GT:=8+N\=UD<IZY9/+95$V@ ,J6H408&^Q6NVKTV
MF&BUL1?H%,YT"R71'T[.CVS]>KQ$OKAKKMY =SE!42$<-$D,U*.0M[(>JUME
M=^?)K_)UAA]C5>X'XK@?BF/-VCLBWT:'%#HE[&QQ=M\+O&CLYR#[[A+/$)/P
M'I^BYRF%LNK0D!X^**\EBP;@+R9:V11'0.KG5FIIKW+"15ZZUI]7SA!I-4."
M!N#(\)9*U#,+',C8ABUH9[ABIA6&4&;X%EL1QZYG9#6MU%$@!QIQ6+6.PC:B
M>BJ2:U#,U:TEXB6#RGB_/$O!Q(2C'< O* YP[6.: -#>41YP[NOR#G[O<\]S
MI!_^[>AD_^0^"(>?2Y+*AY0G3':V)FHC2-84*2YJ"&1RV4$3A=#4(KJ,L%[J
M"R4SNA0FPLL&W1(66@5\2QNN4IV-2SYUT_H2Y!B!.2]M-KY"7-;3=?D]JZ P
MV\F"?%(@'(HZH\MF;'?P#H9,EP'O[<?]GMN0 [15?2JDE?K^0OAB.]K_Y>CD
M$/[_/J3PA4CA/G*<.[P(U&H'G*B! R%6;B"BZSCF_UV:AA,S=,USV?&E*KQ0
MS87,G-UTG+&$M.?DN$.)G9)/CH G$SM$G#*!U9KHUA).7%_U6>"=H+ZHMJ5Q
MMF@UF2F7C\T9; ##>3E,5K,+>6OB%8\@BH^W6TI.6:U>+5Z1V/ER^]F:)GCP
M]1.LQ:UM>;?QK>8?,YPZ!<""7*B[V +X:4F!@M?\])4'O1_OY"V_C512--]*
M7(TZZNZ"2KE\(9M ,XQ#(ORU 84[#!&/$>P0%H6\;86)/Y?M.GM#'##JQ $#
MB4_=ZNVZK4E,?$(3KD'=TW.;':19*^'F]1H7KZYW*HY!-W1(DA?;Q&-MR2AG
M4(41V&\E)0D*"2SV7)$(&OOD!DD&.K]GFNG"1VYT#PW158V.(/C4YCIFD*<0
M80.E &R07E04]2,DF()*E2GG8S;+E#3."_^P#D^%;$ <4!B$&RHW#T)1A96^
MKF+414(4/2V7[/W/INVV)@H3Y_&1S)#-SB(C\:6VB"(,\K$W]<=WF_I^S\U]
M]#BG_FK38SIU.#UY$12CH Z<EE7A2B#[/488*L@=XM?M!=PU+D?OC+$Q\.2U
M#S=NZ#(NJLQH"LLJ?+%-W:^.O@@AQ?YP;G?I6@NCK@:2PA5K.R3:(1DCH:HL
M)\S$9EO#;'MDM*X[+2AAL.NB)E))" BU;Z%UO#U21$^Z/6^M#F6CO8Z@H6,F
MV.XKH>8>;R+0[NZ3Q^J;:H>K35[0HTILGY!*PB8-LZ.Y:2Q[A;8V404+9Z<@
MB<-6RIVE)$<M!*VKK&\*(;S&)7#?FO4JW71[%ZB.NKGKS!,V;H5;A^)#!B%'
MIXF6&-"BUSSS9;G.L5:/L_:0H@KO?:SD1(E@+3GO9#IMWV +6\-)!X,QR@7C
M:MU=WI@+8+::CIIZHA/4X,MMCOBJT-6+[=V@=I*!%##PLN'\3BU)'7@+2$T]
MC*X1G&A)!&<N$^+%;2BHL]#X3=Z,W\0U0L1PSUDZD]_*7[+7YB_QG24/QDM"
M*, V 4UC^#1:MR"3L9)A<^&\@[D_H? G[O>"!9%@E@Z'O&:F&)(K<6_GCQ:9
M%NT-H0P1S7Q]:<AHUJ.KSZM)%@$54G 1C#%S0;_U6M!P [04*ZSP['R=IB,B
MLB6J#C<=3#6ZJ:[3&D_4$C=3>^O(0>CW[EF7K138O?M191;"]OOILN_K:>8T
MKR._^,'I-=9?QU.=2A5Q;Z9\>/2;3,PR+N\:"8L$*N*@GI%1SX*J1H5"P6 =
MT9.U% QQ[9%?]QRP?JQ$[H5!!GU:&L7NE?=N4D&#304,I=XFE-C10MO%,3CA
MP:TQ?%95M%0D@_KB<@K)#Q3?&HU6["LVZYQSG^;203KW^\CM$I=S2 #74Q>;
M*](K.&91BG%00;LDYSE(XKP/^>5H-4=HVH3W5PL9Y\]+38J]GMQ0?)LE4IA4
MD8\XS2DT^4F+L-N]-BD<VZ/P7-0>BXX:="V4<4,!=Y^$ [X^P Q5_MA@<0]F
MT,OMZ./Y^Z/3Z-/IQ]^.SXX_GIQ%']]&[XY.CD[W/T3[GSY].#[8/X?KWUT,
M7DH$BS,#^;S64#&<-$V3Z</D[G,..3WG4!<0ZZ.:2KJN8]H-UZR4(%.^H:PZ
M+BIVF0XVE[A&@%ZO<[)@W([D R35(F'8;$/:/S%:0>4"4E62CMUC8'\(U7@&
MRL+B5+2^@,*\V!<$W1^'3#2&=\N:OQ'+NA4E?,#'X4$R_*SD!+FC$IF@2XZY
M5U<JUVD^W=+.J(*EI$*!\ K]IFR>;4+GI!Z5MN9^;V.WG&]&/NM=#=Z)D>7&
MB((Q2^:P$-/QXW4:[3TYC;Y&8_1[3MIA5\C2?W.2]VI9-5_F6R!;*J?*[TY)
M>DC#>C&ES?W6+P*+HDBY3F%CY /NPE$+)!R5A-(CI&._^0/EC]?"92D2-R,R
M5#%6-:\*1]@L"4((=00["@&7SK"&(1V%RM F?=1T88MR"YB)R&OK$B\*427N
MDD/N&!A8GA0W\2U^VB05_,91#H@YC6"%PNRB$(9^IF5>:Z\/K^;2Z'&#KN>?
M6CU.1U..W3 RQ%T"N'.<7BS[F-[!#9>.VQ)Z?L*E'K3#O?2E4U6=FLO75%_A
MC]A]=MONH/GT7S_L_OCB];?Y#X4?EO3B)F[EIUX\]>+FO?@^Z^((%>-/:#SM
M[+Z^8Y?PT1MVHM/6_@:ZRJ6:_IJ!>8F6%E]JZ,XGG?4?O$Z>>O%P>O&DLSH[
MP9D\8"C.%M&&3U)5XT9ARQ##R5\-\7;[D3[-9Z9D[?>G9#)[';TKX$C[X<.G
M)=;H]Y'<'W9V^KTW^2+#C(OH;%X@N/I]-^)-CE^/HU_VHYV]W1]_O/\)V<?3
M N']A1)]A+='?]V./F:C\K(R]Z]:;K[Z#BX+Y(N8X>GF<!LSZ$U2K5&+=.H'
M@P]NYSRB_Q>]8^4%R/\V'.X>\O@.W?AB4V%P;][V;^4+W?-\H1X7.[L[_TX0
M!S4GLZT6'C.$:?A@7"MEE&+IBGB'X?%L(6?G#<GC\.B_.;]28)8SC8Z.S&@3
MO6\UIR@7)<9!X6?-1<'I]HFCH.:0!KM!7/EH' 64!W_2\(;6="8$K,AQN;*M
M2#3F.'8R5QI+O '_+.?D1U2(T;FEHK%W\05[7TK1AIAPPA2T64/+@D.@@2(>
M88861?R1I"3 @<(TYP3]H[;0G=T\4R&C)I>H@R(AYXOW^IAPAO#]G.FJ(._R
MB3*WT^"YM--AA4Y=/^+@Y9!:41@N:GV1DNE&_<\-0M7?:C5P@%/.)[9PD7W]
M^R56.X?U5LX02$K&CG"@(AH9\T+O(9ZL!Z,I&50D%BTI8+@"H5W13:HP+ _+
M0MH4\C4YBB:)E';63SBOEC!B2W"ILWOU#'[G^ZNE3UB*N(URDRJFO=I#$:.J
M&%Z"1!>,:C[,*L(H%$H#3J]@/IBR&F!:R%RR'A!2AKU@XA-3HI<-U ,4\/T3
M1R0P)X?&QQ@<N#]Q5&*S/6N:\TGE]L<;!WCV% ?XNCB PR*C A>.D-EPZF"A
M"P3%!4FP6[)ZMJ-]RRZO C4AJ@1+OO8]URWHU[LO7$U!2C+;]I(!T! [.]17
M-ZT:.V[BIU%^#[U_(JDVL&SU@S9-A]+K.49./R$"7#KV*(\WE;L(]JAIO^>!
M?OE(4%Z.Q^H7BNYK'2S,P6B-] ]2SEKCE)-T*GLM3MW 3,TXE:D;<4X+M&QH
MJ*D864T\.=%:\Q8<+4: XC*C&F%#OY=W$'3*'3B]^@EG_ BZ%)'2%1<2*YF"
M+*9LJGC5!G>?_EHR]5PIJ9*I3UWMR4(+VA[-&+6Q(*@^UTJX1? [;(V6[=^-
MXLQVJ#3NYJ2>A]W:JJH/J-C-KW=WY42P:+0*4,KD1WZ=?'M=-F<_(4@D@1,C
M(6 %+_) Q+0,A/G(VN_VQ)W7.@8B+7J(4UDKJO$"N>-\!GFU@"#3>^^7+^+E
M]O-MRE5^PTNI],J/;6-9T\ A!R&,VR@ VJA='.R-&"52_^CSU7<5EL9U<2M#
M6S)1.8K#?%2=PAK5?>O3,.-^(#3!]DFNR;F4Y'-ZOE4RK 8RJN5!NPIIAFF!
M":\GEO:,:+\@U,C.G"WAEJ\AB=9+W!R@:.P@?4,)\U(UF>Y.SSI,">24(UR+
MPR2T[SW2_D!'J\:9T^\<@K9-\RP,)U6[Q>U!HW$\6I>R!5BHPS+X#'2VYHN@
MY>Q"%YKK6Q>/*-T/A?)9K&N+WJ.:GGMC2[(D@^.L!31CB([#[6.C-OA:6(K>
M\5,':]I2J&VS!OH]/]G3\C_*5U07KF0@LHH !\>FDX,DLV:0.2*R6BP1=)"X
M6K7IE?O0"0N7!<\F%_R0T79]F6=2$2H\ ;<M X)!DX2#?L\=YUNSU'09^"!U
M9+?0B3_VDLJ*PESEM*/>AUIFHOIWL-X+8@[YD%PKT4NH>UT=H_ 6RF'8*WC%
M)"S8+XG:23-H.>_>]NZ"/D3RQHO;P<\WET4L'IIK1[PUEWRO0_C"=5(0%PER
M=K*/:NP>X/)?6L7.=<5?5\7H+)=9D4Z'Z2QC4!%,SH%?6$?(RRAG7+TX2,SN
ME6D.C6'Y;( .NW%HD- HI J,Z$^.[]B(%40)\IRHX@D$L\!44UN:3H=I.5?P
MQ("Y-TG=L=J=R7^OH'5"=$IW@M15.)3P]7TOH?#@$H>_0/"6JIC7Q[W?TX&W
M8D#H[^1VR]"71CE/8B*BKHRCC3?R>A#V#<QT)MV3"M ]W\ZT9+"=81(_M(>.
M^O10E@P_E]:*%984OS,L)&<5F#@IX<>T--N*2U0*3PI\$)?!05*"LL*'L*!E
M:9=(JW.?*)_K8&6ORJ!;9=@ORES]]6<8'#*PL9NK>QE4[T:'J1PD#G0,V_NL
MW>J<(^2^SC*ND,<,4]<#S$D+6>E:.S._+/+J@K8Q&!=7#N!\.+8QU-8R=.6$
MY-BKUH"5=P+E*Y1EA!8B*(%:7<>M$^?(J6O=TE[B&[J?):Y(Q?B4L9:6OI$@
M>\ =JD-W!77M#NM_8U<&3KP>1%>6,[,A'R6T<*!-:0G&O8(OU^8)5N]>^':/
ML1EMSR;Y2O>GI+3_TH"^EB/5G"K$'9IY\_//Y//7">);V3G!DA'TQ\N)-&5/
M*MG,,DP6CA83L$%2<O&R#'Y77B+L23K''0P]Y=?$N6N=.\S=RA\+=">".B<+
M<?&K$EW1\_;>L=P_OU$'@Z(2>(L<.!%<7LK8I@QL 2U*I<:@FNC+T+,R1X/>
M07)V[&'M+67#6052K"GFK4(D[^SQNEJ?/[E:O\[5:GE@T^F*16!M0)!2M4HX
M0AB>1) UE4X=_K(K.1:8SK7BSGZ7[7?G485V316B9<3KQ;/TF@@9KV% :P41
M\'=TF5]C10X72)"L3WV_!#DHS47N.F;=>K9DI'Z$H/W*?.8;8+/9LGT@FN^Q
MHY^/U0E T<PL8D.*<8MHO<VQ?%2V<7W+MB+L,0:"*"6DP[RP-:ABLWNS,C#S
M:\3B]G><%LK$-CX-@@)D'KG$.SJWX'F@(,CY>:ZD[UP#:JX$.%BV4X$W;&EU
MJRC52@O1O.>HET7Y1PSS>0Y'CH5U'HP-5[\UZ#I\;HU6]^7R9M&A4GWOZHWB
MFV2"X5K#@K#BSSUI!+9BO-"4Q@9@O*M4DNGS*9UJ?$ZS9"%^H2E:PQ3D'20E
M@0>W#-9]G$-?;K.-!+T4G[:X/!#8#3:_T'75XN>D02D1]XJ(?]@!YKOI54&E
M\RI1XCB\$.SN7J38Q<(=DU#A'/_L=[?(IA-AWN1P4LUKUDI)<K,WYV/+'],8
M!5_O]7NN8W65Z/>0L*UUVW9*=,P NGQTPD"!(;,C&)N1 9NO\&W FTQ,BNNJ
M?4KB0.MX9H4[&$Z([5*(8\5<K-> "&T(HLZB<),GCY]HM$^8P(E4T'JGKL%2
M9Y"WRR*1^A;2)S,XE9F.-TD(K.4'D42>6U8PGA2R0S/!E$1< \,,"T"51P6/
M&5K9QK#^'E2<&\5^+Y3LEFYV1J &IJMA)>6)2+EK;3-1"L?"8U^WE"MN]"\0
MLI553&H/I$RO0'2MY'EKF?/:8'?)"TQTUS2T]ZEC<EA?#B^1>C9VKA(VM(7J
M@-L)6\HTGZ3#V-4@NGI26[ZK^3&=JJ?1CGLIY7W%Q,X.%IL;?T9D %5AVOQ\
M=CO2T!<AZN8VM.R!;)<^%]9@<8.">_C;?9LC=7GA"E-I*K=GHS'N0C ]9)[%
M&OCR4WJ%MA(1%JFH5I<5TQ.R5#G4;WVFQE)"OGD_;.[WK<DZK%'>VND</N 7
M[K65FMW']OD#S;4'N-8ZN1KJ5CTJH4U">(E(7&DC$KH;OYOBQ_7)]SA4SYN5
M"R[X8;<&-F(^Q7=I/(2K>)>2NH3<+';NIN+MM:I9.KUI6<+%W/39P)WY0UP)
M(UCBE042T(0_D/0ADE3!RX-";35?.4Q20U.%%KH #$J4=<FH:#5B^C'AL]IS
M23,%$FW8<6;Q,.JYC!:9EKAR;XBG5Q\$]')YN(@=F3 LXD'5><"*1FJTZ\O!
M_-7Q #'$$S7W=,_RJH7]W$&*K=V%,@-0 *%=5FR)>%U8K,ZX/:H6!:BDM25A
M$GMN-N\3]['R?V2P## 5,&4O#*6WQ7!^X10,-[T.,X43CXZ^7*:#%#7O/AR!
MO@B$ @F@8+,?IB7:+2@!9\-+,ZHPY\;=-!TCT!.F^J%J<!_RBC!HAKC)B2]G
MF(>!>$@CPP 9-*/VCE+\GR@2$A2$5L+873K6:6*B2[(8%P4C.>D)U\-S]I0W
M_IT6-IT59])?I7451GM,Z*87/"'++T%Q(OF[EC:3U,!JN\QE#Z"6\WDD'F6A
MNNJ3V Y?(N$N25FB<&F>,4U//847XU"/F"#FQ9,;[RNQ5G;$6 P6KVJ1SGAV
MX O&C3;//Q.2-D8_R$"DC"95MV I)?,$G=ES/2Y+@IU:UWKJM?;30EY>4#"3
M(-1&0F7-0")U7+&IN<BA^7H0IJ-D4A0+SWVUG-)5=E-:O[HCHA>$LEZ4$R.V
M7C\\^#.>@XR;;W0RT5F_=Y5G\,ZDP**B$6M/WH6]3%!*6XHU(..@D.VFO<J3
MN0W;);F)8C8EG'])/XE^*'.%@Y70RF\;;^NU]/L43"2=[O!1HF[#?<(W:R[(
M:N_W0$MR@L9PKDD^9C++\H4Q94TQ>DQS#O<9W52<M>9S?]83WMK1666S'[E]
M2M"U0//2YG:CT;R'(]KNKE_)\*Y*Z  M)[-:U77$*%#1A=[%F%]+TP@#3NEZ
M2FQ'!8/G-V11]B-_ <QNG2(-,8BRA9TV#K?I]VX,I+O$%(T;8T+[G'Z004;<
M%V_W\NT&%,>WGO#ZMO7/OQS_?$H*9,06/>X[SO%#H4S4_M$@2Z:?T?G[K\>[
M1;]\VJ*7E#O?&J#S^ 2:?WYR='86_?W]T>G1Q[=QJW\"R58)&[/A#^0SH'7T
M,'DF,IG!SD7PF*QV,9SNX1N*TL?]2;XT2CC@OD \3$Z]2 9()RLV>>,0Y/5S
M[Y9P$301,E-T&*2)^LOY_IL/1]'!T8</9Y_V#XY/WOV?/^S\@?[^M']XJ'_+
M=#_'V7[S\?3PZ)0N2ZOXRA:(R(?]3V='/^D_ELY#?=)0"%B6ST]_EG\<ZH=?
M_?$/(/3GA^Z'WZ0KW%DGD'IC^/R/>WH=_N?4^Y)VP5L3*7G'?DJN<CCBW[(+
MM<;!Q,!8?L2A/<'%]/,_/^V?PBKYEVM*V SO?=[KWA\=OWM_#IU[&7;.N^Z^
MLN=W]+XZ^?.;Q4]^R^JS(PT0V=EZ\_'\_.,OT,<O$14R1/^U0__GY+7Y*AK+
M4.!N])K['8<E@["B;S^?)!/ST^-J\CG&73O;O%*8@Z5Q_ST//G^69VB U9T6
M*Y//& G\/V((3C[^]C$Z@:5U?/:W:/_/9T]*ZDE)_0<J*32BR>KYF8WIZ,FJ
M?K*JGZSJQVQ5G^(6<Q;MOWNRK9^VK:=MZ_^S;>MK?&M80WUR<O0_T3&75-\>
M^>MKOGZ&H5@LZ3A/OD2G9I875&%U[,,\WW.3_OFG__KQY:L?7_]+/_PD8U\M
M8V]4QE#(WMRWD,'GWWX\_07)* Z.3L^/WR(-Q1'^>7QR\/'TT\=39J6 "^?O
MCZ*S7T]_._X-3)3(_]%K]Y- ? .E\_;X[?E[IK4_.HSV3PZCTZ.S<YB7PW7H
M(0Q?+Q.-]30)FJ$?OAW8_-=N"'\[.OV(:^%T_]/1K^?'!V=QOP<#LKVB.3<"
M9[WUN6J7LPBFB9"4X)EIZ"C<,3R[_]D4.=Y5)#-3S=-A&<,>,MR.-L)*4H_Y
MW:\BO5NX]JLZ]?_:NYK>MHT@>A>@_\!##S(@*)+LQ'$#%' <)#VD<-&D*'H*
M:)&R&4ND05%R_>^[;V9V=Y8?AF([4AOXU-3BQ^[L[.S,<-Z;J?!)J$8-%,>Y
M&9[I&7:A<\UUBV+&M9C5S]'L!0DAN/=SN5Y5MOIJ&$VFXY/HO*1N<D+<:N&;
M9X(<^"M;+,TA3.2J FXV?_6(9_.0D]?CQJH$DXFYUJ-R;>T(!&N&>^_P]K .
MAP)/]#W]JMH(&:6;YI?\?96!4?'M?(TR<&9<0>D7A(<B#RXU5OKI:C&*\C+F
M7B"^;/)#FAN=7?1[^HT?X]MN$'I-H]]]./O85.5=;L\CEF!5@/W(=]9=71'<
M _^JBMFUQV:HF?9[JAF'I#08@Y2M5FM2;W.ZJ4<!EXQ23SQQ&/TT'HW'$^15
M4,*_)J8BOC@:Z#U/]WS"/:&D"##-UZ,5L+JN'22&FM1-4:5[4-.7H^B3DT(P
M4E$N$AA5^\[+>.:X76*>G\S5_F06ZANF'=.DR4R@*Q5<="[D84QA[9F[5\!7
M(S12E[HGS]?A0)P.2N(J==,5.)&RU17W^&&PO]54KG1UBMSOJ5R;UT1!L3.?
MU"HM,ZWK=DWR&:J3N.8L2>W_$.,#%W<MBMOP;?8-4@R*_^:Z+>J!Y=J)Y^@!
M%%/-*2V/&(PKWW@U-N/XRCM*?C07$ER2\#8MIDZM.LK.*B:4<;6M-H\9E#S+
MQR&AWSF:#BX.!E/7T17F:?<:<<PF*8#=&('%6;EJF[8G(#)WQY=<W^4XL"BA
MFI6"YY3;WQ8(6F&7Z9>B%)@[1MA]C6Z0Y-@+8MT 273UXDX3UZBQ4ND_")2Y
MS)T)I="]32JHZL?#6WI0:/8P3NI^R?/I]Q(WOCQ-$U%-Q4\479A1%Y7MRDUS
MXP%*%7MAZPQWO]2O"6PV7Y?8,8[]#E,P4B(T7ZS7C52?^ /G*:%U'8JC9;4T
M6T+G8M+9Y?"#R_@:%(Y)<8/ZMP411W-S90RK3!TB.UPU+]* =)&<*J8AXN&3
M>;%;7-MHVJQM;?'(@"^(<10EM#("63X 6:Q!:=/HYWCWJ=3T9 1(4'0:V;W6
M;8=D^_FNC9&PFHI"Z#L YR32-JT7<P(.Y6F%2M@D7AK1\Q\A?_X<A0"#&4NB
M>9:L9QE=N@:-D;&6;I"NH!AW>\"6 S?-A6G /]@;R\*SH-&#08=5W!E5O&N?
M2%2?AVI6.6<GF]FUE\;5P>%#K&G8Y9=%D:".U"B_\[^S?%,L-D$]9&1N!/G-
M6ISVZ#IG$-DF*Q;.2-"&'\QLOSTZ 8(C;G)\I ^WH#V?E0?UT10>"]KL/"@M
M'',"E%2"#NZ5)7?[=&MN:1$)"^+>!,Y4F!+T]%1-M1M8)0H?WV=S(X]3OIZ,
MSQ\I45,ET1FS&LWD<A,GJX6 N;#^CHMB4DO*(7:VWN\\:"KO)N$5AGILBE49
MLD^#*X,+XBVV!G$$RJO9JZHQ+]Y'?&/E.!2TLLAR]T>646MB)G!M?X?V8*"-
MF_#:*(1/OQ=HX$DDS(K &68*61=8@18A0E4=4Q;H=WTSZ$*)1]$8<(-Y:N).
M_@:46PZDTO;<)L?Q'Q/XDS/-,9YM*!NV-^Z<9[WFB-A+9A73&KL-S^C*DHE'
M<(9L^WC2+E9+QF!@H-K./6S8>P@#T>&VGD%1;H@'TP, (?SZPI.3$<TE]<&
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MEQBHOA2$E<:[:RM67?!2(KNJ;7 X%@R113?VC>7\EXL+.-X0*SBV)6WJ.DO
M6-Z"S0:4<:6!:>*,^7!;0Z^%<=?T4RGT-B\O/C?620ENNF(;LZ6P4,?;]I#[
M=S(DG!<0"NK[EH7>A"M4M<AD6Z=JW878&;<66AA'T-\4[YO+W0_R&9Z)Z-7U
MHQ'/03?G'IZ8],_5OP!02P,$%     @ ]X-)6V=7CQI.'   >70  !    !D
M-#(V-3!D97@Y.3$N:'1M[5U94R-)DGZ7&?\AC)ENJS*3A XHSF)7"%&H&A C
MJ:J:?0NE0E(VJ4Q-'E#:A_WM^[E'1"IU(*!',//0,VU0Y!'IX>'^^9$>GB>7
MW>NKTY/+1NW\="MWTFUVKQJGC=\+AX?%\LF._A/'=\P%XN2L=7XGSK[46U>M
M]N?M'Y?-;F-;=+IW5XW/VY[KJ\)(N<-1?'03A&/I;9^*K1SNKRL_5N'IR7GS
MN[WXT>W'HZ.#XI[K;POIN4,? ZA!O,V/N;67C64X=/U"'$R.2I/X6)B_>T$<
M!V-]:!#X<2%R_U<=E6=_#^38]:9'77>L(G&C'D4[&$L\J7;5_'+S>3LD(K=/
M3\Y.&S]';L^-!<U8G.R<G9[LW-*45U%0KFR0!(=YPC34[E48B.Y(A7*BDMAU
M(A$'HJ=$S?EGXH:J+WI3<1,\!/@1]MWH'@\(13*AJ_Z^5ZR(,]?SW,!_COY/
M;T%^\[0SDJ$:!5Y?A4QX6SG*?5 @;5?<JE#P>>'ZHBZCD9!^7]2_MT4P$'__
ME#E_LM/\-]!>ZS](W\%5O :__NV@4MX_CL2U&T7$4!!Y%KH^'CJD!5">6257
M\4QO9>QBK$@\NO%(7$*HQ#=_K&)QK?JN(ST\6_6CYZ:V$;$B.>JTOG4O1:=V
M(R[:M9MZLU-OY<%TSQT4\Z+EQ$51.LR+2JFRQY+"LRT?BV7QRXNF[Q3%![JB
M4CI.>5,I'W\4'VYDU)?_/!*UW]JMCWDAA0/-I^D6HE@.E7""\43Z4]%78%@P
M >^V<G$H_6A H!"#K^!,'"H9CYEY),R3.4Y&*G2#)!)@I>P%GNL(2+V2$68,
M-MUKA1@1NQ-F]]BPVP>[\UB8OIQ"SOP@P=+V13R2L8"*CV0D>.5QS/6Q?!(D
M#D!Z3-(JAZ%21)#1/?F4[M5V.BEGLB=2!J7*N94C[?S5[T63XYY14:B! S4H
M"A*(U4"W&7GXYD,?,7<E,.-Q1*),?Z33S)MUC[+:^P@J13C3WV*I)"88)K(J
M[+ *QUCR("*E(&V6XN2B==,%U%ML'[FQ*D03Z:@C/WB$6&V?^@$FQT( ,>MY
MZF2'[CD5=<P! Q'?OTLO4:)-T)PR&$AA^5H4#>F,&#N83-SBQAZH@M1H^FGE
M+/%2DSJ14UY31IOYV203+,<@P4C?BITB;APFGHR#$*(SF83! ^0)=ZE!F/QT
M0?08L[=4-2Y^SZXVB;>19KJ%Y%_YD8PA/(X;AB.P*A)]S WT7=<ZER127Q-?
M:<FHED@GJ^6W%PFH.&8]"'&-X4X0Q@;F2#:<P(]<\)%U% R9A"IBI92^4-"&
M>"H>>(V"P5:.F?33A4(K;RK^OEO<GQ-TPH7RX2\"8XS=9$Q3GX=8+3-K)*9:
M*D"/K9Q\#[QDK,0/=B_ V-H#Z 38W(:NH\2'[S]JMX1%+(Z[E37/M9([X1LQ
MSVLYU927+3CB5,#"Q& 3BVBB')(-3*NXE:L'XQX\'0*:##_IR9,@)J&$X#@S
MJ=8<LW*8,C4OW $P9N0")/OY%1P6"PQ>1!)B<'7=1%_+8'#0,G!O/SON5FZC
M''QS,9^GUH4=>) ,\5!;4!8,0SD6UO@- B>)($^8QLQ>O0S2GF5P3T5Q 3-Q
M/!E%AL^6W3/$('.1,733: "S19PJX*[ <1E'HAB7!R-%=C(&FE@D(CA)H<C.
MB>&14,C3!FW12C%?/"4)\D?NA'#]!=/]<G5;*%OR>Y*8-B-[9LZ+JQ_W&(1>
MGQ]*_'7D1$*.,145:;."JX/"DKVW2#\B)TT+I^,HCR!*"46J(BV T>)B)-+)
MVQ'=6A6=NYOZ9;MU<V=7/4]2/9$&X(CQ<BL7)1@R M>99V,5.J3!GL0JC+1"
M])4'\8%A,(^!7*?^"AY)7H>0(;R-/C]^Z 4]]?9B;B3@!_@":Z9^.BX)"FAC
M'T=[./$(LL)F5[)(:?>*%F@K9U8H+[#8L*N#P/."QX@,)R0'+@%,&"E-J!Y<
M/#0A=R*6]\HGZQ4DH3@+L&C$DG.X20X,)]Q&PRGRW*2/A2:F:D"S\#3G;^0-
M;$8N$1>)A+UJ]7-"AS,V=:)/LZ.H HCU$KOQ+QP9CE8*WU;.]?M)%(?3@A5
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MQGII3KYI](A_%O&TDYUO9LF(1.U>X^JM7."GEU^Y/C2]Z<]=FY[]?7:8@\2
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M(C8S"C^ZD7G+$EC@I,(0]Z,.E'#)5LXX?9G"T$9*6<ORD4LC@Q!./+T'^!+
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MSO1L;G>*[@'N/W#/!=ZO(77+ NHF8/KD^:825!>(7CQ-O<8XI6M*9X?-Q"W
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M,# X7VQA8BYX;6Q02P$"% ,4    " #W@TE;<_#<%-X$  #]+0  %0
M        @ %0"@  86MR;RTR,#(U,3 P.%]P<F4N>&UL4$L! A0#%     @
M]X-)6Y"6]TI/,   #/X   T              ( !80\  &0T,C8U,&0X:RYH
M=&U02P$"% ,4    " #W@TE;K1KT,05X 0"H)P@ #P              @ ';
M/P  9#0R-C4P9&5X,C$N:'1M4$L! A0#%     @ ]X-)6\.>>(H'!   M0H
M  \              ( !#;@! &0T,C8U,&1E>#,Q+FAT;5!+ 0(4 Q0    (
M />#25MG5X\:3AP  'ET   0              "  4&\ 0!D-#(V-3!D97@Y
<.3$N:'1M4$L%!@     '  < N $  +W8 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d42650d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="akro-20251008.xsd" xlink:type="simple"/>
    <context id="duration_2025-10-08_to_2025-10-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001744659</identifier>
        </entity>
        <period>
            <startDate>2025-10-08</startDate>
            <endDate>2025-10-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-423">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-10-08_to_2025-10-08"
      id="Hidden_dei_EntityCentralIndexKey">0001744659</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="duration_2025-10-08_to_2025-10-08"
      id="Hidden_dei_CurrentFiscalYearEndDate_duration_2025-10-08_to_2025-10-08">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-435">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-436">2025-10-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-437">AKERO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-438">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-439">001-38944</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-440">81-5266573</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-441">601 Gateway Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-442">Suite 350</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-443">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-444">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-445">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-446">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-447">487-6488</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-448">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-449">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-450">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-451">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-452">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-453">AKRO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-454">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-10-08_to_2025-10-08" id="ixv-455">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
